

CITATION REPORT

List of articles citing

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

DOI: 10.1016/s0140-6736(84)91816-6
Lancet, The, 1984, 1, 1311-5.

Source: <https://exaly.com/paper-pdf/17107588/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2134	References. 501-518		
2133	Rational choice of drugs for ulcer therapy. 1985 , 142, 204		
2132	Antibiotic sensitivity of "Campylobacter pylori". 1984 , 3, 444		24
2131	Campylobacter-like organisms unusual in type A (pernicious anaemia) gastritis. <i>Lancet, The</i> , 1984 , 2, 1091-4	40	66
2130	Gastric microflora. 1985 , 291, 367-8		8
2129	Duodenal ulcer disease. 1985 , 20, 70A-E passim		
2128	Relapse of duodenal ulcers after cimetidine treatment: idiosyncrasy 'indecently' assaulted?. 1985 , 15, 291-2		2
2127	Attempt to fulfil Koch's postulates for pyloric Campylobacter. 1985 , 142, 436-9		1005
2126	Pyloric Campylobacter infection and gastroduodenal disease. 1985 , 142, 439-44		525
2125	Future treatment of peptic ulcers. 1985 , 117, 47-53		4
2124	Infective gastroenteritis and its relationship to reduced gastric acidity. 1985 , 111, 17-23		90
2123	Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. 1985 , 26, 1183-8		171
2122	Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa. 1985 , 38, 1127-31		192
2121	In vitro susceptibilities of Campylobacter-like organisms to twenty antimicrobial agents. 1985 , 28, 188-91		39
2120	Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. 1985 , 28, 837-8		165
2119	Isolation from gastric epithelium of Campylobacter-like bacteria that are distinct from "Campylobacter pyloridis". <i>Lancet, The</i> , 1985 , 1, 111-2	40	41
2118	Immune response to Campylobacter pyloridis. <i>Lancet, The</i> , 1985 , 1, 1217	40	36

2117	Urease-positive thermophilic campylobacters. <i>Lancet, The</i> , 1985 , 1, 1217-8	40	63
2116	Rapid urea hydrolysis by gastric Campylobacters. <i>Lancet, The</i> , 1985 , 1, 111	40	65
2115	Secondary amyloidosis of the gastrointestinal tract: an electron microscopic study. 1985 , 16, 596-601		4
2114	The use of picolinyl esters for the characterization of microbial lipids: application to the unsaturated and cyclopropane fatty acids of campylobacter species. 1985 , 1, 95-99		36
2113	Birth-cohort analysis of peptic ulcer mortality in Europe. 1985 , 38, 309-17		55
2112	New developments in infectious diarrhea. 1986 , 32, 165-244		4
2111	A study on the correlation of duodenal-ulcer healing with campylobacter-like organisms. 1986 , 1, 69-74		28
2110	Urea hydrolysis in patients with Campylobacter pyloridis infection. <i>Lancet, The</i> , 1986 , 1, 965-6	40	87
2109	Campylobacter pyloridis--a new factor in peptic ulcer disease?. 1986 , 27, 635-41		126
2108	Colloidal bismuth subcitrate and ranitidine in the short-term treatment of benign gastric ulcer. An endoscopically controlled trial. 1986 , 122, 42-5		10
2107	Campylobacter-like organisms and acute purulent gastritis. <i>Lancet, The</i> , 1986 , 2, 975-6	40	16
2106	Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. <i>Lancet, The</i> , 1986 , 2, 15-7	40	175
2105	Campylobacter-like organisms in association with symptomatic gastritis in children. 1986 , 109, 80-3		109
2104	Dyspepsia and non-ulcer dyspepsia: an historical perspective. 1986 , 145, 614-8		3
2103	Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro. 1986 , 91, 84-93		15
2102	Emerging zoonoses. 1986 , 27, 621-647		4
2101	Rapid identification of pyloric Campylobacter in Peruvians with gastritis. 1986 , 31, 1089-1094		48
2100	Occurrence of campylobacter pyloridis in patients from Vienna with gastritis and peptic ulcers. 1986 , 14, 275-8		12

2099	Characterization of thermophilic Campylobacter: I. Carbon-substrate utilization tests. 1986 , 13, 117-122	24
2098	Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. 1986 , 30, 510-1	104
2097	Campylobacter like organisms in duodenal and antral endoscopic biopsies: relationship to inflammation. 1986 , 27, 1132-7	111
2096	Protective drugs in the treatment of gastroduodenal ulcer disease. 1986 , 125, 156-64	10
2095	The role of colloidal bismuth subcitrate in gastric ulcer and gastritis. 1986 , 122, 22-9	31
2094	The influence of colloidal bismuth subcitrate on duodenal ulcer relapse. 1986 , 122, 35-8	5
2093	Campylobacter-like organisms and surface epithelium abnormalities in active, chronic gastritis in humans: an ultrastructural study. 1986 , 10, 113-22	105
2092	Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. 1986 , 27, 106-10	97
2091	Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate. 1986 , 122, 14-6	18
2090	Clinical Pharmacology and Therapy of Peptic Ulcer Disease. 1986 , 151-174	
2089	Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. 1986 , 27, 642-7	243
2088	There is more to healing ulcers than suppressing acid. 1986 , 27, 475-80	14
2087	Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin. 1986 , 30, 328-9	28
2086	Association of Campylobacter pylori on the gastric mucosa with antral gastritis in children. 1987 , 316, 1557-61	310
2085	Campylobacter-like organisms in patients with gastric ulcer. 1987 , 22, 487-90	29
2084	Campylobacter-like organisms in chronic gastritis, peptic ulcer, and gastric carcinoma. 1987 , 22, 553-8	74
2083	Campylobacter pyloridis in peptic ulcer disease. I. Gastric and duodenal infection caused by C. pyloridis: histopathologic and microbiologic findings. 1987 , 22, 219-24	86
2082	Campylobacter-like organisms and gastritis: histopathology, bile reflux, and gastric fluid composition. 1987 , 22, 478-86	55

2081	Relationship between gastric secretion and infection. 1987 , 28, 96-107		158
2080	Gastritis and gastric campylobacter-like organisms in patients without peptic ulcer. 1987 , 63, 543-5		2
2079	Comparative susceptibilities of <i>Campylobacter pylori</i> to norfloxacin and other agents. 1987 , 31, 949-50		22
2078	<i>Campylobacter pyloridis</i> : a new organism to explain an old problem?. 1987 , 63, 533-7		15
2077	Isolation of <i>Campylobacter pyloridis</i> from human gastric mucosa and characterization of the isolates. 1987 , 31, 603-14		30
2076	Gastric <i>Campylobacter</i> -like organisms, gastritis, and peptic ulcer disease. 1987 , 93, 371-83		404
2075	Reply. 1987 , 92, 2051		
2074	<i>Campylobacter pylori</i> , gastritis, and peptic ulcer disease in central Africa. 1987 , 295, 1174		37
2073	Jazz ballet bottom. 1987 , 295, 1173-4		5
2072	Peptic ulcer: an infectious disease?. 1987 , 22, 87-96		10
2071	Immunoblot and enzyme-linked immunosorbent assays of <i>Campylobacter</i> major outer-membrane protein and application to the differentiation of <i>Campylobacter</i> species. 1987 , 1, 261-74		14
2070	Rapid diagnosis of <i>Campylobacter pyloridis</i> -associated gastritis. 1987 , 110, 569-70		39
2069	Pathogenetic role of <i>Campylobacter pyloridis</i> in gastric ulcer. 1987 , 2, 309-316		13
2068	Infectious diarrhoea in tropical and subtropical regions. 1987 , 1, 335-59		6
2067	Immunological aspects of gastritis and pernicious anaemia. 1987 , 1, 487-506		17
2066	Serological screening for <i>Campylobacter pylori</i> in candidates for renal transplantation. <i>Lancet, The</i> , 1987 , 1, 1140-1	40	7
2065	Frequency of occurrence of <i>Campylobacter pylori</i> and analysis of the systemic and local immune response. 1987 , 266, 526-42		5
2064	<i>Campylobacter pylori</i> et gastrites : résultats ^ propos de 95 biopsies gastriques. 1987 , 17, 543-548		1

2063	Comparative investigations about three different identification systems for <i>Campylobacter pyloridis</i> from human antrum mucosa. 1987 , 266, 212-7	
2062	Assessment of <i>Campylobacter</i> -like organisms in the postoperative stomach, iatrogenic gastritis, and chronic gastroduodenal diseases: preliminary observations. 1987 , 62, 265-8	26
2061	Screening for <i>Campylobacter pyloridis</i> in patients with upper dyspepsia and the relation to inflammation of the human gastric antrum. 1987 , 22, 568-72	23
2060	Invasion of <i>campylobacter</i> -like organisms in the duodenal mucosa in patients with active duodenal ulcer. 1987 , 65, 144-6	24
2059	Lack of invasiveness of <i>Campylobacter pylori</i> . 1987 , 6, 500	2
2058	Persistence of <i>Campylobacter pyloridis</i> despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. 1987 , 32, 1255-60	47
2057	<i>Campylobacter pylori</i> (<i>C. pyloridis</i>): A new organism implicated as a cause of gastritis and peptic ulcers. 1987 , 9, 141-144	
2056	Gastrite associée au <i>Campylobacter pylori</i> : Essai thérapeutique en double-insu amoxicilline versus placebo. 1987 , 17, 251-261	
2055	Comparaison entre cytologie, histologie et bactériologie de prélèvements obtenus en cours d'endoscopie pour recherche du <i>Campylobacter pylori</i> (CP) dans deux situations cliniques : La dyspepsie non ulcéreuse et l'ulcère duodéal résistant. 1987 , 17, 271-281	1
2054	Détection et identification de <i>Campylobacter pylori</i> à partir de biopsies gastriques obtenues par endoscopie. 1987 , 17, 293-301	
2053	Low degree of relatedness between <i>Campylobacter pyloridis</i> and enteropathogenic <i>Campylobacter</i> species as revealed by DNA-DNA blot hybridization and immunoblot studies. 1987 , 42, 129-133	10
2052	Rapid staining of <i>Campylobacter pyloridis</i> . 1987 , 11, 1223	26
2051	Comparison of different antigen preparations in an evaluation of the immune response to <i>Campylobacter pylori</i> . 1988 , 7, 570-5	51
2050	A microbiological etiology for gastritis and peptic ulceration. 1988 , 12, 718-22	
2049	Susceptibility of clinical isolates of <i>Campylobacter pylori</i> to 24 antimicrobial and anti-ulcer agents. 1988 , 4, 154-7	36
2048	Chronic gastritis--a pathogenetic approach. 1988 , 154, 113-24	170
2047	Assay-IgG to <i>Campylobacter pylori</i> in histological chronic and biopsy <i>Campylobacter</i> positive gastritis. 1988 , 55, 321-325	1
2046	Prevalence of <i>Campylobacter pylori</i> and association with antral mucosal histology in subjects with and without upper gastrointestinal symptoms. 1988 , 33, 649-53	55

2045	Campylobacter pylori et gastrite: étude biologique, immunologique, histologique et endoscopique. 1988 , 18, 91-96		2
2044	Campylobacter pylori nancy, le 16/1/1988. 1988 , 18, XVII		
2043	Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin. 1988 , 113, 908-12		72
2042	Microabscesses in gastric biopsies shown by acridine orange staining. 1988 , 20, 553-7		3
2041	Pathogenetic Implications of Ultrastructural Findings in Campylobacter pylori Related Gastroduodenal Disease. 1988 , 23, 25-39		119
2040	Prevalence of Campylobacter pylori in an unselected Swedish population of patients referred for gastroscopy. 1988 , 23, 358-62		18
2039	Prevalence of Campylobacter pylori in Duodenal and Gastric Mucosa Relationship to Inflammation. 1988 , 23, 69-75		23
2038	Mannose-resistant haemagglutination by Campylobacter pylori. 1988 , 20, 353-4		54
2037	Relapse rate as a major determinant of drug selection in peptic ulcer therapy. 1988 , 35, 329-33		12
2036	In search of an animal model for experimental Campylobacter pylori infection: administration of Campylobacter pylori to rodents. 1988 , 268, 341-6		9
2035	Histological Aspects of Campylobacter pylori Colonisation and Infection of Gastric and Duodenal Mucosa. 1988 , 23, 21-24		20
2034	Campylobacter pylori in patients with gastritis, peptic ulcer, and carcinoma of the stomach in Lanzhou, China. <i>Lancet, The</i> , 1988 , 1, 1055	40	31
2033	Campylobacter pylori and Barrett's esophagus. 1988 , 63, 1176-80		57
2032	Campylobacter gastritis and vomiting. <i>Lancet, The</i> , 1988 , 2, 1502	40	2
2031	Culture of the organisms and histochemical identification. 1988 , 142, 16-20		5
2030	Distribution of Campylobacter pylori in the human stomach obtained at postmortem. 1988 , 23, 257-64		23
2029	Campylobacter pylori in health and disease: An ecological perspective. 1988 , 1, 1-16		61
2028	Heterogeneity of Campylobacter pylori as Demonstrated by Co-agglutination Testing with Rabbit Antibodies. 1988 , 23, 58-63		25

2027	Bismuth: effects on gastritis and peptic ulcer. 1988 , 142, 82-6	11
2026	<i>Campylobacter pylori</i> in peptic ulcer disease. III. Symptoms and paraclinical and epidemiologic findings. 1988 , 23, 347-50	28
2025	<i>Campylobacter pylori</i> infection and its relation to chronic gastritis. An endoscopic, bacteriologic, and histomorphologic study. 1988 , 23, 867-74	22
2024	The <i>Campylobacter pylori</i> story. 1988 , 146, 58-66	47
2023	<i>Campylobacter pylori</i> in a sample of Finnish population: relations to morphology and functions of the gastric mucosa. 1988 , 29, 909-15	108
2022	Mechanisms of antibiotic resistance in <i>Campylobacter</i> species. 1988 , 32, 1107-12	134
2021	Epidemiology of peptic ulcer disease. 1988 , 1-31	2
2020	The pathophysiological and pharmacological basis of peptic ulcer therapy. 1988 , 16, 260-6	5
2019	The efficacy of antimicrobial treatment in <i>Campylobacter pylori</i> -associated gastritis and duodenal ulcer. 1988 , 142, 76-81	75
2018	Effect of treatment on <i>Campylobacter pylori</i> in peptic disease: a randomised prospective trial. 1988 , 29, 279-83	57
2017	<i>Campylobacter pylori</i> in peptic ulcer disease. II. Endoscopic findings and cultivation of <i>C. pylori</i> . 1988 , 23, 760-4	20
2016	The genus <i>Campylobacter</i> : a decade of progress. 1988 , 1, 157-72	255
2015	Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of <i>Campylobacter pylori</i> . 1988 , 29, 1386-91	104
2014	Peptic ulcer. 1988 , 18, 237-44	2
2013	<i>Campylobacter pylori</i> : prospective analysis of clinical and histological factors associated with colonization of the upper gastrointestinal tract. 1988 , 18, 133-8	37
2012	<i>Campylobacter pylori</i> . 1988 , 155, 68-81	16
2011	Antacids reduce <i>Campylobacter pylori</i> colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. 1988 , 95, 619-24	52
2010	Bacterial gastroenteritis. 1988 , 35, 69-87	10

2009	Nitrofurans in the treatment of gastritis associated with <i>Campylobacter pylori</i> . The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. 1988 , 95, 1178-84	99
2008	Peptic ulcer disease in the pediatric population. 1988 , 35, 117-40	17
2007	Relationship between <i>Campylobacter pylori</i> and gastritis in healthy humans after administration of placebo or indomethacin. 1988 , 95, 1185-97	54
2006	Acid secretion and serum gastrin levels in individuals with <i>Campylobacter pylori</i> . 1988 , 94, 923-7	60
2005	<i>Campylobacter pylori</i> gastritis in the acquired immunodeficiency syndrome. 1988 , 95, 209-12	21
2004	Gastric and esophageal <i>Campylobacter pylori</i> in patients with Barrett's esophagus. 1988 , 95, 216-8	77
2003	<i>Campylobacter pyloridis</i> -associated chronic active antral gastritis. 1988 , 94, 33-40	733
2002	The 14C-urea breath-test for the detection of gastric <i>Campylobacter pylori</i> infection (for editorial comment, see page 426; see also page 431). 1989 , 151, 435-439	21
2001	<i>Campylobacter pylori</i> infection: diagnosis and therapy. 1989 , 151, 426-7	5
2000	Recurrence of duodenal ulcer and <i>Campylobacter pylori</i> infection after eradication. 1989 , 151, 431-5	191
1999	14C-urea breath test in <i>C pylori</i> gastritis. 1989 , 30, 798-803	92
1998	<i>Campylobacter pylori</i> infection in Meckel's diverticula containing gastric mucosa. 1989 , 30, 1233-5	24
1997	Effect of bismuth subcitrate on amphibian gastroduodenal bicarbonate secretion. 1989 , 30, 917-21	10
1996	<i>Campylobacter pylori</i> infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error. 1989 , 42, 727-32	72
1995	<i>Campylobacter</i> associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. 1989 , 30, 1206-12	99
1994	<i>Campylobacter pylori</i> and ulcer disease--a causal connection?. 1989 , 160, 53-8	11
1993	The potential impact of <i>Campylobacter pylori</i> on the treatment of duodenal ulcer disease. 1989 , 160, 39-45	11
1992	<i>Campylobacter pylori</i> in Relation to Other Aerobic and Anaerobic Microorganisms in Patients with Gastric Diseases. 1989 , 2, 107-114	6

1991	Campylobacter pylori--a role in non-ulcer dyspepsia?. 1989 , 160, 7-13	70
1990	Erosive prepyloric changes--a manifestation of stress?. 1989 , 24, 522-8	10
1989	Pernicious anaemia and Campylobacter like organisms; is the gastric antrum resistant to colonisation?. 1989 , 30, 60-4	65
1988	Campylobacter pylori in esophagus, antrum, and duodenum. A histological and microbiological study. 1989 , 34, 445-8	20
1987	Relationship of Campylobacter pylori and duodenogastric reflux. 1989 , 34, 1021-4	10
1986	Campylobacter pylori is not associated with gastroparesis. 1989 , 34, 1677-80	50
1985	Campylobacter pylori in alcoholic hemorrhagic "gastritis". 1989 , 34, 677-80	20
1984	Haemolytic activity of Campylobacter pylori. 1989 , 8, 706-10	14
1983	Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. 1989 , 8, 888-9	142
1982	Campylobacter pylori in Japan: bacteriological feature and prevalence in healthy subjects and patients with gastroduodenal disorders. 1989 , 24, 494-504	21
1981	Superficial gastritis and Campylobacter pylori in dyspeptic patients--a quantitative study using computer-linked image analysis. 1989 , 158, 303-10	27
1980	Investigation of the relationship between gastric antral inflammation and Campylobacter pylori using graphic tablet planimetry. 1989 , 159, 281-5	15
1979	Campylobacter pylori, non-ulcer dyspepsia, and race in Malaysia. <i>Lancet, The</i> , 1989 , 1, 1018	40 3
1978	Campylobacter pylori: a new pathogen. 1989 , 114, 670-2	5
1977	Is antibacterial therapy against Campylobacter pylori useful in the treatment of indigestion and chronic peptic ulceration?. 1989 , 10, 36-40	4
1976	Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori. 1989 , 86, 60-5	29
1975	Review of the modes of action of colloidal bismuth subcitrate. 1989 , 157, 3-6; discussion 21-2	18
1974	Diagnostic value of an immunoassay to detect anti Campylobacter pylori antibodies in non-ulcer dyspepsia. <i>Lancet, The</i> , 1989 , 1, 1182-5	40 48

1973	Na ⁺ /H ⁺ ion-exchange property of postmortem human gastric mucus. The effects of <i>Campylobacter pylori</i> infection and sucralfate. 1989 , 24, 781-6	9
1972	Duodenal ulcer disease: what role does <i>Campylobacter pylori</i> play?. 1989 , 160, 14-8	3
1971	Ammonia produced by <i>Campylobacter pylori</i> neutralizes H ⁺ moving through gastric mucus. 1989 , 24, 761-8	33
1970	<i>Campylobacter pylori</i> and gastroduodenal disease. Is there a relationship?. 1989 , 86, 31-3, 37-8, 41	1
1969	Different effect of <i>Helicobacter pylori</i> on the human gastric antral and body mucosal intracellular mucin. 1990 , 25, 997-1003	21
1968	Maintenance of duodenal ulcer healing by antacids. 1990 , 174, 54-9	4
1967	Bismuth therapy in gastrointestinal diseases. 1990 , 99, 863-75	170
1966	Urea protects <i>Helicobacter</i> (<i>Campylobacter</i>) <i>pylori</i> from the bactericidal effect of acid. 1990 , 99, 697-702	315
1965	<i>Helicobacter mustelae</i> -associated gastritis in ferrets. An animal model of <i>Helicobacter pylori</i> gastritis in humans. 1990 , 99, 352-61	225
1964	L'ulcère duodéal: une maladie infectieuse ?. 1990 , 20, 47-49	
1963	Gastrite antrale Relation particulière avec les modifications positives prépyloriques Corrélation histo-endoscopique. 1990 , 20, 473-494	
1962	Possible evidence of invasiveness of <i>Helicobacter</i> (<i>Campylobacter</i>) <i>pylori</i> . 1990 , 9, 135-8	47
1961	<i>Helicobacter pylori</i> in gastroduodenal disease. 1990 , 12, 46-50	2
1960	<i>Helicobacter pylori</i> infection of gastric mucin cell metaplasia: the duodenum revisited. 1990 , 162, 239-43	18
1959	Gastritis. 1990 , 12, 203-17	18
1958	Identification of <i>Campylobacter pylori</i> by gastric brush cytology. 1990 , 6, 223-4	2
1957	Identification of <i>Campylobacter pylori</i> by endoscopic brush cytology. 1990 , 6, 227-34	11
1956	<i>Campylobacter pylori</i> and gastroduodenal disease. 1990 , 3, 1-12	123

1955	Cure of duodenal ulcer after eradication of <i>Helicobacter pylori</i> . 1990 , 153, 145-9	206
1954	Acridine orange fluorescence, <i>Campylobacter pylori</i> , and chronic gastritis. 1990 , 25, 127-33	7
1953	Evaluation of ¹³ C-urea breath test in the detection of <i>Helicobacter pylori</i> and in monitoring the effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia. 1990 , 31, 1237-41	74
1952	Antral <i>Helicobacter pylori</i> in patients with chronic renal failure. 1990 , 43, 397-9	32
1951	Quantitative histological study of mucosal inflammatory cell densities in endoscopic duodenal biopsy specimens from dyspeptic patients using computer linked image analysis. 1990 , 31, 858-61	16
1950	Effect of bismuth subcitrate and sucralfate on rat duodenal and human gastric bicarbonate secretion in vivo. 1990 , 31, 26-31	11
1949	Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. 1990 , 31, 476-80	71
1948	Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with <i>Helicobacter pylori</i> . 1990 , 31, 522-5	156
1947	Association of <i>Helicobacter pylori</i> with Gastritis, Duodenitis and Peptic Ulcer Diseases. 1990 , 2, 46-51	8
1946	Direct detection and amplification of <i>Helicobacter pylori</i> ribosomal 16S gene segments from gastric endoscopic biopsies. 1990 , 13, 473-9	69
1945	Does <i>Helicobacter pylori</i> colonize the gastric mucosa of Meckel's diverticulum?. 1990 , 65, 187-91	29
1944	BISMUTH AND DYSPEPSIA. <i>Lancet, The</i> , 1990 , 336, 472-473	40
1943	The Detection of <i>Campylobacter pylori</i> (Cp) in Gastro-Duodenal Disease: The Efficacy of the Rapid Urease (RU) Test and Relationship between Endoscopic Findings, Histological Gastritis and Presence of Cp. 1990 , 2, 13-18	1
1942	Cure of duodenal ulcer associated with eradication of <i>Helicobacter pylori</i> . <i>Lancet, The</i> , 1990 , 335, 1233-540	811
1941	Association of <i>Helicobacter pylori</i> infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. 1990 , 89, 464-9	80
1940	<i>Campylobacter pylori</i> infection: experience in a multiracial population. 1990 , 5, 277-80	12
1939	Serum immune response to <i>Helicobacter pylori</i> in children: epidemiologic and clinical applications. 1991 , 119, 205-10	62
1938	The Sydney System: histological division. 1991 , 6, 209-22	764

1937	Mucosal IgA recognition of <i>Helicobacter pylori</i> 120 kDa protein, peptic ulceration, and gastric pathology. <i>Lancet, The</i> , 1991 , 338, 332-5	40	572
1936	Environmental aspects of <i>Campylobacter</i> infections. 1991 , 146, 3-15		15
1935	Is <i>Helicobacter pylori</i> a cause of duodenal ulcer? A methodologic critique of current evidence. 1991 , 91, 566-72		17
1934	The Distribution of <i>Helicobacter pylori</i> in Human Gastric Mucosa in vivo. 1991 , 3, 457-460		13
1933	<i>Helicobacter pylori</i> : enquête sérologique chez les militaires du contingent avec étude endoscopique, microbiologique et histologique de 10 sujets à sérologie positive. 1991 , 21, 308-312		1
1932	The Importance of Urease in Acid Protection for the Gastric-colonising Bacteria <i>Helicobacter pylori</i> and <i>Helicobacter felis</i> sp. nov. 1991 , 4, 121-134		66
1931	<i>Helicobacter pylori</i> infection and gastric carcinoma among Japanese Americans in Hawaii. 1991 , 325, 1132-6		1578
1930	Duodenal ulcer: the villain unmasked?. 1991 , 302, 919-21		48
1929	<i>Helicobacter pylori</i> : aggressor or innocent bystander?. 1991 , 75, 815-29		13
1928	Aetiology and management of dyspepsia in Africa. 1991 , 21, 107-12		4
1927	Eradicating <i>Helicobacter pylori</i> and symptoms of non-ulcer dyspepsia. 1991 , 303, 1238-40		84
1926	Young onset peptic ulcer disease and non-ulcer dyspepsia are separate entities. 1991 , 186, 33-44		10
1925	<i>Helicobacter pylori</i> in dyspeptic patients: quantitative association with severity of gastritis, intragastric pH, and serum gastrin concentration. 1991 , 186, 124-34		25
1924	<i>Helicobacter pylori</i> : histological and serological study on gastric and duodenal ulcer patients in Estonia. 1991 , 186, 84-9		17
1923	Maintenance therapy in peptic ulcer disease. 1991 , 75, 1013-38		10
1922	A novel enzyme immunoassay for serodiagnosis of <i>Helicobacter pylori</i> infection. 1991 , 101, 77-83		24
1921	Basophil-bound and serum immunoglobulin E directed against <i>Helicobacter pylori</i> in patients with chronic gastritis. 1991 , 101, 131-7		62
1920	Continuous production of [¹¹ C]urea for medical application. 1991 , 42, 407-409		3

1919	Helicobacter pylori affects the quality of experimental gastric ulcer healing in a new animal model. 1991 , 55, 261-8	17
1918	Pathogenetic role of Helicobacter pylori in duodenal ulcer disease. Multivariate analysis of factors affecting relapse. 1991 , 36, 424-30	22
1917	Chronic effect of intragastric ammonia on gastric mucosal structures in rats. 1991 , 36, 33-8	51
1916	Characterization of a plasmid from Helicobacter pylori encoding a replication protein common to plasmids in gram-positive bacteria. 1991 , 5, 2377-89	71
1915	Epithelial damage by Helicobacter pylori in gastric ulcers. 1991 , 19, 47-53	27
1914	Helicobacter pylori in Barrett's oesophagus. 1991 , 18, 568-570	18
1913	Helicobacter-associated duodenitis and gastric metaplasia in duodenal ulcer patients. 1991 , 99, 997-1000	16
1912	Transport conditions and number of biopsies necessary for culture of Helicobacter pylori. 1991 , 10, 166-7	28
1911	Acute lethality of Helicobacter pylori in mice. A novel heat-labile toxin. 1991 , 26, 230	2
1910	Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. 1991 , 32, 1473-7	421
1909	Studies of Helicobacter pylori in a gastric mucosa in vitro animal model. 1991 , 26, 43-8	12
1908	Neutrophil activation by Helicobacter pylori. 1991 , 32, 853-7	112
1907	Immune responses to Helicobacter pylori in children with recurrent abdominal pain. 1991 , 44, 768-71	84
1906	Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men. 1991 , 32, 25-8	129
1905	Helicobacter pylori and Gastritis in Children with Abdominal Complaints. 1991 , 26, 95-99	29
1904	Diagnostic efficiency of an ultrarapid endoscopy room test for Helicobacter pylori. 1991 , 32, 467-9	58
1903	Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. 1991 , 35, 490-6	247
1902	Helicobacter pylori Urease: Properties and Role in Pathogenesis. 1991 , 26, 39-46	95

1901	Long term serological surveillance after treatment of <i>Helicobacter pylori</i> infection. 1991 , 32, 1291-4	83
1900	<i>Helicobacter pylori</i> : a Jordanian study. 1991 , 67, 994-8	11
1899	Adhesion of <i>Helicobacter pylori</i> to human gastric mucosal biopsy specimens cultivated in vitro. 1991 , 26, 1179-87	13
1898	Relationship between gastric inflammatory response and symptoms in patients infected with <i>Helicobacter pylori</i> . 1991 , 181, 33-7	22
1897	Gastric <i>Helicobacter</i> and upper gastrointestinal symptoms in chronic renal failure. 1991 , 23, 403-6	25
1896	Is gastroduodenitis a cause of chronic dyspepsia?. 1991 , 182, 33-9	33
1895	<i>Helicobacter pylori</i> eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. 1992 , 27, 281-4	37
1894	Observer homogeneity in the histologic diagnosis of <i>Helicobacter pylori</i> . Latent class analysis, kappa coefficient, and repeat frequency. 1992 , 27, 933-9	66
1893	Eradication of <i>Helicobacter pylori</i> : therapies and clinical implications. 1992 , 68, 549-57	24
1892	Use of Romanowsky type (Diff-3) stain for detecting <i>Helicobacter pylori</i> in smears and tissue sections. 1992 , 45, 448-9	12
1891	Chemical gastritis and <i>Helicobacter pylori</i> related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration. 1992 , 45, 135-9	76
1890	Influence of age and <i>Helicobacter pylori</i> infection on serum pepsinogens in healthy blood transfusion donors. 1992 , 33, 452-5	25
1889	Ecology of <i>Helicobacter pylori</i> in Peru: infection rates in coastal, high altitude, and jungle communities. The Gastrointestinal Physiology Working Group of the Cayetano Heredia and the Johns Hopkins University. 1992 , 33, 604-5	20
1888	Non-immunological defence mechanisms of the gut. 1992 , 33, 987-93	66
1887	Effect of <i>Helicobacter pylori</i> infection on colloidal bismuth subcitrate concentration in gastric mucus. 1992 , 33, 592-6	8
1886	<i>Helicobacter pylori</i> infection in children. A clinical overview. 1992 , 31, 481-7	17
1885	Longitudinal study of influence of <i>Helicobacter pylori</i> on current risk of duodenal ulcer relapse. The Hvidovre Ulcer Project Group. 1992 , 27, 421-6	9
1884	Chemotactic activity of <i>Helicobacter pylori</i> sonicate for human polymorphonuclear leucocytes and monocytes. 1992 , 33, 738-42	106

1883	Helicobacter pylori: past, present, and future. 1992 , 194, 25-9	10
1882	Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. 1992 , 27, 362-6	76
1881	Helicobacter pylori associated phospholipase A2 activity: a factor in peptic ulcer production?. 1992 , 45, 221-4	52
1880	Mechanism of gastric mucosal damage induced by ammonia. 1992 , 102, 1881-8	109
1879	Activation of human phagocyte oxidative metabolism by Helicobacter pylori. 1992 , 103, 1747-53	94
1878	Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides. 1992 , 174, 1370-7	151
1877	Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy. 1992 , 38, 357-60	56
1876	Role of Helicobacter pylori in duodenal ulcer. 1992 , 44, 921-7	10
1875	Helicobacter pylori. New diagnostic tools. Clinical and experimental studies on local and systemic immune response. Minireview based on a doctoral thesis. 1992 , 97, 1-26	2
1874	A comparison of diagnostic tests to determine Helicobacter pylori infection. 1992 , 7, 203-9	52
1873	Fluoride as a possible aetiological factor in non-ulcer dyspepsia. 1992 , 7, 355-9	15
1872	Pathologic changes of gastric mucosa colonized by Helicobacter pylori. 1992 , 23, 548-56	56
1871	Helicobacter pylori Distribution in Human Gastric Mucosa with Chronic, Atrophic Gastritis. 1992 , 4, 376-381	3
1870	Inoculation of Rhesus Monkeys with Human Helicobacter pylori: A Long-term Investigation on Gastric Mucosa by Endoscopy. 1992 , 4, 19-30	16
1869	Blood ammonia and Helicobacter pylori. 1992 , 22, 311	
1868	Eicosanoid synthesis and Helicobacter pylori associated gastritis: increase in leukotriene C4 generation associated with H. pylori colonization. 1992 , 44, 75-86	23
1867	A prospective study of atrophic gastritis and stomach cancer risk. 1992 , 83, 1137-42	106
1866	Noninvasive detection of Helicobacter pylori colonization in stomach using [11C]urea. 1992 , 37, 618-21	8

1865	Helicobacter pylori and luminal gastric pH. Relationships in nonulcer dyspepsia. 1992 , 37, 378-84	11
1864	Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. 1992 , 420, 489-98	74
1863	Characterization of a 25,000-dalton Helicobacter pylori protein, cross-reacting with a Campylobacter jejuni protein. 1992 , 100, 470-478	3
1862	Helicobacter pylori and peptic ulcer disease. 1992 , 62, 518-20	2
1861	Metalle in Biologie und Medizin, III. Bismutlactat: Darstellung und Strukturchemie eines Hydroxycarboxylat-Komplexes. 1992 , 125, 43-46	26
1860	Lebensräume - Lebensformen Helicobacter pylori Ein infektiöser Keim besiedelt den menschlichen Magen. 1992 , 22, 54-56	
1859	The association of Helicobacter pylori with differentiated-type early gastric cancer. 1993 , 72, 1841-5	54
1858	Helicobacter pylori and gastric carcinoma. 1993 , 26, 106-7	
1857	Evaluation of rapid urease test for detection of Helicobacter pylori in gastric biopsy specimens. 1993 , 9, 450-2	11
1856	Gastritis in patients on non-steroidal anti-inflammatory drugs. 1993 , 23, 341-8	62
1855	Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates. 1993 , 38, 1132-6	33
1854	Helicobacter pylori potentiates histamine release from serosal rat mast cells in vitro. 1993 , 38, 944-9	31
1853	Link between Helicobacter pylori-associated gastritis and duodenal ulcer. 1993 , 38, 117-22	13
1852	Treatment of Helicobacter pylori-associated gastroduodenal disease in children. Clinical evaluation of antisecretory vs antibacterial therapy. 1993 , 38, 123-8	11
1851	Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Biochemical and biophysical studies. 1993 , 38, 2071-80	56
1850	Production of chemoattractant by Helicobacter pylori. 1993 , 38, 1697-701	19
1849	Helicobacter pylori potentiates histamine release from rat serosal mast cells. 1993 , 38, C197-C199	
1848	Reduced incidence of stress ulcer in germ-free Sprague Dawley rats. 1993 , 53, 1099-104	7

1847	Helicobacter pylori-associated gastric ulcer mimicking a gastric malignancy. 1993 , 39, 738-9	
1846	Pathogenetic classification of chronic gastritis. 1993 , 53, 122-126	
1845	Comparison of three different therapeutic regimens for eradicating Helicobacter pylori. 1993 , 53, 557-564	3
1844	Management of non-ulcer dyspepsia. 1993 , 8, 279-86	6
1843	Humoral and cellular immunity in HIV positive and HIV negative Helicobacter pylori infected patients. 1993 , 280, 186-96	8
1842	Role of the systemic cellular immune response in the pathogenesis of Helicobacter pylori-associated duodenal ulcer. 1993 , 280, 177-85	7
1841	Detection of H. pylori in saliva using a monoclonal antibody. 1993 , 279, 466-71	3
1840	Clinical Significance of Sterilization of Endoscopic Instrument. 1993 , 5, 33-37	
1839	Significance of Helicobacter Pylori Infection in Human Peptic Ulcers. 1993 , 5, 43-48	1
1838	Local gastric and serum amoxicillin concentrations after different oral application forms. 1993 , 37, 1506-9	78
1837	Eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. 1993 , 196, 30-3	24
1836	Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. 1993 , 37, 769-74	141
1835	Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial. 1993 , 28, 438-42	39
1834	Helicobacter pylori: 10th anniversary of its culture in April 1982. 1993 , 34, 293-4	10
1833	Development of a 14C-urea breath test in ferrets colonised with Helicobacter mustelae: effects of treatment with bismuth, antibiotics, and urease inhibitors. 1993 , 34, 181-6	24
1832	Evaluation of a commercial enzyme-linked immunosorbent assay (ELISA) kit for serological diagnosis of Helicobacter pylori infection in a group of non-ulcer dyspepsia sufferers. 1993 , 69, 456-60	2
1831	Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients. 1993 , 46, 826-8	24
1830	Non-steroidal anti-inflammatory drug-induced gastropathy: a comparative endoscopic and histopathological evaluation of the effects of tenoxicam and diclofenac. 1993 , 21, 89-97	2

1829	Helicobacter pylori and peptic ulcer disease. 1993 , 94, 38-45	2
1828	Helicobacter pylori: isolation from gastric biopsy specimens. 1993 , 87, 483-6	3
1827	Helicobacter pylori: a decade later. 1993 , 306, 393-4	2
1826	Cell kinetics of mucosal atrophy in rat stomach induced by long-term administration of ammonia. 1993 , 104, 796-801	59
1825	Chronic gastritis and Helicobacter pylori in digestive form of Chagas' disease. 1993 , 35, 117-21	10
1824	Overview: Recent Advances in Anti-ulcer Agents. 1993 , 3, 1305-1312	
1823	Polymerase chain reaction assay for the detection of Helicobacter pylori in gastric biopsy specimens: comparison with culture, rapid urease test, and histopathological tests. 1994 , 35, 905-8	65
1822	Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. 1994 , 35, 1167-71	50
1821	The urea breath test for Helicobacter pylori. 1994 , 35, 723-5	119
1820	Gastric T lymphocyte responses to Helicobacter pylori in patients with H pylori colonisation. 1994 , 35, 1379-84	113
1819	Helicobacter pylori infection in north-eastern peninsular Malaysia. Evidence for an unusually low prevalence. 1994 , 29, 209-13	45
1818	Immune Response in Helicobacter pylori Infection. 1994 , 2, 295-306	6
1817	Chronic nonatropic ('superficial') gastritis increases the risk of gastric carcinoma. A case-control study. 1994 , 29, 336-40	48
1816	Low incidence of clinically significant gastroduodenal pathology despite a high incidence of Helicobacter pylori infection. 1994 , 88, 569-71	16
1815	The relationship between Helicobacter pylori-associated gastritis or ulcer disease and gastric emptying. 1994 , 21, 209-11	4
1814	Helicobacter pylori and gastro-oesophageal reflux disease--a prospective study. 1994 , 163, 369-73	55
1813	Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. 1994 , 39, 1090-8	95
1812	Helicobacter pylori infection in children. Is there specific symptomatology?. 1994 , 39, 1488-92	48

1811	Primary antral gastritis in young American children. Low prevalence of <i>Helicobacter pylori</i> infections. 1994 , 39, 1859-63		15
1810	<i>Helicobacter pylori</i> . 1994 , 24, 501-10		21
1809	Salvage synthesis of purine nucleotides by <i>Helicobacter pylori</i> . 1994 , 77, 674-81		24
1808	De novo synthesis of pyrimidine nucleotides by <i>Helicobacter pylori</i> . 1994 , 77, 1-8		33
1807	Duodenal ulcer treatment: progress from pH to HP. 1994 , 19, 73-80		2
1806	Do clinicians accept the role of <i>Helicobacter pylori</i> in duodenal ulcer disease: a survey of European gastroenterologists and general practitioners. 1994 , 236, 501-5		12
1805	Pyruvate metabolism in <i>Helicobacter pylori</i> . 1994 , 162, 187-92		42
1804	Gastritis: terminology, etiology, and clinicopathological correlations: another biased view. 1994 , 25, 1006-19		53
1803	Salivary antibodies to <i>Helicobacter pylori</i> : screening dyspeptic patients before endoscopy. <i>Lancet, The</i> , 1994 , 344, 511-2	40	81
1802	Effect of ammonium ion on the hydrophobic and barrier properties of the gastric mucus gel layer: implications on the role of ammonium in <i>H. pylori</i> -induced gastritis. 1994 , 9 Suppl 1, S13-9		19
1801	Awakenings to the pathogenicity of urease and the requirement for continuous long term therapy. 1994 , 48, 157-66		22
1800	<i>Helicobacter pylori</i> Eradication: The Rational Treatment for Peptic Ulcer Disease—Chairmen’s Conclusion. 1994 , 29, 59-60		1
1799	Formulary management of antiulcer drugs: clinical considerations. 1994 , 5, 213-26		1
1798	<i>Helicobacter pylori</i> induces inflammation in mouse urinary bladder and pelvis. 1994 , 38, 331-6		4
1797	Immunization of BALB/c mice against <i>Helicobacter felis</i> infection with <i>Helicobacter pylori</i> urease. 1994 , 107, 1002-11		229
1796	Natural gastric infection with <i>Helicobacter pylori</i> in monkeys: a model for spiral bacteria infection in humans. 1994 , 106, 1405-17		141
1795	The GroES homolog of <i>Helicobacter pylori</i> confers protective immunity against mucosal infection in mice. 1995 , 92, 6499-503		233
1794	<i>Helicobacter pylori</i> and gastrointestinal disease. 1995 , 35, 647-54		9

1793	Steryl glycosides: a characteristic feature of the <i>Helicobacter</i> spp.?. 1995 , 177, 5334-7	50
1792	Allelic variation in the <i>Helicobacter pylori</i> flagellin genes <i>flaA</i> and <i>flaB</i> : its consequences for strain typing schemes and population structure. 1995 , 114, 257-66	38
1791	Chapter 16. Therapy of <i>Helicobacter pylori</i> Infections: Current Status and Future Directions. 1995 , 151-158	3
1790	<i>Helicobacter pylori</i> : more than 10 years on and still catchy. 1995 , 10, 465-8	1
1789	Detection of <i>Helicobacter pylori</i> infection in early stage gastric cancer. A comparison between intestinal- and diffuse-type gastric adenocarcinomas. 1995 , 75, 2203-8	44
1788	Presence of <i>Helicobacter pylori</i> in the oral cavity, oesophagus, stomach and faeces of patients with gastritis. 1995 , 14, 234-7	73
1787	Development of a rapid PCR method for identification of <i>Helicobacter pylori</i> in dental plaque and gastric biopsy specimens. 1995 , 14, 780-6	25
1786	Effect of an acidic environment on the susceptibility of <i>Helicobacter pylori</i> to trospectomycin and other antimicrobial agents. 1995 , 14, 353-5	32
1785	Delayed gastric emptying and <i>Helicobacter pylori</i> infection in patients with chronic renal failure. 1995 , 22, 1282-5	16
1784	The relationship between <i>Helicobacter pylori</i> infection and gastric emptying in patients with non-insulin-dependent diabetes mellitus. 1995 , 22, 122-5	14
1783	Cell surface characteristics of <i>Helicobacter pylori</i> . 1995 , 10, 271-80	51
1782	Inhibition of <i>Helicobacter pylori</i> urease by phenyl phosphorodiamidates: mechanism of action. 1995 , 3, 605-10	45
1781	Long-term prospective study of <i>Helicobacter pylori</i> in nonulcer dyspepsia. 1995 , 40, 114-9	123
1780	Mechanism of <i>Helicobacter pylori</i> -associated gastric mucosal injury. 1995 , 40, 1332-9	51
1779	Pathogenic mechanisms. 1995 , 9, 487-506	10
1778	Effects of acid suppression on microbial flora of upper gut. 1995 , 40, 81S-95S	37
1777	<i>Helicobacter pylori</i> : diagnostic dans les annès 90. 1995 , 25, 261-274	
1776	<i>Helicobacter pylori</i> et lésions précancéuses de l'estomac. 1995 , 25, 33-44	4

1775	Influence of <i>Helicobacter pylori</i> colonization on histological grading of chronic gastritis in Korean patients with peptic ulcer. 1995 , 10, 125-9	7
1774	Serum gastrin and mucosal somatostatin in <i>Helicobacter pylori</i> -associated gastritis. 1995 , 30, 1064-8	25
1773	Higher incidence of <i>Gastrospirillum</i> sp. in swine with gastric ulcer of the pars oesophagea. 1995 , 32, 134-9	52
1772	<i>Gastrospirillum hominis</i> -associated chronic active gastritis. 1995 , 15, 429-35	15
1771	Antibacterial treatment of gastric ulcers associated with <i>Helicobacter pylori</i> . 1995 , 332, 139-42	233
1770	Activation of phagocytes by <i>Helicobacter pylori</i> correlates with the clinical presentation of the gastric infection. 1995 , 27, 347-50	13
1769	Lack of association of <i>Helicobacter pylori</i> seroprevalence and gastric cancer in a population with low gastric cancer incidence. 1995 , 30, 958-63	32
1768	Evaluation of antibiotic therapies for eradication of <i>Helicobacter hepaticus</i> . 1995 , 39, 1292-4	35
1767	Prevalence of <i>Helicobacter pylori</i> in patients with gall stones before and after cholecystectomy: a longitudinal study. 1995 , 36, 675-8	7
1766	Activity in the <i>Limulus</i> amoebocyte lysate assay and induction of tumor necrosis factor- β by diverse <i>Helicobacter pylori</i> lipopolysaccharide preparations. 1995 , 2, 455-462	18
1765	Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of <i>Helicobacter pylori</i> . 1995 , 212, 34-7	15
1764	Inhibitory action of lansoprazole and its analogs against <i>Helicobacter pylori</i> : inhibition of growth is not related to inhibition of urease. 1995 , 39, 567-70	41
1763	Effect of <i>Helicobacter pylori</i> eradication on gastric metaplasia of the duodenum. 1995 , 36, 193-7	28
1762	Lymphocytic gastritis and <i>Helicobacter pylori</i> infection in gastric lymphoma. 1995 , 37, 471-6	24
1761	Disorders of the upper gastrointestinal tract. 1995 , 5, 399-412	
1760	Ten year follow up study of lymphocytic gastritis: further evidence on <i>Helicobacter pylori</i> as a cause of lymphocytic gastritis and corpus gastritis. 1995 , 48, 1111-6	38
1759	[<i>Helicobacter pylori</i> in children: many questions, few answers]. 1995 , 2, 299-302	1
1758	Characterisation of glucose transport in <i>Helicobacter pylori</i> . 1995 , 1244, 269-76	24

1757	Genetic evidence for host specificity in the adhesin-encoding genes hxaA of <i>Helicobacter acinonyx</i> , hnaA of <i>H. nemestrinae</i> and hpaA of <i>H. pylori</i> . 1995 , 163, 97-102	9
1756	Treatment of <i>Helicobacter pylori</i> infection. 1995 , 49, 5-10	2
1755	Cytoprotective effects of colloidal bismuth subcitrate in patients with ulcer disease. 1995 , 56, 684-689	
1754	Histamine chloramines have a persistent stimulating effect on histamine H2 receptors and gastric acid secretion. 1995 , 275, 179-84	
1753	Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. 1995 , 108, 320-9	51
1752	Oral immunization with <i>Helicobacter pylori</i> urease B subunit as a treatment against <i>Helicobacter</i> infection in mice. 1995 , 109, 115-21	171
1751	Resolution of <i>Helicobacter pylori</i> -associated gastric lymphoproliferative disease in a child. 1995 , 109, 973-7	84
1750	Pouvoir pathogène de <i>Helicobacter pylori</i> . 1995 , 6, 167-178	2
1749	<i>Helicobacter pylori</i> -associated gastritis. Evolution of histologic changes over 10 years. 1995 , 30, 542-9	37
1748	Fréquence actuelle et implications cliniques de la résistance de <i>Helicobacter pylori</i> aux antibiotiques. 1995 , 6, 216-223	
1747	Vaccination contre les infections à <i>Helicobacter pylori</i> . 1995 , 6, 237-244	
1746	Detection of <i>Helicobacter pylori</i> in gastric biopsy and resection specimens. 1996 , 49, 107-11	73
1745	Infectious gastroenterocolitides in children: an update on emerging pathogens. 1996 , 43, 391-407	5
1744	Upper gastrointestinal tract bleeding. 1996 , 14, 523-45	12
1743	Gastric adenocarcinoma in patients 40 years of age or younger. 1996 , 172, 473-6; discussion 476-7	86
1742	Risk factors of peptic ulcer disease: different impact of <i>Helicobacter pylori</i> in Dutch and Japanese populations?. 1996 , 11, 825-31	10
1741	Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. 1996 , 128, 415-21	47
1740	Small organism, many challenges. 1996 , 27, 1-4	8

1739	Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. 1996 , 27, 35-41	205
1738	Evaluation of initial noninvasive therapy in pediatric patients presenting with suspected ulcer disease. 1996 , 44, 554-61	8
1737	Quantitative noninvasive testing for Helicobacter pylori does not predict gastroduodenal ulcer disease. 1996 , 44, 679-82	15
1736	Transmission of Helicobacter pylori infection via flexible fiberoptic endoscopy. 1996 , 24, 396-401	39
1735	Helicobacter pylori infection and peptic ulcer disease. 1996 , 7, 265-271	1
1734	A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. 1996 , 15, 30-52	4
1733	Helicobacter pylori Infection and Dyspepsia. 1996 , 31, 38-47	105
1732	History of Helicobacter Infection. 1996 , 31, 2-4	9
1731	Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. 1996 , 31, 546-50	213
1730	Helicobacter pylori and Non-ulcer Dyspepsia. 1996 , 31, 19-22	27
1729	Introduction. 1996 , 31, 1-1	
1728	Lipid profile of Helicobacter spp.: presence of cholesteryl glucoside as a characteristic feature. 1996 , 178, 2065-70	87
1727	[Helicobacter pylori gastric infection in symptomatic patients from Sõ Luõ Island, MA: endoscopic, anatomicopathologic and microbiological correlations]. 1996 , 29, 245-50	1
1726	Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. 1996 , 25, 42-6	21
1725	Understanding Ulcers: Medical Knowledge, Social Constructionism, and Helicobacter Pylori. 1996 , 6, 1-39	6
1724	Different expression of Helicobacter pylori gastritis in children: evidence for a specific pediatric disease?. 1996 , 1, 92-7	32
1723	Eosinophils and Mast Cells in Helicobacter Pylori Infected Gastric Mucosa. 1996 , 2, 229-236	3
1722	Blood leukocyte differential in Helicobacter pylori infection. 1996 , 41, 1332-6	29

1721	Bacterial protein toxins and cell vesicle trafficking. 1996 , 52, 1026-32	15
1720	Morphologic conversion of <i>Helicobacter pylori</i> from bacillary to coccoid form. 1996 , 15, 216-9	65
1719	Cytokine gene expression in the gastric mucosa: its role in chronic gastritis. 1996 , 31, 485-90	14
1718	Bacteria closely resembling <i>Helicobacter pylori</i> detected immunohistologically and genetically in resected gallbladder mucosa. 1996 , 31, 294-8	73
1717	Myths and realities in clinical research. 1996 , 11, 887-91	3
1716	Diagnosis of <i>Helicobacter pylori</i> infection. 1996 , 11, 662-9	15
1715	High acid secretion may protect the gastric mucosa from injury caused by ammonia produced by <i>Helicobacter pylori</i> in duodenal ulcer patients. 1996 , 11, 674-80	7
1714	Growth factors and ulcerative gastrointestinal disease. 1996 , 10, 135-49	3
1713	Synthesis of a piperidinomethylthiophene derivative as H ₂ -antagonist with inhibitory activity against <i>Helicobacter pylori</i> . 1996 , 6, 1795-1798	7
1712	Design, synthesis, and pharmacological evaluation of dual histamine H ₂ and gastrin receptor antagonists. 1996 , 6, 1421-1426	12
1711	Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. 1996 , 16, 105-15	199
1710	Cell envelope characteristics of <i>Helicobacter pylori</i> : their role in adherence to mucosal surfaces and virulence. 1996 , 16, 141-55	13
1709	Hydrogen uptake hydrogenase in <i>Helicobacter pylori</i> . 1996 , 141, 71-6	84
1708	Human serum antibody response against iron-repressible outer membrane proteins of <i>Helicobacter pylori</i> . 1996 , 144, 29-32	21
1707	Variability of gene order in different <i>Helicobacter pylori</i> strains contributes to genome diversity. 1996 , 20, 833-42	144
1706	Prospective relations between <i>Helicobacter pylori</i> infection, coronary heart disease, and stroke in middle aged men. 1996 , 75, 568-72	129
1705	Gastric metaplasia and duodenal ulcer disease in children infected by <i>Helicobacter pylori</i> . 1996 , 38, 513-7	30
1704	Expression of CD44 and its variants on gastric epithelial cells of patients with <i>Helicobacter pylori</i> colonisation. 1996 , 38, 507-12	31

1703	Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. 1996 , 76, 305-7	54
1702	Reflux oesophagitis and Helicobacter pylori infection in elderly patients. 1996 , 72, 221-3	35
1701	Mucosal Inflammation and Disease in Helicobacter pylori Infection. 1996 , 31, 86-91	13
1700	Helicobacter colonization of biopsy specimens cultured in vitro is dependent on both mucosal type and bacterial strain. 1996 , 31, 434-41	5
1699	Refinement of, and new applications for, Helicobacter pylori colonization in pig gastric biopsy specimens cultured in vitro. 1996 , 31, 541-5	
1698	Helicobacter pylori infection in young patients with gastric carcinoma. 1996 , 31, 643-7	52
1697	Verification of decreased basal and stimulated serum pepsinogen-I levels is a useful non-invasive method for determining the success of eradication therapy for Helicobacter pylori. 1996 , 31, 103-10	17
1696	Bersicht. 1996 , 20, 70-86	
1695	Review: Molecular mimicry of host structures by lipopolysaccharides of Campylobacter and Helicobacter spp.: implications in pathogenesis. 1996 , 3, 521-531	53
1694	Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori. 1997 , 40, 463-9	32
1693	In vitro evaluation of the role of antibodies against Helicobacter pylori in inhibiting adherence of the organism to gastric cells. 1997 , 40, 731-8	26
1692	Helicobacter pylori infection and growth delay in older children. 1997 , 77, 46-9	98
1691	Colony variation of Helicobacter pylori: pathogenic potential is correlated to cell wall lipid composition. 1997 , 32, 445-54	50
1690	Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. 1997 , 40, 9-13	106
1689	Effects of Helicobacter pylori eradication therapy on hyperammonaemia in patients with liver cirrhosis. 1997 , 40, 726-30	43
1688	Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. 1997 , 41, 865-9	5
1687	Binding of Helicobacter Pylori (HP) to the Human Stomach Mucosa. 1997 , 1, 13-15	
1686	Lewis X biosynthesis in Helicobacter pylori. Molecular cloning of an alpha(1,3)-fucosyltransferase gene. 1997 , 272, 21349-56	104

1685	The G cell. 1997 , 59, 273-98		32
1684	Omeprazole-based dual and triple regimens for <i>Helicobacter pylori</i> eradication in children. 1997 , 100, E3		41
1683	Evaluation of experimental therapeutics in a new mouse model of <i>Helicobacter felis</i> utilizing 16S rRNA polymerase chain reaction for detection. 1997 , 32, 297-302		6
1682	<i>Helicobacter pylori</i> and its role in peptic ulcer disease. 1997 , 97, 141-145		
1681	Susceptibility of <i>Helicobacter pylori</i> isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. 1997 , 41, 7-12		26
1680	Adhesins of <i>Helicobacter pylori</i> (HP). 1997 , 1, 21-23		
1679	<i>Helicobacter pylori</i> survival in gastric mucosa by generation of a pH gradient. 1997 , 73, 1081-8		16
1678	<i>Helicobacter pylori</i> lipopolysaccharide inhibits acid secretion in pylorus-ligated conscious rats. 1997 , 236, 532-7		11
1677	Isolation of a genetic locus associated with metronidazole resistance in <i>Helicobacter pylori</i> . 1997 , 236, 785-8		43
1676	Pathophysiology of <i>Helicobacter pylori</i> -induced gastritis and peptic ulcer disease. 1997 , 102, 200-7		89
1675	A practical approach to the diagnosis and therapy of <i>Helicobacter pylori</i> infection. 1997 , 16, 81-86		2
1674	Molecular biology in diagnosis and epidemiology of <i>Helicobacter pylori</i> : PCR for the detection and AP-PCR for characterization of patient isolates. 1997 , 285, 368-78		4
1673	Immune responses to mucosal infection: the <i>Helicobacter pylori</i> paradigm. 1997 , 148, 91-107		5
1672	Gastro-oesophageal ulcers in man and horse: semblance and dissemblance. 1997 , 29, 410-2		7
1671	Not all <i>Helicobacter pylori</i> strains are created equal: should all be eliminated?. <i>Lancet, The</i> , 1997 , 349, 1020-2	40	141
1670	What role does <i>Helicobacter pylori</i> play in dyspepsia and nonulcer dyspepsia? Arguments for and against <i>H. pylori</i> being associated with dyspeptic symptoms. 1997 , 113, S67-77		80
1669	Significance of <i>Helicobacter Pylori</i> Infection and Gastric Cancer: Implications for Screening. 1997 , 7, 47-64		13
1668	The major sigma factor (RpoD) from <i>Helicobacter pylori</i> and other gram-negative bacteria shows an enhanced rate of divergence. 1997 , 179, 6196-200		12

1667	Macrolide resistance in <i>Helicobacter pylori</i> : rapid detection of point mutations and assays of macrolide binding to ribosomes. 1997 , 41, 2724-8	187
1666	<i>Helicobacter pylori</i> . 1997 , 10, 720-41	1089
1665	<i>Helicobacter pylori</i> infection in an Australian regional city: prevalence and risk factors. 1997 , 167, 310-3	39
1664	Urease and Cytotoxin of <i>Helicobacter Pylori</i> (HP) - Immune Response. 1997 , 1, 17-19	
1663	Structural characterization of the lipid A component of <i>Helicobacter pylori</i> rough- and smooth-form lipopolysaccharides. 1997 , 179, 6453-63	172
1662	Gastric Mucosal Interleukin (IL)-8 Level and IL-8 mRNA Expression in Endoscopic Biopsy Specimens from Patients with Peptic Ulcers. 1997 , 9, 173-177	
1661	37 kBq ¹⁴ C-urea breath test and gastric biopsy analyses of <i>H. pylori</i> infection. 1997 , 67, 31-4	9
1660	Analysis of interleukin-8 secretion induced by <i>Helicobacter pylori</i> from the gastric epithelial cell line MKN45: a mechanism independent of the intensity of cytotoxicity. 1997 , 12, 368-72	16
1659	<i>Helicobacter pylori</i> may cause "reflux" gastritis after gastrectomy. 1997 , 1, 479-86	2
1658	Current Regimen for Peptic Ulcer Treatment. 1997 , 9, 163-166	
1657	Gastric Carcinogenesis and <i>H. pylori</i> Infection. 1997 , 9, 258-266	
1656	A Trial of ¹³ C-urea Breath Test Combined with Endoscopic Phenol Red Test for Detection of <i>Helicobacter pylori</i> Infection. 1997 , 9, 283-289	3
1655	A Rapid Identification Scheme for <i>Helicobacter pylori</i> and Other Species of <i>Helicobacter</i> Based on 23S rRNA Gene Polymorphisms. 1997 , 20, 222-231	24
1654	<i>Helicobacter pylori</i> duodenal colonization in children. 1997 , 86, 356-60	12
1653	Morphological diversity of cultured canine gastric <i>Helicobacter</i> spp. 1997 , 20, 285-97	9
1652	Ultrastructural study of antral G cells in patients with duodenal ulcer: effect of <i>Helicobacter pylori</i> eradication. 1997 , 2, 118-22	2
1651	<i>Helicobacter pylori</i> infection among patients with alcoholic and nonalcoholic cirrhosis. 1997 , 2, 149-51	14
1650	Plasma and gastric mucosal endothelin-1 concentrations in patients with peptic ulcer. 1997 , 42, 314-8	15

1649	Ammonia inhibits proliferation and cell cycle progression at S-phase in human gastric cells. 1997 , 42, 1394-9	12
1648	Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication. 1997 , 42, 1835-40	28
1647	Diagnosis of Helicobacter pylori. 1997 , 64, 815-27	0
1646	Increased frequency of sister chromatid exchange in Helicobacter pylori infection. 1997 , 25, 53-4	1
1645	The evaluation of tissue kallikrein in Helicobacter pylori-associated gastric ulcer disease. 1997 , 36, 263-9	11
1644	Evaluation of immunohistochemistry for the detection of Helicobacter pylori in gastric mucosal biopsies. 1997 , 35, 149-54	55
1643	Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. 1997 , 11, 705-10	28
1642	Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. 1997 , 11, 193-9	35
1641	Helicobacter pylori and gastric cancer. 1997 , 84, 1190-1199	
1640	Helicobacter pylori and primary gastric lymphoma. 1997 , 79, 3-11	113
1639	Delayed gastric emptying by Helicobacter pylori lipopolysaccharide in conscious rats. 1998 , 43, 90-4	45
1638	Comparison of rapid office-based serology with formal laboratory-based ELISA testing for diagnosis of Helicobacter pylori gastritis. 1998 , 43, 103-8	10
1637	Heterogeneity of protein profiles of Helicobacter pylori isolated from individual patients. 1998 , 3, 152-62	4
1636	Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment. 1998 , 13, 511-5	2
1635	Association of Helicobacter pylori infection with gastric adenocarcinoma. 1998 , 89, 597-603	14
1634	Helicobacter pylori: a surprisingly conserved bacterium. 1998 , 16, 216-7	23
1633	Effect of host Lewis and ABO blood group antigen expression on Helicobacter pylori colonisation density and the consequent inflammatory response. 1998 , 20, 257-66	41
1632	Non-random fragmentation of ribosomal RNA in Helicobacter pylori during conversion to the coccoid form. 1998 , 22, 217-24	14

1631	Helicobacter pylori infection and the pathogenesis of duodenal ulceration. 1998 , 859, 96-111	51
1630	Panmictic structure of Helicobacter pylori demonstrated by the comparative study of six genetic markers. 1998 , 161, 231-9	42
1629	Antibacterial tests of bismuth(III)-quinolone (ciprofloxacin, cf) compounds against Helicobacter pylori and some other bacteria. Crystal structure of (cfH ₂) ₂ [Bi ₂ Cl ₁₀].4H ₂ O. 1998 , 71, 53-60	79
1628	Hyperammonemia reduces water immersion--restraint stress gastric ulcers in rats. 1998 , 31, 87-91	10
1627	Does NADH play a central role in energy metabolism in Helicobacter pylori?. 1998 , 23, 412-3	25
1626	Density of Helicobacter pylori infection in patients with peptic ulcer perforation. 1998 , 186, 659-63	45
1625	Research and vision. 1998 , 26 Suppl 1, S1	
1624	Development of a chemiluminescent urease activity assay for Helicobacter pylori infection diagnosis in gastric mucosa biopsies. 1998 , 264, 47-52	5
1623	Unique features of gastric carcinoma in the young: a population-based analysis. 1998 , 83, 25-33	53
1622	Can cancer risks be altered by changing nutritional traditions?. 1998 , 83, 1278-81	8
1621	Helicobacter pylori et lésions malignes gastriques: une piste pour la prévention et le traitement?. 1998 , 28, 187-196	1
1620	Infection par Helicobacter pylori chez l'enfant. 1998 , 28, 213-220	
1619	The role of azithromycin in the treatment of Helicobacter pylori infection - a retrospective report. 1998 , 26, 256-62	5
1618	Relationship between mucosal levels of interleukin 8 and toxinogenicity of Helicobacter pylori. 1998 , 6, 109-17	4
1617	Inhibitory action of YJA20379, a new proton pump inhibitor on Helicobacter pylori growth and urease. 1998 , 21, 6-11	5
1616	Natural competence for DNA transformation in Helicobacter pylori: identification and genetic characterization of the comB locus. 1998 , 28, 1027-38	98
1615	Helicobacter pylori eradication as a surrogate marker for the reduction of duodenal ulcer recurrence. 1998 , 12, 619-33	4
1614	Peptic ulcer: Moynihan's or Marshall's disease?. <i>Lancet, The</i> , 1998 , 352, 645-6	40 14

1613	Ulcers and bacteria I: discovery and acceptance. 1998 , 29, 107-136	39
1612	Ulcers and bacteria II: Instruments, experiments, and social interactions. 1998 , 29, 317-342	12
1611	[The 13C-urea breath test in Helicobacter pylori gastric infection in children]. 1998 , 5, 1359-65	3
1610	Molecular basis of vaccination. 1998 , 19, 1-70	13
1609	Inhibitory effect of somatostatin on Helicobacter pylori proliferation in vitro. 1998 , 115, 1123-30	25
1608	Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. 1998 , 114, 245-55	87
1607	A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). 1998 , 114, 256-61	78
1606	The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. 1998 , 114, 50-7	92
1605	Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins. 1998 , 33, 1249-55	34
1604	Implications of gastric topical bioactive peptides in ammonia-induced acute gastric mucosal lesions in rats. 1998 , 33, 386-93	8
1603	Helicobacter pylori--a conundrum of genetic diversity. 1998 , 144 (Pt 11), 2925-2939	63
1602	Antibody to a Helicobacter pylori species specific antigen in patients with adenocarcinoma of the stomach. 1998 , 244, 360-3	14
1601	Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. 1998 , 345, 193-8	31
1600	Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. 1998 , 10, 285-9	3
1599	Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?. 1998 , 43 Suppl 1, S14-20	18
1598	High seroprevalence of Helicobacter pylori in active bronchiectasis. 1998 , 158, 1047-51	67
1597	Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. 1998 , 93, 1271-6	101
1596	Risk factors for infection with Helicobacter pylori--a study of children in rural Ethiopia. 1998 , 30, 371-6	25

1595	The application of infrared spectroscopy to breath CO ₂ isotope ratio measurements and the risk of spurious results. 1998 , 43, 1225-39	16
1594	Managing dyspepsia: what do we know and what do we need to know?. 1998 , 93, 920-4	20
1593	The origin of 20th century discoveries transforming clinical gastroenterology. 1998 , 93, 862-71	8
1592	Barrett's esophagus and the presence of <i>Helicobacter pylori</i> . 1998 , 93, 542-6	34
1591	Semiquantitative evaluation for diagnosis of <i>Helicobacter pylori</i> infection in relation to histological changes. 1998 , 93, 26-9	23
1590	Triple versus dual therapy for eradicating <i>Helicobacter pylori</i> and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 , 93, 584-90	50
1589	Capturing the unexpected benefits of medical research. 1998 , 339, 693-8	84
1588	Inflammatory large bowel disease in immunodeficient rats naturally and experimentally infected with <i>Helicobacter bilis</i> . 1998 , 35, 202-8	58
1587	Conserved residues and motifs in the NixA protein of <i>Helicobacter pylori</i> are critical for the high affinity transport of nickel ions. 1998 , 273, 235-41	67
1586	The effect of class II major histocompatibility complex expression on adherence of <i>Helicobacter pylori</i> and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage. 1998 , 187, 1659-69	172
1585	Gastric diseases related to <i>Helicobacter pylori</i> and Epstein-Barr virus infection. 1998 , 42, 415-21	6
1584	Impact of <i>Helicobacter hepaticus</i> infection in B6C3F1 mice from twelve National Toxicology Program two-year carcinogenesis studies. 1998 , 26, 602-11	84
1583	<i>Helicobacter pylori</i> and gastric diseases. 1998 , 316, 1507-10	220
1582	Mouse model of gastric infection with cytotoxin-expressing strain of <i>Helicobacter pylori</i> in studying of pathogenesis of chronic gastric ulcer. 1998 , 13, S178-S184	
1581	Gastric adaptation to aspirin and <i>Helicobacter pylori</i> infection in man. 1998 , 13, S193-S198	
1580	Antimicrobial activity of novel furanonaphthoquinone analogs. 1998 , 42, 700-2	30
1579	Australian medical research: more resources and the right balance. 1998 , 168, 535-536	4
1578	Epithelial attachment alters the outcome of <i>Helicobacter pylori</i> infection. 1998 , 95, 3925-30	250

1577	In vitro and in vivo activities of tea catechins against <i>Helicobacter pylori</i> . 1999 , 43, 1788-91	166
1576	Long-term follow-up study of serum immunoglobulin G and immunoglobulin A antibodies after <i>Helicobacter pylori</i> eradication. 1999 , 104, e22	29
1575	The morphological transition of <i>Helicobacter pylori</i> cells from spiral to coccoid is preceded by a substantial modification of the cell wall. 1999 , 181, 3710-5	99
1574	Comparison of five PCR methods for detection of <i>Helicobacter pylori</i> DNA in gastric tissues. 1999 , 37, 772-4	150
1573	Molecular epidemiology, pathogenesis and prevention of gastric cancer. 1999 , 20, 2195-208	153
1572	Diffusion of knowledge of <i>Helicobacter pylori</i> and its practical application by Nordic clinicians. 1999 , 34, 974-80	6
1571	<i>Helicobacter pylori</i> infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. 1999 , 20, 669-76	114
1570	Identification of the minimal intracellular vacuolating domain of the <i>Helicobacter pylori</i> vacuolating toxin. 1999 , 274, 9277-82	96
1569	ACP. Best practice no 154. February 1999. <i>Helicobacter pylori</i> . 1999 , 52, 338-44	10
1568	Bacteriophages in the evolution of pathogen-host interactions. 1999 , 96, 9452-4	82
1567	A future for epidemiology?. 1999 , 20, 15-33	85
1566	Lack of association of <i>Helicobacter pylori</i> infection with gastric hypersensitivity or delayed gastric emptying in functional dyspepsia. 1999 , 94, 3165-9	30
1565	Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. 1999 , 94, 1209-13	8
1564	Gastric <i>Helicobacter</i> Infection in Dogs. 1999 , 29, 397-414	7
1563	An epizootic of lymphoplasmacytic gastritis attributed to <i>Helicobacter pylori</i> infection in cynomolgus monkeys (<i>Macaca fascicularis</i>). 1999 , 36, 1-13	40
1562	Microanalysis of a selective potent anti- <i>Helicobacter pylori</i> compound in a Brazilian medicinal plant, <i>Myroxylon peruiferum</i> and the activity of analogues. 1999 , 9, 1109-12	59
1561	Principe du traitement de l'infection par <i>Helicobacter pylori</i> et rôle du biologiste dans sa surveillance. 1999 , 1999, 55-62	
1560	Failure of a 1-day high-dose quadruple therapy for cure of <i>Helicobacter pylori</i> infection. 1999 , 13, 173-7	8

1559	Mouse model of <i>Helicobacter pylori</i> infection: studies of gastric function and ulcer healing. 1999 , 13, 333-46	40
1558	The effect of <i>Helicobacter pylori</i> eradication on intragastric pH during dosing with lansoprazole or ranitidine. 1999 , 13, 731-40	45
1557	Personal review: <i>Helicobacter pylori</i> , NSAIDs and cognitive dissonance. 1999 , 13, 695-702	29
1556	A systematic review of <i>Helicobacter pylori</i> eradication therapy--the impact of antimicrobial resistance on eradication rates. 1999 , 13, 1047-55	241
1555	Injurious effect of <i>Helicobacter pylori</i> culture fluid to gastroduodenal mucosa, and its detoxification by sucralfate in the rat. 1999 , 13, 1363-71	7
1554	<i>Helicobacter pylori</i> infection is not a correlate of plasma fibrinogen in the Australian population. 1999 , 21, 41-3	5
1553	Mucosal macrophage inflammatory protein-1alpha activity in <i>Helicobacter pylori</i> infection. 1999 , 14, 20-6	23
1552	<i>Helicobacter pylori</i> and extra-digestive diseases. 1999 , 14, 844-50	32
1551	Analysis of <i>Helicobacter pylori</i> binding site on HEP-2 cells and three cell lines from human gastric carcinoma. 1999 , 13, 555-61	10
1550	Prevalence of <i>Helicobacter pylori</i> infection in the Vallès Occidental, Catalonia. 1999 , 5, 704-706	5
1549	Phenotypic changes of <i>Helicobacter pylori</i> components during an experimental infection in mice. 1999 , 24, 27-33	15
1548	Lack of a relationship between Lewis antigen expression and <i>cagA</i> , <i>CagA</i> , <i>vacA</i> and <i>VacA</i> status of Irish <i>Helicobacter pylori</i> isolates. 1999 , 24, 79-90	35
1547	<i>Helicobacter pylori</i> detection in human biopsies: a competitive PCR assay with internal control reveals false results. 1999 , 24, 201-8	13
1546	Serological response to <i>Helicobacter pylori</i> recombinant antigens in Chilean infected patients with duodenal ulcer, non-ulcer dyspepsia and gastric cancer. 1999 , 107, 1069-1078	13
1545	Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and <i>H. pylori</i> infection. 1999 , 44, 1823-36	4
1544	Practice patterns for peptic ulcer disease: are family physicians testing for <i>H. pylori</i> ?. 1999 , 4, 243-8	4
1543	Attenuation of hydrophobic phospholipid barrier is an early event in <i>Helicobacter felis</i> -induced gastritis in mice. 1999 , 44, 108-15	39
1542	Apoptosis in <i>Helicobacter pylori</i> -associated gastric and duodenal ulcer disease is mediated via the Fas antigen pathway. 1999 , 44, 465-78	54

1541	Smoking and male gender rather than CagA protein are associated with increased risk for duodenal ulcer in <i>Helicobacter pylori</i> -infected patients in Taiwan. 1999 , 44, 2076-80	7
1540	Reactions from rat gastric mucosa during one year of <i>Helicobacter pylori</i> infection. 1999 , 44, 116-24	40
1539	The search for unrecognized pathogens. 1999 , 284, 1308-10	180
1538	Inhibition of growth and adhesion of <i>Helicobacter pylori</i> using egg yolk antibodies. 1999 , 4, 219-223	3
1537	Prevalence of <i>Helicobacter pylori</i> infection in Japan: Relation to educational levels and hygienic conditions. 1999 , 3, 202-6	4
1536	Therapy for <i>H. pylori</i> infection. 1999 , 1, 518-23	
1535	Pathology, diagnosis and epidemiology of the rodent <i>Helicobacter</i> infection. 1999 , 22, 41-61	26
1534	The tricarboxylic acid cycle of <i>Helicobacter pylori</i> . 1999 , 260, 258-67	67
1533	Two- to four-year histological follow-up of gastric mucosa after <i>Helicobacter pylori</i> eradication. 1999 , 188, 24-9	57
1532	Epidemiology of <i>Helicobacter pylori</i> Infection. 1999 , 6, 9-18	3
1531	<i>Helicobacter pylori</i> infection potentiates the inhibition of gastric acid secretion by omeprazole. 1999 , 44, 468-75	111
1530	Decision analysis of histamine H ₂ -receptor antagonist maintenance therapy versus <i>Helicobacter pylori</i> eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer. 1999 , 16, 355-65	11
1529	<i>Helicobacter pylori</i> infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. 1999 , 94, 1834-40	177
1528	Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. 1999 , 2, 289-294	60
1527	<i>Helicobacter pylori</i> attaches to NeuAc alpha 2,3Gal beta 1,4 glycoconjugates produced in the stomach of transgenic mice lacking parietal cells. 1999 , 3, 263-74	72
1526	Microbiological and histological study of the gastrointestinal tract of germ-free mice infected with <i>Helicobacter troglontum</i> . 1999 , 150, 205-12	10
1525	Activation of <i>Helicobacter pylori</i> ureA promoter by a hybrid <i>Escherichia coli</i> - <i>H. pylori</i> rpoD gene in <i>E. coli</i> . 1999 , 239, 351-9	25
1524	Induction of mucosal and systemic immune response by oral immunization with <i>H. pylori</i> lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles. 1999 , 17, 607-16	42

1523	Association of <i>Rickettsia helvetica</i> with chronic perimyocarditis in sudden cardiac death. <i>Lancet, The</i> , 1999 , 354, 1169-73	40	198
1522	John Lykoudis: an unappreciated discoverer of the cause and treatment of peptic ulcer disease. <i>Lancet, The</i> , 1999 , 354, 1634-5	40	12
1521	<i>Helicobacter pylori</i> , hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. 1999 , 30, 260-4		33
1520	Effect of intragastric ammonia on gastrin-, somatostatin- and somatostatin receptor subtype 2 positive-cells in rat antral mucosa. 1999 , 64, 2497-504		2
1519	Oral immunization with urease and <i>Escherichia coli</i> heat-labile enterotoxin is safe and immunogenic in <i>Helicobacter pylori</i> -infected adults. 1999 , 116, 804-12		256
1518	Host specificity of <i>Helicobacter pylori</i> strains and host responses in experimentally challenged nonhuman primates. 1999 , 116, 90-6		96
1517	Treatment of <i>Helicobacter pylori</i> infection in rhesus monkeys using a novel antiadhesion compound. 1999 , 117, 1316-25		129
1516	Isolation of a <i>Helicobacter pylori</i> protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach. 1999 , 117, 82-8		38
1515	Comparison of invasive and noninvasive tests for detecting <i>Helicobacter pylori</i> infection in bleeding peptic ulcers. 1999 , 49, 302-6		84
1514	The induction of apoptosis by bacterial pathogens. 1999 , 53, 155-87		328
1513	Antibiotic resistance problems with <i>Helicobacter pylori</i> . 1999 , 12, 19-26		99
1512	Stable isotopes in routine clinical use. 1999 , 35, 143-5		
1511	<i>Helicobacter pylori</i> -induced chronic active gastritis, intestinal metaplasia, and gastric ulcer in Mongolian gerbils. 1999 , 154, 951-60		134
1510	<i>Helicobacter pylori</i> virulence and genetic geography. 1999 , 284, 1328-33		887
1509	HELICOBACTER. 1999 , 1047-1052		
1508	<i>Helicobacter pylori</i> infection in children: update. 2000 , 12, 460-2		5
1507	The relationship between persistent secretion of RANTES and residual infiltration of eosinophils and memory T lymphocytes after <i>Helicobacter pylori</i> eradication. 2000 , 192, 243-50		34
1506	Growth of <i>Helicobacter pylori</i> in various liquid and plating media. 2000 , 30, 192-6		22

1505	High incidence of reflux oesophagitis after eradication therapy for <i>Helicobacter pylori</i> : impacts of hiatal hernia and corpus gastritis. 2000 , 14, 729-35	129
1504	Is autonomic dysfunction a necessary condition for chronic peptic ulcer formation?. 2000 , 14 Suppl 1, 82-6	8
1503	Pharmacokinetics of clarithromycin in <i>Helicobacter pylori</i> eradication therapy in patients with liver cirrhosis. 2000 , 14 Suppl 1, 216-22	4
1502	CXC chemokines Gro(alpha)/IL-8 and IP-10/MIG in <i>Helicobacter pylori</i> gastritis. 2000 , 122, 192-9	74
1501	Overcoming the restriction barrier to plasmid transformation of <i>Helicobacter pylori</i> . 2000 , 37, 1066-74	92
1500	Plaunotol suppresses interleukin-8 secretion induced by <i>Helicobacter pylori</i> : therapeutic effect of plaunotol on <i>H. pylori</i> infection. 2000 , 15, 374-80	5
1499	Functional dyspepsia and <i>Helicobacter pylori</i> infection: a recent consensus up to 1999. 2000 , 15 Suppl, D60-5	5
1498	<i>Helicobacter pylori</i> and dyspepsia: still an unresolved controversy?. 2000 , 15, 470-2	
1497	Elevation of TFF1 gene expression during healing of gastric ulcer at non-ulcerated sites in the stomach: semiquantification using the single tube method of polymerase chain reaction. 2000 , 15, 604-9	15
1496	A short-term eradication therapy for <i>Helicobacter pylori</i> acute gastritis. 2000 , 15, 1377-81	14
1495	Expression of human telomerase catalytic subunit gene in cancerous and precancerous gastric conditions. 2000 , 15, 744-51	22
1494	Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of <i>Helicobacter pylori</i> . 2000 , 15, 1113-9	14
1493	The oral cavity as a reservoir of bacterial pathogens for focal infections. 2000 , 2, 897-906	157
1492	The clinician-scientist in the 21st century. 2000 , 30, 68-70	6
1491	The relationship between O-chain expression and colonisation ability of <i>Helicobacter pylori</i> in a mouse model. 2000 , 29, 263-70	33
1490	Characteristics of <i>Helicobacter pylori</i> natural transformation. 2000 , 186, 275-80	59
1489	A comprehensive review of the natural history of <i>Helicobacter pylori</i> infection in children. 2000 , 31, 431-69	177
1488	Development of a new method for the determination of immune responses in the human stomach. 2000 , 234, 51-9	20

1487	Relation of <i>Helicobacter pylori</i> infection and angiographically demonstrated coronary artery disease. 2000 , 45, 1227-32	23
1486	Detection of <i>Helicobacter pylori</i> DNA in human biliary tree and its association with hepatolithiasis. 2000 , 45, 1405-12	42
1485	Pathogenesis of duodenal ulcer disease: the rest of the story. 2000 , 14, 97-107	18
1484	Analysis of <i>iceA1</i> transcription in <i>Helicobacter pylori</i> . 2000 , 5, 1-12	25
1483	Distinction of gastric <i>Helicobacter</i> spp. in humans and domestic pets by scanning electron microscopy. 2000 , 5, 232-9	11
1482	Egg Yolk antibody and its application. 2000 , 5, 79-83	4
1481	<i>Helicobacter Pylori</i> and Precancerous Gastric Lesions. 2000 , 12, 221-224	3
1480	Demographic and endoscopic characteristics of patients with <i>Helicobacter pylori</i> positive and negative peptic ulcer disease. 2000 , 173, 515-9	36
1479	Salivary agglutinin, which binds <i>Streptococcus mutans</i> and <i>Helicobacter pylori</i> , is the lung scavenger receptor cysteine-rich protein gp-340. 2000 , 275, 39860-6	175
1478	The human gastric colonizer <i>Helicobacter pylori</i> : a challenge for host-parasite glycobiology. 2000 , 10, 761-71	32
1477	Development of a selective medium for isolation of <i>Helicobacter pylori</i> from cattle and beef samples. 2000 , 66, 723-7	41
1476	Increased prevalence of <i>Helicobacter pylori</i> infection in patients with celiac disease. 2000 , 95, 3682-3	26
1475	The description of outcomes in Medicare patients hospitalized with peptic ulcer disease. 2000 , 95, 264-70	3
1474	Tumor necrosis factor alpha and interleukin 1beta up-regulate gastric mucosal Fas antigen expression in <i>Helicobacter pylori</i> infection. 2000 , 68, 1189-95	66
1473	Two distinct antigenic types of the polysaccharide chains of <i>Helicobacter pylori</i> lipopolysaccharides characterized by reactivity with sera from humans with natural infection. 2000 , 68, 151-9	31
1472	Anti-CagA immunoglobulin G responses correlate with interleukin-8 induction in human gastric mucosal biopsy culture. 2000 , 7, 803-9	18
1471	Digestive System 1. 2000 , 312-431	1
1470	A novel 3-methyladenine DNA glycosylase from <i>Helicobacter pylori</i> defines a new class within the endonuclease III family of base excision repair glycosylases. 2000 , 275, 20077-83	37

1469	Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. 2000 , 191, 593-602	407
1468	In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. 2000 , 44, 458-61	39
1467	Distribution of open reading frames of plasticity region of strain J99 in Helicobacter pylori strains isolated from gastric carcinoma and gastritis patients in Costa Rica. 2000 , 68, 6240-9	74
1466	Membrane topology of the NixA nickel transporter of Helicobacter pylori: two nickel transport-specific motifs within transmembrane helices II and III. 2000 , 182, 1722-30	53
1465	Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. 2000 , 277, 159-63	45
1464	A 26 kDa protein of helicobacter pylori shows alkyl hydroperoxide reductase (AhpC) activity and the mono-cistronic transcription of the gene is affected by pH. 2000 , 29, 257-66	32
1463	John Lykoudis and peptic ulcer disease. <i>Lancet, The</i> , 2000 , 355, 150	40
1462	Physics and chemistry Nobel Laureates and medicine. <i>Lancet, The</i> , 2000 , 356, 1360	40 1
1461	Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. 2000 , 1474, 107-13	33
1460	IgE-containing cells in gastric mucosa with and without Helicobacter pylori infection. 2000 , 196, 831-4	10
1459	[Is atherosclerosis an infectious disease]. 2000 , 21, 499-501	
1458	Helicobacter pylori sero-prevalence in asthma. 2000 , 94, 756-9	52
1457	Bacterial dormancy and culturability: the role of autocrine growth factors. 2000 , 3, 238-43	106
1456	N alpha-methylhistamine: association with Helicobacter pylori infection in humans and effects on gastric acid secretion. 2000 , 301, 181-92	9
1455	Patents and intellectual property: a salvation for patient-oriented research?. <i>Lancet, The</i> , 2000 , 356, 849-50	10
1454	Accurate diagnosis helicobacter pylori infection by stool antigen test and 6 other currently available tests in children. 2000 , 136, 823-827	80
1453	Membrane topology of VacA cytotoxin from H. pylori. 2000 , 481, 96-100	12
1452	Infecçã por helicobacter pylori. 2000 , 8, 69-76	

1451	The disease spectrum of <i>Helicobacter pylori</i> : the immunopathogenesis of gastroduodenal ulcer and gastric cancer. 2000 , 54, 615-40	453
1450	The nonsteroidal anti-inflammatory drugs controversy. 2000 , 29, 791-805	10
1449	Possible clinical importance of the transformation of <i>Helicobacter pylori</i> into coccoid forms. 2000 , 35, 897-903	16
1448	Clarithromycin for <i>Helicobacter pylori</i> infection. 2000 , 1, 507-14	20
1447	Apoptosis of human gastric epithelial cells via caspase-3 activation in response to <i>Helicobacter pylori</i> infection: possible involvement of neutrophils through tumor necrosis factor alpha and soluble Fas ligands. 2000 , 35, 40-8	47
1446	Different patterns of <i>Helicobacter pylori</i> adherence to gastric mucosa cells in children and adults. An ultrastructural study. 2000 , 35, 1033-40	15
1445	[Effect of <i>Helicobacter pylori</i> eradication on histological lesions of gastric mucosa. An 18-month follow-up study]. 2000 , 200, 480-4	7
1444	Fifty landmark discoveries in gastroenterology during the past 50 years. A brief history of modern gastroenterology at the millennium: Part I. Gastrointestinal procedures and upper gastrointestinal disorders. 2000 , 29, 223-63, viii	7
1443	[Benefits of treatment to eradicate <i>Helicobacter pylori</i> infection in patients with ulcer at a primary care center]. 2000 , 25, 377-82	1
1442	Gastric pathology associated with <i>Helicobacter pylori</i> . 2000 , 29, 705-51	66
1441	Potential of the action of metronidazole on <i>Helicobacter pylori</i> by omeprazole and bismuth subcitrate. 2000 , 14, 231-4	10
1440	<i>Helicobacter pylori</i> seroprevalence in hepatitis C virus positive patients with cirrhosis. 2000 , 33, 648-650	35
1439	Antimicrobial activity and postantibiotic effect of flurithromycin against <i>Helicobacter pylori</i> strains. 2001 , 17, 151-4	11
1438	<i>Helicobacter pylori</i> is not a risk factor for hepatic encephalopathy. 2001 , 33, 414-9	15
1437	Diagnosis of <i>Helicobacter pylori</i> infection: noninvasive methods compared to invasive methods and evaluation of two new tests. 2001 , 96, 353-8	118
1436	Differential virulence-gene mRNA expression in coccoid forms of <i>Helicobacter pylori</i> . 2001 , 285, 530-6	19
1435	Marked reduction of <i>Helicobacter pylori</i> -induced gastritis by urease inhibitors, acetohydroxamic acid and flurofamide, in Mongolian gerbils. 2001 , 285, 728-33	25
1434	Identification of genes associated with natural competence in <i>Helicobacter pylori</i> by transposon shuttle random mutagenesis. 2001 , 288, 961-8	22

1433	Helicobacter felis does not stimulate human neutrophil oxidative burst in contrast to 'Gastrospirillum hominis' and Helicobacter pylori. 2001 , 30, 187-95	5
1432	Identification of a putative chromosomal replication origin from Helicobacter pylori and its interaction with the initiator protein DnaA. 2001 , 29, 2251-9	44
1431	Helicobacter pylori and the gastroduodenal mucosa. 2001 , 130, 13-6	9
1430	Experimental Helicobacter pylori infection of rhesus macaques (Macaca mulatta). 2001 , 291, 33-43	5
1429	[How to determine the diagnosis of Helicobacter pylori infection in the elderly?]. 2001 , 22, 339-47	5
1428	New immunoassay for the detection of Helicobacter pylori infection compared with urease test, 13C breath test and histology: validation in the primary care setting. 2001 , 46, 235-40	10
1427	Evidence for infection with Helicobacter pylori in patients with acute myocardial infarction. 2001 , 313, 87-94	10
1426	Gastrointestinal infections. 2001 , 15, 1073-108	20
1425	[Helicobacter pylori infections: antigen detection in stool samples]. 2001 , 19, 49-52	7
1424	Peptic ulcer disease. 2001 , 28, 487-503, v	7
1423	The emerging nosocomial pathogens Cryptosporidium, Escherichia coli O157:H7, Helicobacter pylori, and hepatitis C: epidemiology, environmental survival, efficacy of disinfection, and control measures. 2001 , 22, 306-15	43
1422	¿Ha disminuido la incidencia de la úlcera péptica perforada en la última década?. 2001 , 69, 118-120	2
1421	Recent developments in Helicobacter pylori vaccination. 2001 , 15-21	9
1420	Vaccination against Helicobacter pylori--an old companion of man. 2001 , 1, 795-802	5
1419	Histochemical Tracing of Bismuth in Helicobacter pylori after In Vitro Exposure to Bismuth Citrate. 2001 , 36, 144-148	9
1418	Association Between the IgG Subclass Response, Inflammation and Disease Status in Helicobacter pylori Infection. 2001 , 36, 149-155	10
1417	Determination of Helicobacter pylori virulence by simple gene analysis of the cag pathogenicity island. 2001 , 8, 181-6	79
1416	Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. 2001 , 11, 1R-10R	209

1415	Helicobacter pylori: ulcers and more: the beginning of an era. 2001 , 131, 2789S-2793S	52
1414	What is the best method to diagnose Helicobacter infection in bleeding peptic ulcers?: a prospective trial. 2001 , 16, 147-52	17
1413	Helicobacter pylori prevalences and risk factors among school beginners in a German urban center and its rural county. 2001 , 109, 573-7	48
1412	Liver penetration by a duodenal ulcer in a young woman. 2001 , 33, 56-60	9
1411	Gastro-oesophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis. 2001 , 13, 535-9	21
1410	Surgical Management of Peptic Ulcer Disease in the Helicobacter Era—Management of Bleeding Peptic Ulcer. 2001 , 11, 2-8	5
1409	Recent advances in gastrointestinal pathophysiology: role of heat shock proteins in mucosal defense and ulcer healing. 2001 , 24, 1-9	82
1408	Characterization and application of a gastric surface mucous cell line GSM06 established from temperature-sensitive simian virus 40 large T-antigen transgenic mice. 2001 , 85, 117-23	7
1407	Allelic exchange mutagenesis of rpoN encoding RNA-polymerase sigma54 subunit in Helicobacter pylori. 2001 , 7, 148-55	8
1406	Is there a role for psychology in ulcer disease?. 2001 , 36, 75-83	10
1405	Review article: pre-neoplastic states of the gastric mucosa—a practical approach for the perplexed clinician. 2001 , 15 Suppl 1, 43-50	18
1404	Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. 2001 , 15, 1187-91	17
1403	pathogenesis of Helicobacter pylori-induced gastric inflammation. 2001 , 15, 1271-90	115
1402	Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. 2001 , 15, 1875-82	39
1401	Helicobacter pylori and tonsillectomy. 2001 , 26, 505-9	38
1400	RECENT PROGRESS IN ENDOSCOPY-BASED DIAGNOSIS OF HELICOBACTER PYLORI INFECTION. 2001 , 13, 3-6	4
1399	Is there another chapter in the Helicobacter pylori/peptic ulcer disease story?. 2001 , 31, 181-3	3
1398	Helicobacter pylori vaccines and mechanisms of effective immunity: is mucus the key?. 2001 , 79, 67-73	13

1397	Helicobacter pylori alters n-6 fatty acid metabolism and prostaglandin E2 synthesis in rat gastric mucosal cells. 2001 , 16, 1197-205	8
1396	Animal models of Campylobacter jejuni colonization and disease and the lessons to be learned from similar Helicobacter pylori models. 2001 , 90, 57S-67S	61
1395	Helicobacter pylori: a clinical update. 2001 , 90, 126S-33S	3
1394	Antibiotic resistance of Helicobacter pylori. 2001 , 90, 134S-44S	14
1393	The AmiE aliphatic amidase and AmiF formamidase of Helicobacter pylori: natural evolution of two enzyme paralogues. 2001 , 40, 596-609	62
1392	Laboratory tests for the evaluation of Helicobacter pylori infections. 2001 , 15, 301-7	16
1391	Lack of gastritis and of an adaptive immune response in interferon regulatory factor-1-deficient mice infected with Helicobacter pylori. 2001 , 31, 396-402	43
1390	Impaired development of HIV-1 gp160-specific CD8(+) cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection. 2001 , 31, 516-26	2
1389	Paradoxical role of Helicobacter pylori infection: protective effect against ethanol-induced gastric mucosal injury in Mongolian gerbils. 2001 , 46, 2433-9	6
1388	Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998. 2001 , 46, 2716-23	31
1387	The effect of Helicobacter pylori eradication on gastric juice and blood ammonia concentrations and on visual evoked potentials in cirrhotics. 2001 , 6, 325-30	15
1386	A new rapid test for detecting anti-Helicobacter pylori antibody excreted into urine. 2000 , 5, 160-4	23
1385	Probing 23S ribosomal RNA cleavage sites in coccoid Helicobacter pylori. 2001 , 6, 100-9	5
1384	Interactions among gastric somatostatin, interleukin-8 and mucosal inflammation in Helicobacter pylori-positive peptic ulcer patients. 2001 , 6, 136-45	19
1383	Immune response to a 26-kDa protein, alkyl hydroperoxide reductase, in Helicobacter pylori-infected Mongolian gerbil model. 2001 , 6, 274-82	14
1382	T cell-mediated cytotoxicity via Fas/Fas ligand signaling in Helicobacter pylori-infected gastric corpus. 2001 , 6, 283-93	14
1381	Seroprevalence of Helicobacter pylori infection in Siberia. 2001 , 6, 331-6	21
1380	Purification and characterization of protein methylase II from Helicobacter pylori. 2001 , 195, 53-8	

- 1379 Rapid molecular identification and subtyping of *Helicobacter pylori* by pyrosequencing of the 16S rDNA variable V1 and V3 regions. **2001**, 199, 103-7 65
- 1378 Formulations of single or multiple *H. pylori* antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. **2001**, 30, 157-65 19
- 1377 Gut-wrenching bugs. **2001**, 8, 487
- 1376 Maternal transmission of *Helicobacter pylori* in the perinatal period. **2001**, 27, 225-30 27
- 1375 Serological Immunoglobulin G antibody titers to *Helicobacter pylori* in Japanese Brazilian and Non-Japanese Brazilian gastric cancer patients and controls in São Paulo. **2001**, 92, 829-35 14
- 1374 Survival of *Helicobacter pylori* in ready-to-eat foods at 4 degrees C. **2001**, 63, 281-6 37
- 1373 *Helicobacter pylori* lipopolysaccharide provokes iNOS-mediated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. **2001**, 95, 257-9 16
- 1372 Acid-induced gene expression in *Helicobacter pylori*: study in genomic scale by microarray. **2001**, 69, 1679-86 114
- 1371 Antigastric autoantibodies in ferrets naturally infected with *Helicobacter mustelae*. **2001**, 69, 2708-13 21
- 1370 Apoptotic signaling pathway activated by *Helicobacter pylori* infection and increase of apoptosis-inducing activity under serum-starved conditions. **2001**, 69, 3181-9 45
- 1369 Urine-based enzyme-linked immunosorbent assay for the detection of *Helicobacter pylori* infection in children. **2001**, 107, E87 23
- 1368 Effects of *Helicobacter pylori* infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. **2001**, 48, 765-73 117
- 1367 One more dysplasia. **2001**, 13, 1411-4 3
- 1366 Histological and immunohistochemical detection of different *Helicobacter* species in the gastric mucosa of cats. **2001**, 13, 3-12 28
- 1365 *Helicobacter pylori* activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells. **2001**, 69, 3965-71 66
- 1364 Identification of novel *Helicobacter* species in pig stomachs by PCR and partial sequencing. **2001**, 39, 3311-5 35
- 1363 Gastric leptin and *Helicobacter pylori* infection. **2001**, 49, 324-9 99
- 1362 Strain-specific genes of *Helicobacter pylori*: distribution, function and dynamics. **2001**, 29, 4395-404 35

1361	History of Surgery of the Gastrointestinal Tract. 2001 , 399-412	1
1360	H. pylori Pathogenesis. 2001 , 509-558	31
1359	Helicobacter pylori resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescence-activated cell sorting. 2001 , 69, 2604-11	45
1358	gamma-Glutamyltransferase is a Helicobacter pylori virulence factor but is not essential for colonization. 2001 , 69, 4168-73	80
1357	Helicobacter typhlonius sp. nov., a Novel Murine Urease-Negative Helicobacter Species. 2001 , 39, 3920-6	52
1356	"Helicobacter rappini" isolates from 2 homosexual men. 2001 , 33, e8-11	15
1355	Reducing community dyspepsia drug costs: a controlled trial. 2001 , 49, 495-501	18
1354	Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. 2001 , 14, 59-97	283
1353	Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production. 2001 , 69, 6597-603	45
1352	Does history repeat itself in medicine?. 2001 , 77, 263-4	1
1351	A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers. 2001 , 29, 147-53	19
1350	The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. 2001 , 49, 341-6	47
1349	Role of Helicobacter pylori cag region genes in colonization and gastritis in two animal models. 2001 , 69, 2902-8	66
1348	Composition and gene expression of the cag pathogenicity island in Helicobacter pylori strains isolated from gastric carcinoma and gastritis patients in Costa Rica. 2001 , 69, 1902-8	46
1347	Vacuolating cytotoxin of Helicobacter pylori induces apoptosis in the human gastric epithelial cell line AGS. 2001 , 69, 5080-7	140
1346	Diethyl phthalate, a chemotactic factor secreted by Helicobacter pylori. 2001 , 276, 48847-53	18
1345	Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. 2001 , 49, 18-22	83
1344	Expression of human beta-defensin 2 (hBD-2) in Helicobacter pylori induced gastritis: antibacterial effect of hBD-2 against Helicobacter pylori. 2001 , 49, 481-7	79

1343	Historical and professional perspectives of complementary and alternative medicine with a particular emphasis on rediscovering and embracing complementary and alternative medicine in contemporary Western society. 2001 , 7 Suppl 1, S11-8	7
1342	Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. 2002 , 51, 634-40	62
1341	Rapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice. 2002 , 99, 8354-9	31
1340	Role of tumor necrosis factor alpha in Helicobacter pylori gastritis in tumor necrosis factor receptor 1-deficient mice. 2002 , 70, 3149-55	32
1339	A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. 2002 , 97, 3045-51	27
1338	Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. 2002 , 70, 4621-7	48
1337	In vivo behavior of a Helicobacter pylori SS1 nixA mutant with reduced urease activity. 2002 , 70, 685-91	60
1336	Fluorescence resonance energy transfer microscopy of the Helicobacter pylori vacuolating cytotoxin within mammalian cells. 2002 , 70, 3824-32	26
1335	Helicobacter pylori functional genomics. 2002 , 33, 291-319	4
1334	No radiation protection reasons for restrictions on 14C urea breath tests in children. 2002 , 75, 982-6	23
1333	Conserved low-affinity nickel-binding amino acids are essential for the function of the nickel permease NixA of Helicobacter pylori. 2002 , 184, 1438-43	28
1332	Gastritis and hypergastrinemia due to Acinetobacter lwoffii in mice. 2002 , 70, 2630-9	48
1331	Phenotypic variation in molecular mimicry between Helicobacter pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms. Acid-induced phase variation in Lewis(x) and Lewis(y) expression by H. Pylori lipopolysaccharides. 2002 , 277, 5785-95	70
1330	Specific entry of Helicobacter pylori into cultured gastric epithelial cells via a zipper-like mechanism. 2002 , 70, 2108-20	135
1329	Commentary: peptic ulcer, Susser and Stein and the cohort phenomenon. 2002 , 31, 27-8	2
1328	Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. 2002 , 70, 6383-8	55
1327	In vivo complementation of ureB restores the ability of Helicobacter pylori to colonize. 2002 , 70, 771-8	49
1326	Induction of cyclo-oxygenase-2 expression in naturally occurring gastric ulcers. 2002 , 50, 923-34	6

1325 . **2002**, 22, 819-820

1324 Immunohistochemical Analysis of the Pathogenicity of Helicobacter pylori Infection: Excess Nitric Oxide Induced Indirectly by Lewis X and Y is the Cause of the Pathogenicity of Helicobacter pylori Infestation in the Stomach.. **2002**, 35, 93-100 2

1323 Peer Reviewers. **2002**, 22, 819-820

1322 Detection of specific Helicobacter pylori DNA and antigens in stool samples in dyspeptic patients and healthy subjects. **2002**, 46, 657-65 12

1321 Functional analysis of iceA1, a CATG-recognizing restriction endonuclease gene in Helicobacter pylori. **2002**, 30, 3839-47 26

1320 Intraperitoneal immunization led to T cell hyporesponsiveness to Helicobacter pylori infection in mice. **2002**, 46, 441-7 3

1319 Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. **2002**, 34, 398-402 42

1318 Comparison of two new rapid serology tests for diagnosis of Helicobacter pylori infection in Chinese patients. **2002**, 34, 111-5 39

1317 Nizatidine and omeprazole enhance the effect of metronidazole on Helicobacter pylori in vitro. **2002**, 19, 195-200 4

1316 Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation. **2002**, 123, 1962-71 67

1315 Complex disease and the new clinical sciences. **2002**, 296, 698-700 109

1314 [Helicobacter pylori infection]. **2002**, 202, 99-110 0

1313 Eradication of Helicobacter pylori: current perspectives. **2002**, 3, 1031-8

1312 Peptic-ulcer disease. *Lancet, The*, **2002**, 360, 933-41 40 171

1311 Anti-Helicobacter pylori flavonoids from licorice extract. **2002**, 71, 1449-63 247

1310 Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. **2002**, 122, 119-33 110

1309 Does colonization of Helicobacter pylori in the heterotopic gastric mucosa play a role in bleeding of Meckel's diverticulum?. **2002**, 37, 1540-2 9

1308 Prevalence and specificity of antigastric autoantibodies in adolescents infected with Helicobacter pylori. **2002**, 140, 68-74 8

1307	Role of the alpAB proteins and lipopolysaccharide in adhesion of <i>Helicobacter pylori</i> to human gastric tissue. 2002 , 292, 247-56	53
1306	CagA tyrosine phosphorylation and interleukin-8 induction by <i>Helicobacter pylori</i> are independent from alpAB, HopZ and bab group outer membrane proteins. 2002 , 292, 257-66	60
1305	Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding <i>Helicobacter pylori</i> -catalase. 2002 , 20, 2336-42	31
1304	Safety and efficacy of <i>E coli</i> enterotoxin adjuvant for urease-based rectal immunization against <i>Helicobacter pylori</i> . 2002 , 21, 194-201	42
1303	Suppressive effects of garlic extract on <i>Helicobacter pylori</i> -induced gastritis in Mongolian gerbils. 2002 , 187, 61-8	59
1302	[Management of dyspepsia, gastroduodenal ulcer and <i>Helicobacter pylori</i> infection in primary care]. 2002 , 29, 486-94	4
1301	Monoassociation of SCID mice with <i>Helicobacter muridarum</i> , but not four other enterics, provokes IBD upon receipt of T cells. 2002 , 122, 1346-54	77
1300	Pathogenesis and therapy of gastric and duodenal ulcer disease. 2002 , 86, 1447-66, viii	48
1299	[Prevalence of <i>Helicobacter pylori</i> infection in gastroesophageal reflux disease and Barretts esophagus]. 2002 , 119, 217-23	9
1298	Mutations in the 16S rRNA genes of <i>Helicobacter pylori</i> mediate resistance to tetracycline. 2002 , 184, 2131-40	126
1297	Acute inflammatory response in the stomach of BALB/c mice challenged with coccoidal <i>Helicobacter pylori</i> . 2002 , 97, 1201-6	6
1296	Follow up of serial urea breath test results in patients after consumption of antibiotics for non-gastric infections. 2002 , 8, 703-6	21
1295	Localization of antigen-presenting cells in <i>Helicobacter pylori</i> -infected gastric mucosa. 2002 , 52, 265-71	34
1294	Intrauterine infection and prematurity. 2002 , 8, 3-13	433
1293	<i>Helicobacter pylori</i> strain-specific modulation of gastric mucosal cellular turnover: implications for carcinogenesis. 2002 , 37 Suppl 13, 10-6	29
1292	Gastric mucosa: long-term outcome after cure of <i>Helicobacter pylori</i> infection. 2002 , 37 Suppl 13, 17-23	40
1291	Pathological issues of gastric and lower esophageal cancer: <i>helicobacter pylori</i> infection and its eradication. 2002 , 37 Suppl 13, 28-33	5
1290	Rescue Therapy for <i>Helicobacter pylori</i> . 2002 , 5, 133-138	17

1289	Separation and surveys of proteins of <i>Helicobacter pylori</i> . 2002 , 771, 251-60	4
1288	Analyses of the <i>cag</i> pathogenicity island of <i>Helicobacter pylori</i> . 1998 , 28, 37-53	434
1287	Comparative proteome analysis of <i>Helicobacter pylori</i> . 2000 , 36, 710-25	184
1286	Functional complementation reveals the importance of intermolecular monomer interactions for <i>Helicobacter pylori</i> VacA vacuolating activity. 2002 , 43, 1243-53	32
1285	Detecting <i>Helicobacter pylori</i> infection in hospitalized frail older patients: the challenge. 2002 , 50, 1674-80	19
1284	Ten-year prospective follow-up study on the relationship between <i>Helicobacter pylori</i> infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. 2002 , 16 Suppl 2, 198-203	41
1283	High molecular protein of <i>Helicobacter pylori</i> responsible for inhibition of ornithine decarboxylase activity of human gastric cultured cells. 2002 , 16 Suppl 2, 167-73	3
1282	Autonomic nervous activity before and after eradication of <i>Helicobacter pylori</i> in patients with chronic duodenal ulcer. 2002 , 16 Suppl 2, 180-6	8
1281	Eradication of <i>Helicobacter pylori</i> infection induces an increase in body mass index. 2002 , 16 Suppl 2, 240-4	47
1280	Review article: after gastritis--an imaginary journey into a <i>Helicobacter</i> -free world. 2002 , 16 Suppl 4, 89-94	14
1279	Inhibition of <i>Helicobacter pylori</i> -induced cyclo-oxygenase-2 aggravates NSAID-caused gastric damage in Mongolian gerbils. 2002 , 16, 847-55	12
1278	Review article: <i>Helicobacter</i> species and hepatobiliary diseases. 2002 , 16, 1037-45	66
1277	Review article: <i>Helicobacter pylori</i> infection in peptic ulcer haemorrhage. 2002 , 16 Suppl 1, 66-78	24
1276	Gastroduodenal lesions in polycythaemia vera: frequency and role of <i>Helicobacter pylori</i> . 2002 , 117, 198-202	17
1275	Nitric oxide synthetase and <i>Helicobacter pylori</i> in patients undergoing appendicectomy. 1999 , 86, 1538X-1542	10
1274	<i>Helicobacter pylori</i> infection in patients with idiopathic short stature. 2002 , 44, 277-80	27
1273	Usefulness of a hemoglobin index determined by electronic endoscopy in the diagnosis of <i>helicobacter pylori</i> gastritis. 2002 , 14, 156-162	8
1272	Relationship between <i>Helicobacter pylori</i> infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer. 1999 , 14, 114-9	14

1271	Management of peptic ulcer disease not related to <i>Helicobacter</i> . 2002 , 17, 488-94	9
1270	Relationship between nuclear factor-kappaB activation and virulence factors of <i>Helicobacter pylori</i> in Japanese clinical isolates. 2002 , 17, 556-62	11
1269	Influences of <i>Helicobacter pylori</i> on gastric angiogenesis and ulcer healing in mice. 2002 , 17, 960-5	7
1268	<i>Fusobacterium varium</i> localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. 2002 , 17, 849-53	152
1267	Stomach-specific anti- <i>H. pylori</i> therapy. I: Preparation and characterization of tetracycline-loaded chitosan microspheres. 2002 , 235, 87-94	117
1266	Synergistic promoting effects of <i>Helicobacter pylori</i> infection and high-salt diet on gastric carcinogenesis in Mongolian gerbils. 2002 , 93, 1083-9	83
1265	Redefining bacterial populations: a post-genomic reformation. 2002 , 3, 462-73	77
1264	Inactivation of a <i>Helicobacter pylori</i> DNA methyltransferase alters <i>dnaK</i> operon expression following host-cell adherence. 2002 , 208, 295-301	25
1263	<i>Helicobacter muricola</i> sp. nov., a novel <i>Helicobacter</i> species isolated from the ceca and feces of Korean wild mouse (<i>Mus musculus molossinus</i>). 2002 , 209, 45-51	17
1262	Experimental colonization of mice by fresh clinical isolates of <i>Helicobacter pylori</i> is not influenced by the <i>cagA</i> status and the <i>vacA</i> genotype. 2002 , 34, 169-72	7
1261	Immuno-chromatographic flow-injection method for detection of human serum immunoglobulin G antibodies to <i>Helicobacter pylori</i> . 2002 , 453, 53-61	6
1260	Does serum nitrite concentration reflect gastric carcinogenesis in Japanese <i>Helicobacter pylori</i> -infected patients?. 2002 , 47, 100-6	9
1259	Cellular immune responses in <i>Helicobacter heilmannii</i> infection: evaluation of the role of the host and the bacterium. 2002 , 47, 823-30	3
1258	Cardiovascular risk factors in subjects with <i>Helicobacter pylori</i> infection. 2002 , 7, 86-90	43
1257	Effect of <i>Helicobacter pylori</i> -induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. 2002 , 7, 129-38	30
1256	<i>Helicobacter pylori</i> infection increases serum nitrate and nitrite more prominently than serum pepsinogens. 2002 , 7, 9-13	11
1255	Accuracy of office-based immunoassays for the diagnosis of <i>Helicobacter pylori</i> infection in children. 2002 , 7, 205-9	14
1254	A novel method for assessing gastritis in the murine model demonstrates genetically determined variation in response to <i>Helicobacter felis</i> infection. 2002 , 7, 265-8	9

1253	A group-specific PCR assay for the detection of Helicobacteraceae in human gut. 2002 , 7, 378-83	41
1252	Antimicrobial activity of essential oils against Helicobacter pylori. 2003 , 8, 207-15	134
1251	CagA tyrosine phosphorylation in gastric epithelial cells caused by Helicobacter pylori in patients with gastric adenocarcinoma. 2003 , 8, 235-43	24
1250	Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3'sialyllactose sodium salt). A double blind, placebo-controlled clinical study. 2003 , 8, 252-6	42
1249	The MUC5AC glycoprotein is the primary receptor for Helicobacter pylori in the human stomach. 2003 , 8, 521-32	101
1248	Relationship between pepsinogen I&II and H. pylori infection considered with grade of atrophy and gastroduodenal diseases. 2003 , 48, 1839-45	4
1247	Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability. 2003 , 46, 49-55	53
1246	The bactericidal effects of Lactobacillus acidophilus, garcinol and Protykin compared to clarithromycin, on Helicobacter pylori. 2003 , 243, 29-35	46
1245	Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. 2003 , 48, 36-46	28
1244	In vitro and in vivo anti- Helicobacter pylori activity of Y-904, a new fluoroquinolone. 2003 , 9, 165-71	8
1243	PCR-based genetic evidence for occurrence of Helicobacter pylori and novel Helicobacter species in the canine gastric mucosa. 2003 , 95, 259-70	21
1242	Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. 2003 , 98, 109-27	61
1241	Helicobacter in the developing world. 2003 , 5, 705-13	202
1240	Animal models of Helicobacter pylori infection and disease. 2003 , 5, 741-8	57
1239	Helicobacter pylori: an invading microorganism? A review. 2003 , 36, 117-26	74
1238	Clinical relevance of the cagA, vacA and iceA genotypes of Helicobacter pylori in Brazilian clinical isolates. 2003 , 36, 181-5	24
1237	Characterization of the roles of NikR, a nickel-responsive pleiotropic autoregulator of Helicobacter pylori. 2003 , 49, 947-63	150
1236	Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. 2003 , 18, 168-71	23

1235	Is apoptosis in antral mucosa correlated with serum nitrite concentration in Japanese Helicobacter pylori-infected patients?. 2003 , 18, 498-504	8
1234	Pulse-wave velocity and cardiovascular risk factors in subjects with Helicobacter pylori infection. 2003 , 18, 771-7	19
1233	Combination therapy of ecabet sodium and cimetidine compared with cimetidine alone for gastric ulcer: prospective randomized multicenter study. 2003 , 18, 1029-33	16
1232	Helicobacter pylori: resurrection of the cancer link. 2003 , 253, 102-19	60
1231	A novel apoptosis-inducing protein from Helicobacter pylori. 2003 , 47, 443-51	85
1230	Is cranberry juice effective in the treatment and prevention of Helicobacter pylori infection of mice?. 2003 , 4, 136-139	15
1229	Structural definition on the surface of Helicobacter pylori type IV secretion apparatus. 2003 , 5, 395-404	113
1228	Review article: what have we learnt from gastric biopsy?. 2003 , 17 Suppl 2, 68-74	11
1227	Efficacy and safety of single-triple capsules of bismuth biscaltrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. 2003 , 17, 415-20	75
1226	Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. 2003 , 17, 1137-43	89
1225	Review article: clinic-based testing for Helicobacter pylori infection by enzyme immunoassay of faeces, urine and saliva. 2003 , 17, 1345-54	31
1224	Influence of Helicobacter pylori on platelets after bone marrow transplantation from unrelated donors. 2003 , 31, 493-6	4
1223	Effects of Helicobacter pylori infection on the link between regenerating gene expression and serum gastrin levels in Mongolian gerbils. 2003 , 83, 1777-86	46
1222	Intoxicated cells and stomach ulcers. 2003 , 33, 328-30	6
1221	Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. 2003 , 5, 693-703	130
1220	Is Helicobacter pylori infection associated with chronic idiopathic urticaria?. 2003 , 31, 209-14	23
1219	Chapter 18 Culture media for the isolation of campylobacters, helicobacters and arcobacters. 2003 , 37, 271-316	14
1218	A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?. 2003 , 35, 357-61	59

1217	Usual and unusual causes of duodenal ulcer. 2003 , 35, 519-22	3
1216	DNA binding specificity of the replication initiator protein, DnaA from <i>Helicobacter pylori</i> . 2003 , 334, 933-47	26
1215	Adoption of the transiently non-culturable state--a bacterial survival strategy?. 2003 , 47, 65-129	77
1214	The gastric biology of <i>Helicobacter pylori</i> . 2003 , 65, 349-69	129
1213	Gastric cancer. <i>Lancet, The</i> , 2003 , 362, 305-15	40 501
1212	Binding and internalization of <i>Helicobacter pylori</i> VacA via cellular lipid rafts in epithelial cells. 2003 , 303, 640-4	41
1211	Comparison of five-day <i>Helicobacter pylori</i> eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment. 2003 , 64, 412-21	4
1210	Effect of <i>H. pylori</i> infection on the expression of cyclooxygenase-2 in human gastric mucosa. 2003 , 68, 1-8	3
1209	Chemistry and Biological Activities of Isoprenylated Flavonoids from Medicinal Plants (Moraceous Plants and Glycyrrhiza Species). 2003 , 28, 199-256	19
1208	Discovering human history from stomach bacteria. 2003 , 4, 213	14
1207	The Entner-Doudoroff pathway has little effect on <i>Helicobacter pylori</i> colonization of mice. 2003 , 71, 2920-3	13
1206	Mucosal immunization with <i>helicobacter</i> , CpG DNA, and cholera toxin is protective. 2003 , 71, 40-6	39
1205	Antigen retrieval trial for post-embedding immunoelectron microscopy by heating with several unmasking solutions. 2003 , 51, 989-94	16
1204	Induction of experimental ulcerative colitis by <i>Fusobacterium varium</i> isolated from colonic mucosa of patients with ulcerative colitis. 2003 , 52, 79-83	183
1203	Modification in the <i>ppk</i> gene of <i>Helicobacter pylori</i> during single and multiple experimental murine infections. 2003 , 71, 1733-9	16
1202	A revised annotation and comparative analysis of <i>Helicobacter pylori</i> genomes. 2003 , 31, 1704-14	63
1201	Gene expression profiling of <i>Helicobacter pylori</i> reveals a growth-phase-dependent switch in virulence gene expression. 2003 , 71, 2643-55	117
1200	Identification of <i>cagA</i> tyrosine phosphorylation DNA motifs in <i>Helicobacter pylori</i> isolates from peptic ulcer patients by novel PCR-restriction fragment length polymorphism and real-time fluorescence PCR assays. 2003 , 41, 3112-8	13

1199	Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice. 2003 , 71, 7140-8	26
1198	Development of an interleukin-12-deficient mouse model that is permissive for colonization by a motile KE26695 strain of Helicobacter pylori. 2003 , 71, 2534-41	39
1197	pH-regulated gene expression of the gastric pathogen Helicobacter pylori. 2003 , 71, 3529-39	194
1196	Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. 2003 , 278, 3664-70	238
1195	Functional characterization of Helicobacter pylori DnaB helicase. 2003 , 31, 6828-40	47
1194	Cellular vacuolation and mitochondrial cytochrome c release are independent outcomes of Helicobacter pylori vacuolating cytotoxin activity that are each dependent on membrane channel formation. 2003 , 278, 48204-9	83
1193	Rate of Helicobacter pylori infection in children and clonality of Taiwan strains. 2003 , 47, 813-21	3
1192	Knowledge and truth: answers or questions?. 2003 , 4, 297-309	3
1191	Elevated levels of anti-Helicobacter pylori antibodies in Henoch-Schleien purpura. 2003 , 36, 307-11	29
1190	Depletion of neutrophils in IL-10(-/-) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. 2003 , 170, 3782-9	108
1189	Development of a plating medium for selection of Helicobacter pylori from water samples. 2003 , 69, 2914-8	33
1188	Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. 2003 , 47, 2249-55	26
1187	Dependence of Helicobacter pylori urease activity on the nickel-sequestering ability of the UreE accessory protein. 2003 , 185, 4787-95	72
1186	Consent to using human tissue. 2003 , 327, 759-60	17
1185	Culturing Helicobacter pylori from clinical specimens: review of microbiologic methods. 2003 , 36, 616-22	32
1184	Defining the pathologic diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma. 2003 , 36, S37-43; discussion S61-2	30
1183	Helicobacter pylori seropositivity among adolescents in Novosibirsk, Russia: prevalence and associated factors. 2003 , 36, 72-6	19
1182	Rapid Point-of-Care Testing for Helicobacter pylori Infection. 2003 , 2, 33-38	

1181	Functional and morphological aspects of <i>Helicobacter pylori</i> -induced gastric cancer in Mongolian gerbils. 2003 , 15, 745-54	12
1180	Interactions among the seven <i>Helicobacter pylori</i> proteins encoded by the urease gene cluster. 2003 , 284, G96-G106	72
1179	Stimulated murine macrophages as a bioassay for <i>H. pylori</i> -related inhibition of nitric oxide production. 2003 , 38, 380-6	4
1178	Evaluation of a Western blot technique (Helicoblot 2.1) for the diagnosis of <i>Helicobacter pylori</i> infection in children. 2003 , 35, 157-160	
1177	Obtaining and using human tissues for research: ethical and practical dilemmas. 2003 , 64, 198-9	1
1176	Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of <i>Helicobacter pylori</i> in Brazilian peptic ulcer patients. 2003 , 121, 15-8	2
1175	<i>Helicobacter pylori</i> , gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. 2003 , 111, 800-3	42
1174	Câncer de coto gástrico em ratos: papel da associaõ de <i>Helicobacter pylori</i> e refluxo fterero-gástrico. 2003 , 30, 452-459	1
1173	Bacteria. 2003 , 57-68	3
1172	Low eradication rate of <i>Helicobacter pylori</i> with triple 7-14 days and quadruple therapy in Turkey. 2004 , 10, 668-71	85
1171	Impact of <i>Helicobacter pylori</i> infection on histological changes in non-erosive reflux disease. 2004 , 10, 1180-2	3
1170	[Bibliometric indicators realities, myth and prospective]. 2004 , 20, 909-15	4
1169	<i>Helicobacter pylori</i> . 2004 , 91-123	
1168	Adenocarcinoma of the stomach: a review. 2004 , 17, 391-9	11
1167	Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of <i>Helicobacter pylori</i> infection. 2004 , 39, 1073-7	26
1166	Overexpression of glycine-extended gastrin inhibits parietal cell loss and atrophy in the mouse stomach. 2004 , 64, 8160-6	38
1165	Effect of glycine on <i>Helicobacter pylori</i> in vitro. 2004 , 48, 3782-8	24
1164	The <i>Helicobacter pylori</i> flaA1 and wbpB genes control lipopolysaccharide and flagellum synthesis and function. 2004 , 186, 2253-65	28

1163	Role of the receptor-mediated apoptosis in Helicobacter pylori in gastric epithelial cells. 2004 , 70, 178-86	10
1162	Helicobacter pylori infection of human and murine primary gastric cells. 2004 , 72, 5464-9	3
1161	Membrane channel structure of Helicobacter pylori vacuolating toxin: role of multiple GXXXG motifs in cylindrical channels. 2004 , 101, 5988-91	70
1160	Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. 2004 , 72, 1029-35	29
1159	Downregulation of CXCR1 and CXCR2 expression on human neutrophils by Helicobacter pylori: a new pathomechanism in H. pylori infection?. 2004 , 72, 6773-9	31
1158	Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. 2004 , 101, 7409-14	80
1157	The cag pathogenicity island of Helicobacter pylori is disrupted in the majority of patient isolates from different human populations. 2004 , 42, 5302-8	73
1156	The diversity within an expanded and redefined repertoire of phase-variable genes in Helicobacter pylori. 2004 , 150, 817-830	77
1155	Induction of peripheral lymph node addressin in human gastric mucosa infected by Helicobacter pylori. 2004 , 101, 17807-12	97
1154	Isolation and characterization of a HpyC1I restriction-modification system in Helicobacter pylori. 2004 , 279, 11156-62	9
1153	Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. 2004 , 53, 187-94	69
1152	Prevalence of Helicobacter pylori infection among adult dyspeptic patients in Ethiopia. 2004 , 98, 181-9	31
1151	Prevalence of Helicobacter pylori detected by polymerase chain reaction in the oral cavity of periodontitis patients. 2004 , 19, 277-80	58
1150	Correlation between serum pepsinogen levels and gastric mucosal histological findings before and after Helicobacter pylori eradication therapy. 2004 , 16, 122-128	4
1149	Immunological rapid urease test using monoclonal antibody for Helicobacter pylori. 2004 , 19, 970-4	6
1148	Gastric epithelial cell CXC chemokine secretion following Helicobacter pylori infection in vitro. 2004 , 19, 982-7	20
1147	Investigation of Helicobacter pylori in bronchoscopic lung specimens of young male patients with bronchiectasis but without gastrointestinal symptoms. 2004 , 10, 257-60	12
1146	Chronic gastritis with expression of inducible nitric oxide synthase is associated with high expression of interleukin-6 and hypergastrinaemia. 2004 , 19, 1309-14	9

1145	DNA typing for <i>Helicobacter pylori</i> isolates from eradication-failed patients: comparison of the isolates before and after therapy. 2004 , 20 Suppl 1, 39-47	3
1144	<i>Helicobacter pylori</i> eradication decreases blood neutrophil and monocyte counts. 2004 , 20 Suppl 1, 74-9	8
1143	Review article: <i>Helicobacter pylori</i> and molecular events in precancerous gastric lesions. 2004 , 20, 261-70	100
1142	CTLA-4 blockade inhibits induction of <i>Helicobacter pylori</i> -associated gastritis in mice. 2004 , 135, 29-34	21
1141	Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in <i>Helicobacter pylori</i> infection. 2004 , 136, 521-6	199
1140	From miasma to fractals: the epidemiology revolution and public health nursing. 2004 , 21, 380-91	20
1139	Role and limitations of epidemiology in establishing a causal association. 2004 , 14, 413-26	22
1138	Bactericidal activity of wasabi (<i>Wasabia japonica</i>) against <i>Helicobacter pylori</i> . 2004 , 94, 255-61	75
1137	Effect of <i>Helicobacter pylori</i> infection on gastric acid secretion and meal-stimulated serum gastrin in children. 2004 , 9, 100-5	18
1136	The prevalence of peptic ulcer not related to <i>Helicobacter pylori</i> or non-steroidal anti-inflammatory drug use is negligible in southern Europe. 2004 , 9, 249-54	63
1135	Characteristics of <i>Helicobacter pylori</i> -induced gastritis and the effect of <i>H. pylori</i> eradication in patients with chronic idiopathic thrombocytopenic purpura. 2004 , 9, 443-52	41
1134	The <i>rdxA</i> gene plays a more major role than <i>frxA</i> gene mutation in high-level metronidazole resistance of <i>Helicobacter pylori</i> in Taiwan. 2004 , 9, 400-7	30
1133	Cellular mucosal defense is attenuated with chronicity of <i>Helicobacter pylori</i> infection. 2004 , 49, 1109-15	2
1132	Inhibition of <i>Helicobacter pylori</i> in vitro by various berry extracts, with enhanced susceptibility to clarithromycin. 2004 , 265, 19-26	73
1131	Sprouting and Solid-State Bioprocessing by <i>Rhizopus oligosporus</i> Increase the In Vitro Antibacterial Activity of Aqueous Soybean Extracts Against <i>Helicobacter pylori</i> . 2004 , 18, 229-249	6
1130	The spectrum of gastric disease associated with <i>Helicobacter pylori</i> and other infectious gastritides. 2004 , 6, 441-6	8
1129	Marginal Zone B-cell Lymphoma (MALT Lymphoma). 2004 , 7, 133-138	1
1128	<i>Helicobacter pylori</i> vacuolating cytotoxin enters cells, localizes to the mitochondria, and induces mitochondrial membrane permeability changes correlated to toxin channel activity. 2004 , 6, 143-54	132

- 1127 Toxins of the Helicobacter Genus and Their Roles in Pathogenesis. **2004**, 23, 1-35
- 1126 Helicobacter pylori infection in pediatric population: epidemiology, pathophysiology, and therapy. **2004**, 23, 11-28 4
- 1125 Changes in Helicobacter pylori status in patients with rheumatoid arthritis under non-steroidal anti-inflammatory drugs. **2004**, 39, 111-8 5
- 1124 Differential roles of interleukin-1beta and interleukin-8 in neutrophil transendothelial migration in patients with Helicobacter pylori infection. **2004**, 39, 313-21 11
- 1123 Does seropositivity for Helicobacter pylori antibodies increase outpatient costs for gastric and duodenal ulcer or inflammation?. **2004**, 22, 975-83 1
- 1122 Towards the ideal regimen for Helicobacter pylori eradication: the search continues. **2004**, 36, 243-7 13
- 1121 Basis for the management of drug-resistant Helicobacter pylori infection. **2004**, 64, 1893-904 54
- 1120 Synthesis of the trisaccharide repeating unit of the atypical O-antigen polysaccharide from Danish Helicobacter pylori strains employing the 2'-carboxybenzyl glycoside. **2004**, 6, 3901-4 35
- 1119 Gastric lymphoid hyperplasia: radiological evidence of childhood Helicobacter pylori infection. **2004**, 59, 758-60
- 1118 Functional variability of cagA gene in Japanese isolates of Helicobacter pylori. **2004**, 343, 165-72 13
- 1117 Chronic disease: long-term outcomes of metabolic dysfunction. **2004**, 15, 519-527 1
- 1116 Development of a large-scale HPLC-based purification for the urease from Staphylococcus leei and determination of subunit structure. **2004**, 34, 111-7 17
- 1115 Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. **2004**, 22, 2273-7 54
- 1114 Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. **2004**, 22, 888-97 33
- 1113 Requirement of hydD, hydE, hypC and hypE genes for hydrogenase activity in Helicobacter pylori. **2004**, 36, 153-7 25
- 1112 Tumor necrosis factor-alpha is required for gastritis induced by Helicobacter felis infection in mice. **2004**, 37, 119-24 18
- 1111 Replacement of Carbohydrate Sulfates by Sugar C-Sulfonic Acid Derivatives. **2004**, 23, 133-146 14
- 1110 Hyperhomocysteinemia due to Helicobacter pylori?. **2004**, 172, 199-200 5

1109	Infección por <i>Helicobacter pylori</i> . Conceptos generales. 2004 , 9, 55-63	
1108	Is the host responsible? -- the role of the immune system in <i>Helicobacter pylori</i> infection. 2004 , 62, 95-6	0
1107	Effect of sucralfate on antibiotic therapy for <i>Helicobacter pylori</i> infection in mice. 2004 , 48, 4582-8	11
1106	Ideology of <i>Helicobacter pylori</i> prevalence in peptic ulcer disease in an inner-city minority population. 2004 , 38, 248-51	9
1105	A 1 year follow-up study of the consequences of <i>Helicobacter pylori</i> eradication in duodenal ulcer patients: unchanged frequency of erosive oesophagitis and decreased prevalence of non-erosive gastro-oesophageal reflux disease. 2004 , 16, 369-74	19
1104	Influence of gastritis on cyclooxygenase-2 expression before and after eradication of <i>Helicobacter pylori</i> infection. 2004 , 16, 969-79	15
1103	Acid acclimation by <i>Helicobacter pylori</i> . 2005 , 20, 429-38	97
1102	Study on the role of gastric <i>Helicobacter</i> infection in gross pathological and histological lesions of the stomach in finishing pigs. 2005 , 53, 371-83	18
1101	<i>Helicobacter pylori</i> seroprevalence in patients with mild asthma. 2005 , 207, 287-91	37
1100	The incidence of reflux oesophagitis after eradication therapy for <i>Helicobacter pylori</i> . 2005 , 17, 1025-8	15
1099	<i>Helicobacter pylori</i> eradication as the sole treatment for gastric and duodenal ulcers. 2005 , 17, 93-101	22
1098	The role of <i>Helicobacter</i> spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. 2005 , 44, 221-5	24
1097	Synthesis and in vitro selective anti- <i>Helicobacter pylori</i> activity of pyrazoline derivatives. 2005 , 15, 603-7	48
1096	Continuous-flow/stopped-flow system using an immunobiosensor for quantification of human serum IgG antibodies to <i>Helicobacter pylori</i> . 2005 , 337, 195-202	16
1095	Influence of IL-1 gene cluster polymorphisms on the development of <i>H. pylori</i> associated gastric ulcer. 2005 , 100, 107-12	8
1094	Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against <i>Helicobacter pylori</i> , and T helper 1 type response and interferon-gamma correlate with the protection. 2005 , 10, 71-9	36
1093	Role of <i>Helicobacter pylori</i> in gastric carcinogenesis: the origin of gastric cancers and heterotopic proliferative glands in Mongolian gerbils. 2005 , 10, 97-106	38
1092	Inhibitory effects of polyphenols on gastric injury by <i>Helicobacter pylori</i> VacA toxin. 2005 , 10, 231-9	36

1091	Cellular mucosal defense during <i>Helicobacter pylori</i> infection: a review of the role of glutathione and the oxidative pentose pathway. 2005 , 10, 298-306	41
1090	Oral vaccination against <i>Helicobacter pylori</i> with recombinant cholera toxin B-subunit. 2005 , 10, 345-52	7
1089	Detection of non- <i>pylori Helicobacter</i> species in " <i>Helicobacter heilmannii</i> "-infected humans. 2005 , 10, 398-406	66
1088	Multiple displacement amplification of isolated DNA from human gallstones: molecular identification of <i>Helicobacter</i> DNA by means of 16S rDNA-based pyrosequencing analysis. 2005 , 10, 592-600	19
1087	Inhibition of proinflammatory cytokine expression by NF-kappaB (p65) antisense oligonucleotide in <i>Helicobacter pylori</i> -infected mice. 2005 , 10, 559-66	14
1086	Pathogenicity of <i>Helicobacter pylori</i> infection. 2005 , 11, 602-10	24
1085	Eradication of <i>Helicobacter pylori</i> : recent advances in treatment. 2005 , 19, 421-7	24
1084	<i>Helicobacter pylori</i> -host cell interactions mediated by type IV secretion. 2005 , 7, 911-9	88
1083	Changing trends in peptic ulcer prevalence in a tertiary care setting in the Philippines: a seven-year study. 2005 , 20, 628-32	29
1082	Characteristics of gastritis in patients with <i>Helicobacter pylori</i> -positive reflux esophagitis. 2005 , 20, 682-7	3
1081	Prevalence of <i>Helicobacter pylori</i> infection, endoscopic gastric findings and dyspeptic symptoms among a young Japanese population born in the 1970s. 2005 , 20, 1352-7	20
1080	Deciphering host migrations and origins by means of their microbes. 2005 , 14, 3289-306	70
1079	Occurrence of <i>Helicobacter pylori</i> DNA in the coastal environment of southern Italy (Straits of Messina). 2005 , 98, 768-74	25
1078	Prevention of the rehaemorrhage of bleeding peptic ulcers: effects of <i>Helicobacter pylori</i> eradication and acid suppression. 2005 , 21 Suppl 2, 79-84	9
1077	From gene mutations to tumours--stem cells in gastrointestinal carcinogenesis. 2005 , 38, 387-405	17
1076	<i>Helicobacter pylori</i> VacA, a paradigm for toxin multifunctionality. 2005 , 3, 320-32	403
1075	Dyspepsia management in primary care: a management trial. 2005 , 59, 194-201	2
1074	Characterization of cinnamyl alcohol dehydrogenase of <i>Helicobacter pylori</i> . An aldehyde dismutating enzyme. 2005 , 272, 1255-64	30

1073	Effect of melatonin on secreted and induced matrix metalloproteinase-9 and -2 activity during prevention of indomethacin-induced gastric ulcer. 2005 , 39, 307-15	43
1072	Peptic ulcer disease. 2005 , 42, 346-454	30
1071	Helicobacter pylori infection and surgical disease---part I. 2005 , 42, 756-89	2
1070	Gastric juice epidermal growth factor concentration and Helicobacter pylori in patients with duodenal ulcer. 1995 , 82, 1204-6	5
1069	High prevalence of Helicobacter pylori infection in duodenal ulcer perforations not caused by non-steroidal anti-inflammatory drugs. 1996 , 83, 1779-81	40
1068	Gastritis from NSAIDS to Helicobacter pylori. 2005 , 30, 142-59	16
1067	Why are physicians so skeptical about positive randomized controlled clinical trials in critical care medicine?. 2005 , 31, 196-204	32
1066	Polyphosphate kinase: a new colonization factor of Helicobacter pylori. 2005 , 243, 45-50	29
1065	Relationship between IL-1beta gene polymorphism and gastric mucosal IL-1beta levels in patients with Helicobacter pylori infection. 2005 , 40, 796-801	23
1064	Association between interleukin-1beta-511C/T polymorphism and reflux esophagitis in Japan. 2005 , 40, 873-7	22
1063	Effect of interleukin-8 on histamine release from totally isolated vascularly perfused rat stomach. 2005 , 40, 1100-6	
1062	Update on Therapeutic Options for Helicobacter pylori-related Diseases. 2005 , 7, 115-120	21
1061	Comparison of the clinical feasibility of three rapid urease tests in the diagnosis of Helicobacter pylori infection. 2005 , 50, 449-52	34
1060	Helicobacter genus DNA fragments are commonly detectable in bile from patients with extrahepatic biliary diseases and associated with their pathogenesis. 2005 , 50, 862-7	44
1059	Infection with Helicobacter pylori affects all major secretory cell populations in the human antrum. 2005 , 50, 1078-86	27
1058	Lectin histochemistry of the gastric mucosa in normal and Helicobacter pylori infected guinea-pigs. 2005 , 36, 51-8	10
1057	23 years of the discovery of Helicobacter pylori: is the debate over?. 2005 , 4, 17	49
1056	In vitro susceptibility of Helicobacter pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders. 2005 , 19, 988-91	143

1055 [Treatment of peptic ulcers with proton pump inhibitors]. **2005**, 34, 206-9

1054 [The Nobel for stomach ulcer]. **2005**, 34, 448-9

1053 Helicobacter pylori protein HP0222 belongs to Arc/MetJ family of transcriptional regulators. **2005**, 59, 303-11 13

1052 Solution structure of conserved hypothetical protein HP0894 from Helicobacter pylori. **2005**, 61, 1114-6 9

1051 Proteomic analysis of proteins expressed by Helicobacter pylori under oxidative stress. **2005**, 5, 3895-901 40

1050 [Second Brazilian Consensus Conference on Helicobacter pylori infection]. **2005**, 42, 128-32 25

1049 The best method of detecting prior Helicobacter pylori infection. **2005**, 11, 5672-6 16

1048 The 2005 Nobel Prize in Physiology or Medicine. **2005**, 183, 612-614 13

1047 Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. **2005**, 11, 2477-81 18

1046 In vitro inhibition of Helicobacter pylori by Enterococcus faecium GM-1. **2005**, 51, 629-36 9

1045 Comparison of Helicobacter spp. in Cheetahs (*Acinonyx jubatus*) with and without gastritis. **2005**, 43, 229-34 31

1044 Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. **2005**, 162, 579-84 54

1043 Evaluation of antibiotic treatment against "Candidatus Helicobacter suis" in a mouse model. **2005**, 49, 4530-5 12

1042 Characterization of the Helicobacter pylori cysteine-rich protein A as a T-helper cell type 1 polarizing agent. **2005**, 73, 4732-42 38

1041 Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. **2005**, 58, 927-31 38

1040 Introduction: what should we do now about H. pylori?. **2005**, 14, 1851-2 1

1039 Helicobacter pylori activates NF-kappaB via the alternative pathway in B lymphocytes. **2005**, 175, 7162-9 35

1038 Experimental induction of bacterial gastritis and gastric ulcer disease in gnotobiotic swine inoculated with porcine Helicobacter-like species. **2005**, 66, 945-52 15

1037	A negative <i>Helicobacter pylori</i> serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current <i>H. pylori</i> infection: a report on histology and <i>H. pylori</i> detection in the general adult population. 2005 , 40, 302-11	38
1036	The diurnal rhythm of the cytoprotective human trefoil protein TFF2 is reduced by factors associated with gastric mucosal damage: ageing, <i>Helicobacter pylori</i> infection, and sleep deprivation. 2005 , 100, 1491-7	17
1035	Analysis of the role of HP0208, a phase-variable open reading frame, and its homologues HP1416 and HP0159 in the biosynthesis of <i>Helicobacter pylori</i> lipopolysaccharide. 2005 , 54, 697-706	7
1034	Evaluation of two enzyme immunoassays for detecting <i>Helicobacter pylori</i> in stool specimens of dyspeptic patients after eradication therapy. 2005 , 54, 863-866	20
1033	Human peripheral and gastric lymphocyte responses to <i>Helicobacter pylori</i> NapA and AphC differ in infected and uninfected individuals. 2005 , 54, 25-32	19
1032	Functional properties of the p33 and p55 domains of the <i>Helicobacter pylori</i> vacuolating cytotoxin. 2005 , 280, 21107-14	58
1031	Identification of non- <i>Helicobacter pylori</i> spiral organisms in gastric samples from humans, dogs, and cats. 2005 , 43, 2256-60	115
1030	Pathogen evolution in vivo: genome dynamics of two isolates obtained 9 years apart from a duodenal ulcer patient infected with a single <i>Helicobacter pylori</i> strain. 2005 , 43, 4237-41	38
1029	The duodenal mucosal bicarbonate secretion. 2005 , 110, 115-49	7
1028	Exfoliation of <i>Helicobacter pylori</i> from gastric mucin by glycopolypeptides from buttermilk. 2005 , 88, 49-54	10
1027	Efficacy and long-term outcome of gastritis therapy in cheetahs (<i>Acinonyx jubatus</i>). 2005 , 36, 401-16	14
1026	Spotlight on gastroenterology - the Nobel Prize Laureates in Physiology or Medicine 2005: John Robin Warren and Barry James Marshall. 2005 , 40, 1383-5	3
1025	Does hospital work constitute a risk factor for <i>Helicobacter pylori</i> infection?. 2005 , 60, 261-8	23
1024	A humble bacterium sweeps this year's Nobel Prize. 2005 , 123, 975-6	33
1023	Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. 2005 , 225, 53-9	24
1022	REG Ialpha protein may function as a trophic and/or anti-apoptotic factor in the development of gastric cancer. 2005 , 128, 642-53	87
1021	<i>Helicobacter pylori</i> and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. 2005 , 128, 1567-78	217
1020	<i>Helicobacter pylori</i> and MALT lymphoma. 2005 , 128, 1579-605	131

1019	Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. 2005 , 51 Suppl 1, 36-66	159
1018	The relation of <i>Helicobacter pylori</i> to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. 2005 , 89, 313-44, viii	102
1017	Infections ^ <i>Helicobacter pylori</i> et lymphome gastrique du MALT. 2005 , 7, 97-105	0
1016	Acid suppression therapy: where do we go from here?. 2006 , 24, 11-46	64
1015	Pathogenesis of <i>Helicobacter pylori</i> infection. 2006 , 19, 449-90	1471
1014	<i>Helicobacter pylori</i> infection and its correlation to extraesophageal and esophageal reflux in contact granuloma patients. 2006 , 31, 57-60	2
1013	Non-steroidal anti-inflammatory drugs request parity with <i>Helicobacter pylori</i> . 2006 , 41, 373-5	2
1012	<i>Helicobacter pylori</i> as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. 2006 , 7, 211-22	74
1011	<i>Helicobacter pylori</i> and antimicrobial resistance: molecular mechanisms and clinical implications. 2006 , 6, 699-709	218
1010	Antibiotic therapy for <i>Helicobacter pylori</i> . 2006 , 90, 1125-40	8
1009	The translation of <i>Helicobacter pylori</i> basic research to patient care. 2006 , 130, 188-206; quiz 212-3	110
1008	Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: Design, synthesis and binding properties of mannoside ligands. 2006 , 4, 3913-22	100
1007	[Seven or ten days? Cost-effectiveness study on the duration of <i>H. pylori</i> treatment in primary care]. 2006 , 38, 555-62	1
1006	Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. 2006 , 173, 991-8	273
1005	The Genus <i>Helicobacter</i> . 2006 , 139-177	4
1004	Genomics of <i>Helicobacter</i> Species. 2006 , 91-107	
1003	The history of <i>Helicobacter pylori</i> : a reflection on the relationship between the medical community and industry. 2006 , 38, 778-80	4
1002	Smoking increases the treatment failure for <i>Helicobacter pylori</i> eradication. 2006 , 119, 217-24	128

1001	Is Mongolian gerbil really adequate host animal for study of Helicobacter pylori infection-induced gastritis and cancer?. 2006 , 347, 297-300	12
1000	Expression cloning of cholesterol alpha-glucosyltransferase, a unique enzyme that can be inhibited by natural antibiotic gastric mucin O-glycans, from Helicobacter pylori. 2006 , 349, 1235-41	41
999	The clinical applications and accuracy of 2 rapid near-patient tests in detecting Helicobacter pylori infection. 2006 , 56, 241-6	10
998	Over-expression of 70-kDa heat shock protein confers protection against monochloramine-induced gastric mucosal cell injury. 2006 , 79, 300-5	38
997	Mucosal immunity in severely malnourished gambian children. 2006 , 149, S100-S106	
996	Epidemiology of gastric cancer. 2006 , 12, 354-62	1262
995	Detection of helicobacter candidatus suis by PCR in oesophagogastric ulcers of swine in Italy. 2006 , 54, 517-24	5
994	[Production of Antibody against Helicobacter pylori HP0231.]. 2006 , 26, 98-102	
993	[Differences and similarities of industrial and institutional promotions]. 2006 , 22, 881-6	
992	Absence of vertical transmission of Helicobacter pylori in an experimental murine model. 2006 , 7, 225-8	2
991	Cellular and molecular aspects of gastric cancer. 2006 , 12, 2979-90	186
990	This year's Nobel Prize to gastroenterology: Robin Warren and Barry Marshall awarded for their discovery of Helicobacter pylori as pathogen in the gastrointestinal tract. 2006 , 12, 3126-7	12
989	Effect of Aging on the Gastrointestinal Tract. 2006 , 405-433	4
988	Interaction of Helicobacter pylori with the gastric mucosa. 327-355	
987	The possible causes of the pandemic of peptic ulcer in the late 19th and early 20th century. 2006 , 185, 667-9	8
986	Heterologous production in Wolinella succinogenes and characterization of the quinol:fumarate reductase enzymes from Helicobacter pylori and Campylobacter jejuni. 2006 , 395, 191-201	34
985	Investigation of Helicobacter pylori in the middle ear of the patients with chronic otitis media by CLO test and 14C urea breath test. 2006 , 27, 871-3	7
984	Helicobacter pylori. 2006 , 429-449	

983	An office-based serological test for detection of current <i>Helicobacter pylori</i> infection: is it useful?. 2006 , 18, 85-8	5
982	<i>Helicobacter pylori</i> : what do we still need to know?. 2006 , 40, 15-9	17
981	The neutrophil-activating protein of <i>Helicobacter pylori</i> promotes Th1 immune responses. 2006 , 116, 1092-101	214
980	Ex vivo visualization of <i>Helicobacter pylori</i> using an endocytoscopic probe. 2006 , 27, 255-7	13
979	CagA protein secreted by the intact type IV secretion system leads to gastric epithelial inflammation in the Mongolian gerbil model. 2006 , 210, 306-14	46
978	Kinetic and structural properties of inorganic pyrophosphatase from the pathogenic bacterium <i>Helicobacter pylori</i> . 2006 , 65, 670-80	7
977	gammadelta T cells increase with gastric mucosal interleukin (IL)-7, IL-1beta, and <i>Helicobacter pylori</i> urease specific immunoglobulin levels via CCR2 upregulation in <i>Helicobacter pylori</i> gastritis. 2006 , 21, 32-40	15
976	Absence of <i>Helicobacter pylori</i> in the oral cavity of 10 non-dyspeptic subjects demonstrated by real-time polymerase chain reaction. 2006 , 21, 407-10	20
975	Pathogenicity islands: a molecular toolbox for bacterial virulence. 2006 , 8, 1707-19	239
974	Prevalence and risk factors of <i>Helicobacter pylori</i> infection in healthy schoolchildren. 2006 , 7, 55-60	23
973	<i>Helicobacter pylori</i> infection and treatment outcome in an urban Australian population. 2006 , 76, 710-4	7
972	Correlation between <i>Helicobacter pylori</i> infection and IL-18 mRNA expression in human gastric biopsy specimens. 2002 , 963, 326-8	11
971	Influence of <i>Helicobacter pylori</i> infection on iron accumulation in hepatitis C. 2006 , 26, 827-33	6
970	Of microbe and man: determinants of <i>Helicobacter pylori</i> -related diseases. 2006 , 30, 131-56	56
969	Persistence of <i>Helicobacter pylori</i> in the oral cavity after systemic eradication therapy. 2006 , 33, 329-33	65
968	<i>Helicobacter pylori</i> infection induces accumulation of V α T cells via CCR2 upregulation. 2006 , 2, 8-15	
967	Correlation of serum pepsinogen with histological atrophy following successful <i>Helicobacter pylori</i> eradication. 2006 , 2, 23-30	4
966	Changes in biochemical parameters related to atherosclerosis after <i>Helicobacter pylori</i> eradication. 2006 , 2, 58-64	10

965	Systematic review: are probiotics useful in controlling gastric colonization by <i>Helicobacter pylori</i> ? 2006 , 23, 1077-86	168
964	Systematic review and meta-analysis: importance of CagA status for successful eradication of <i>Helicobacter pylori</i> infection. 2006 , 24, 273-80	47
963	Synthesis and in vitro selective anti- <i>Helicobacter pylori</i> activity of N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides. 2006 , 41, 208-12	40
962	Inhibition of jack bean urease by organobismuth compounds. 2006 , 16, 1510-3	16
961	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from <i>Helicobacter pylori</i> . 2006 , 16, 2182-8	36
960	Isolation and characterization of a competence operon associated with transformation and adhesion in <i>Helicobacter pylori</i> . 2006 , 8, 2756-65	7
959	History of breastfeeding and <i>Helicobacter pylori</i> infection in children: results of a community-based study from northeastern Brazil. 2006 , 100, 470-5	19
958	Overview: <i>Helicobacter pylori</i> and extragastric disease. 2006 , 84, 291-300	30
957	The effect of CYP2C19 polymorphisms on <i>H. pylori</i> eradication rate in dual and triple first-line PPI therapies: a meta-analysis. 2006 , 101, 1467-75	112
956	Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in <i>Helicobacter pylori</i> -infected Mongolian gerbils. 2006 , 11, 10-20	32
955	Is <i>Helicobacter pylori</i> a true microaerophile?. 2006 , 11, 296-303	45
954	<i>Helicobacter pylori</i> infection and CagA protein translocation in human primary gastric epithelial cell culture. 2006 , 11, 451-9	22
953	Quantitative analysis of representative proteome components and clustering of <i>Helicobacter pylori</i> clinical strains. 2006 , 11, 533-43	25
952	Pharmacoeconomic comparison of <i>Helicobacter pylori</i> eradication regimens. 2006 , 28, 207-14	8
951	Gastric H,K-ATPase as a drug target. 2006 , 51, 823-33	25
950	Factors associated with the development of reflux esophagitis after <i>Helicobacter pylori</i> eradication. 2006 , 51, 539-42	11
949	Intra-familial transmission of <i>Helicobacter pylori</i> infection in children of households with multiple generations in Vietnam. 2006 , 21, 459-63	14
948	Tetracycline-containing Chitosan Microspheres for Local Treatment of <i>Helicobacter pylori</i> Infection. 2006 , 14, 3-14	14

- 947 Beruflich bedingte Helicobacter-pylori-Infektionen bei Gastroenterologen und ihren Assistenten. **2006**, 8, 129-135
- 946 Helicobacter pylori SabA adhesin evokes a strong inflammatory response in human neutrophils which is down-regulated by the neutrophil-activating protein. **2006**, 195, 195-206 25
- 945 Protein evolutionary rates correlate with expression independently of synonymous substitutions in Helicobacter pylori. **2006**, 62, 600-14 5
- 944 Indikationen zur Helicobacter-pylori-Eradikation. **2006**, 1, 259-265
- 943 A bug that can dig a hole in the stomach!. **2006**, 11, 36-40
- 942 Molecular signatures (unique proteins and conserved indels) that are specific for the epsilon proteobacteria (Campylobacteriales). **2006**, 7, 167 35
- 941 2005 Gregg Lecture: Congenital cataract--from rubella to genetics. **2006**, 34, 199-207 7
- 940 Helicobacter: the ease and difficulty of a new discovery (Nobel lecture). **2006**, 1, 672-85 18
- 939 Helicobacter connections. **2006**, 1, 783-802 35
- 938 Helicobacter pylori and infantile hypertrophic pyloric stenosis: is there a possible relationship?. **2006**, 42, 262-4 11
- 937 Expression and characterization of a histidine-rich protein, Hpn: potential for Ni²⁺ storage in Helicobacter pylori. **2006**, 393, 285-93 98
- 936 The power of pharmacological sciences: the example of proton pump inhibitors. **2006**, 76, 148-55; discussion 156 7
- 935 Researchers and clinicians: a growing divide or narrowing gap?. **2006**, 36, 451-61 4
- 934 Helicobacter pylori occurrence and transmission: a family affair?. **2006**, 38, 407-17 73
- 933 Expression profiling of glycosyltransferases using RT-PCR. **2006**, 416, 129-40 2
- 932 Pyloroplasty for benign gastric outlet obstruction--indications and techniques. **2006**, 95, 11-6 21
- 931 CD4⁺ CD25⁺ regulatory T cells modulate the T-cell and antibody responses in helicobacter-infected BALB/c mice. **2006**, 74, 3519-29 47
- 930 Nickel represses the synthesis of the nickel permease NixA of Helicobacter pylori. **2006**, 188, 1245-50 45

929	Quality indicators for colonoscopy. 2006 , 101, 873-85	602
928	Who ate whom? Adaptive Helicobacter genomic changes that accompanied a host jump from early humans to large felines. 2006 , 2, e120	129
927	A past history of gastric ulcers and Helicobacter pylori infection increase the risk of gastric malignant lymphoma. 2006 , 27, 1391-7	22
926	Antimutator role of the DNA glycosylase mutY gene in Helicobacter pylori. 2006 , 188, 6224-34	36
925	Mutation of luxS affects motility and infectivity of Helicobacter pylori in gastric mucosa of a Mongolian gerbil model. 2006 , 55, 1477-1485	50
924	Assay of human gastric mucin as a natural antibiotic against Helicobacter pylori. 2006 , 415, 164-79	5
923	Herbs, spices and gut health. 2006 , 151-176	1
922	A Helicobacter pylori vacuolating toxin mutant that fails to oligomerize has a dominant negative phenotype. 2006 , 74, 1786-94	28
921	The cell-specific phenotype of the polymorphic vacA midregion is independent of the appearance of the cell surface receptor protein tyrosine phosphatase beta. 2006 , 74, 49-55	19
920	Eradication of Helicobacter pylori: are rifaximin-based regimens effective?. 2006 , 73 Suppl 1, 129-35	21
919	Histopathologic examination for Helicobacter pylori as a possible etiopathogenic factor in laryngeal carcinoma. 2006 , 52, 80-2	22
918	Structural studies of FlaA1 from Helicobacter pylori reveal the mechanism for inverting 4,6-dehydratase activity. 2006 , 281, 24489-95	43
917	Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. 2006 , 19, 597-613	171
916	Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911-2000, England and Wales. 2006 , 35, 1090-7	31
915	Helicobacter pylori seropositivity and stool antigen in patients with hyperemesis gravidarum. 2006 , 2006, 73073	22
914	Peptic ulcer disease today. 2006 , 3, 80-9	140
913	Helicobacter pylori-associated immune thrombocytopenia. 2006 , 17, 71-7	39
912	Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. 2006 , 176, 5306-13	61

911	The antioxidant protein alkylhydroperoxide reductase of <i>Helicobacter pylori</i> switches from a peroxide reductase to a molecular chaperone function. 2006 , 103, 2552-7	127
910	Nobel Prize in Medicine awarded to a Gastroenterologist in 2005. 2006 , 101, 211	3
909	Crystal structures of gamma-glutamyltranspeptidase from <i>Escherichia coli</i> , a key enzyme in glutathione metabolism, and its reaction intermediate. 2006 , 103, 6471-6	132
908	Use of a combination of brushing technique and the loop-mediated isothermal amplification method as a novel, rapid, and safe system for detection of <i>Helicobacter pylori</i> . 2006 , 44, 4032-7	26
907	Novel targets against <i>Helicobacter pylori</i> : a bioinformatic approach. 2007 , 2, 111-114	4
906	Targeting <i>Helicobacter pylori</i> in gastric carcinogenesis. 2007 , 11, 757-69	6
905	Roles of His-rich hpn and hpn-like proteins in <i>Helicobacter pylori</i> nickel physiology. 2007 , 189, 4120-6	70
904	<i>Helicobacter pylori</i> VacA enhances prostaglandin E2 production through induction of cyclooxygenase 2 expression via a p38 mitogen-activated protein kinase/activating transcription factor 2 cascade in AZ-521 cells. 2007 , 75, 4472-81	35
903	Crystal structure of the <i>Helicobacter pylori</i> vacuolating toxin p55 domain. 2007 , 104, 16293-8	124
902	Changing antimicrobial susceptibility epidemiology of <i>Helicobacter pylori</i> strains in Japan between 2002 and 2005. 2007 , 45, 4006-10	118
901	A distinctive set of genes is upregulated during the inflammation-carcinoma sequence in mouse stomach infected by <i>Helicobacter felis</i> . 2007 , 55, 263-74	17
900	<i>Helicobacter pylori</i> vacuolating cytotoxin inhibits activation-induced proliferation of human T and B lymphocyte subsets. 2007 , 179, 5433-40	89
899	Evidence-based practice and speech-language pathology: strengths, weaknesses, opportunities and threats. 2007 , 59, 118-29	43
898	<i>Helicobacter pylori</i> in colorectal carcinoma tissue. 2007 , 16, 631-3	16
897	Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. 2007 , 16, 875-85	62
896	Genomic methylation: a tool for typing <i>Helicobacter pylori</i> isolates. 2007 , 73, 4243-9	13
895	The HP0165-HP0166 two-component system (ArsRS) regulates acid-induced expression of HP1186 alpha-carbonic anhydrase in <i>Helicobacter pylori</i> by activating the pH-dependent promoter. 2007 , 189, 2426-34	44
894	The neutrophil-activating protein of <i>Helicobacter pylori</i> crosses endothelia to promote neutrophil adhesion in vivo. 2007 , 178, 1312-20	66

893	Animal models of stomach carcinogenesis. 2007 , 35, 636-48	52
892	Effects of vaccination by a recombinant antigen ureB138 (a segment of the beta-subunit of urease) against <i>Helicobacter pylori</i> infection. 2007 , 56, 847-853	15
891	<i>Helicobacter pylori</i> and gastric cancer: the causal relationship. 2007 , 75, 25-35	40
890	<i>Helicobacter pylori</i> EstV: identification, cloning, and characterization of the first lipase isolated from an epsilon-proteobacterium. 2007 , 73, 2423-31	29
889	Self-starvation in the rat: running versus eating. 2007 , 10, 251-7	27
888	Human gastric epithelium produces IL-4 and IL-4delta2 isoform only upon <i>Helicobacter pylori</i> infection. 2007 , 20, 809-18	9
887	The gastric H,K ATPase as a drug target: past, present, and future. 2007 , 41 Suppl 2, S226-42	107
886	Gastroenterology: 1987 and 2007. 2007 , 20, 49-50	
885	Novel methods of quantitative real-time PCR data analysis in a murine <i>Helicobacter pylori</i> vaccine model. 2007 , 25, 2919-29	21
884	Genomic diversity in <i>Helicobacter</i> and related organisms. 2007 , 158, 737-44	20
883	[<i>Helicobacter pylori</i> infection: what's new after the Nobel Prize?]. 2007 , 28, 359-62	0
882	[<i>Helicobacter pylori</i> infection in elderly patients]. 2007 , 28, 400-11	6
881	Quantitative determination of gland mucous cells-type mucin using a monoclonal antibody, HIK1083: its pathophysiological changes in human gastric juice. 2007 , 377, 261-7	3
880	Association between <i>Helicobacter pylori</i> genotypes and gastric disorders in relation to the <i>cag</i> pathogenicity island. 2007 , 59, 7-16	21
879	[<i>Helicobacter pylori</i> infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes]. 2007 , 36, 1191-5	6
878	Alzheimer's disease and <i>Helicobacter pylori</i> infection: Defective immune regulation and apoptosis as proposed common links. 2007 , 68, 378-88	59
877	Review article: the use of gastric acid-inhibitory drugs--physiological and pathophysiological considerations. 1993 , 7, 589-96	16
876	Current management of <i>Helicobacter pylori</i> infections in the elderly. 2007 , 5, 845-56	13

- 875 Relationship between *Helicobacter pylori* infection and esophageal neoplasia: a meta-analysis. **2007**, 5, 1413-7, 1417.e1-2 156
- 874 Tea catechins as a potential alternative anti-infectious agent. **2007**, 5, 497-506 46
- 873 One-pot synthesis of a pentasaccharide with antibiotic activity against *Helicobacter pylori*. **2007**, 1963-5 22
- 872 Childhood *Helicobacter pylori* infection and growth impairment in developing countries: a vicious cycle?. **2007**, 119, e754-9 59
- 871 You can get here from there. **2007**, 88, 119-30
- 870 Synthesis of the anti-*Helicobacter pylori* agent (+)-spiroloxine methyl ether and the unnatural (2"S)-diastereomer. **2007**, 5, 2572-82 23
- 869 Synthesis and assignment of the absolute configuration of the anti-*Helicobacter pylori* agents CJ-12,954 and CJ-13,014. **2007**, 5, 2858-66 18
- 868 Insulin resistance in children with *Helicobacter pylori* infection. **2007**, 30, 236-40 15
- 867 Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of *H. pylori*. **2007**, 57, 413-27 54
- 866 Infection in the elderly. **2007**, 21, 711-43, ix 52
- 865 *Helicobacter* species are associated with possible increase in risk of biliary lithiasis and benign biliary diseases. **2007**, 5, 94 9
- 864 Intracellular *Helicobacter pylori* and gastric carcinogenesis: an "old" frontier worth revisiting. **2007**, 132, 1177-80 13
- 863 Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to *Helicobacter pylori*. **2007**, 133, 150-163.e3 71
- 862 Immunology of *Helicobacter pylori*: insights into the failure of the immune response and perspectives on vaccine studies. **2007**, 133, 288-308 199
- 861 Scientific blindness and cognitive dissonance. **2007**, 39, 289-90; author reply 290
- 860 Gastric epithelial cell proliferation and *cagA* status in *Helicobacter pylori* gastritis at different gastric sites. **2007**, 42, 545-54 12
- 859 Is *Helicobacter pylori* being treated appropriately? A study of inpatients and outpatients in a tertiary care centre. **2007**, 21, 285-8 4
- 858 [Analysis of molecular fingerprint and virulence factors of *Helicobacter pylori* strains]. **2007**, 44, 107-12 4

857 References. **2007**, 181-195

856 Proteomic Techniques for Functional Identification of Bacterial Adhesins. **2007**, 299-325

1

855 Proteomic Analysis of Helicobacter pylori Whole Cell Proteins using the Narrow Range IPG Strips. **2007**, 37, 203

3

854 Comparison of Proteome Component of Helicobacter pylori in Different Atmospheric CO₂ Concentration. **2007**, 37, 213

853 Nodular gastritis and pathologic findings in children and young adults with Helicobacter pylori infection. **2007**, 48, 240-6

22

852 Gastric and Mucosal Ulceration. **2007**, 603-612

851 Gastrointestinal Overview. **2007**, 597-601

850 Glycoconjugates and Bacterial Infections: Helicobacter pylori. **2007**, 439-451

0

849 Comparison of Helicobacter Pylori Colonization on the Tonsillar Surface versus Tonsillar Core Tissue as determined by the CLO test. **2007**, 86, 498-501

7

848 CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. **2007**, 120, 859-67

101

847 Vitamin C supplementation does not protect L-gulono-gamma-lactone oxidase-deficient mice from Helicobacter pylori-induced gastritis and gastric premalignancy. **2008**, 122, 1068-76

19

846 Helicobacter pylori as a class I carcinogen: physiopathology and management strategies. **2007**, 102, 264-73

33

845 Helicobacter pylori polyclonally activates murine CD4(+) T cells in the absence of antigen-presenting cells. **2007**, 37, 1905-15

2

844 Inhibition of gastric H⁺, K⁺-ATPase and Helicobacter pylori growth by phenolic antioxidants of Zingiber officinale. **2007**, 51, 324-32

65

843 Synthesis of indole analogues of the anti-Helicobacter pylori compounds CJ-13,015, CJ-13,102, CJ-13,104 and CJ-13,108. **2007**, 63, 5379-5385

10

842 A novel class of selective anti-Helicobacter pylori agents 2-oxo-2H-chromene-3-carboxamide derivatives. **2007**, 17, 3065-71

34

841 Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. **2007**, 335, 114-122

97

840 Solution structure of conserved hypothetical protein HP0892 from Helicobacter pylori. **2008**, 70, 599-602

7

839	Providing AID to p53 mutagenesis. 2007 , 13, 404-6	14
838	Ribbon-helix-helix transcription factors: variations on a theme. 2007 , 5, 710-20	117
837	Could a virus contribute to weight gain?. 2007 , 31, 1350-6	22
836	Correlation of <i>Helicobacter pylori</i> virulence genotypes vacA and cagA with histological parameters of gastritis and patient's age. 2007 , 20, 878-83	25
835	Increased prevalence of <i>Helicobacter pylori</i> infection in gastric cardia of patients with reflux esophagitis: a study from Jordan. 2007 , 8, 203-6	3
834	East Asian-type <i>Helicobacter pylori</i> cytotoxin-associated gene A protein has a more significant effect on growth of rat gastric mucosal cells than the Western type. 2007 , 22, 355-62	15
833	Clinical relevance of <i>Helicobacter pylori</i> sabA genotype in Japanese clinical isolates. 2007 , 22, 2228-32	18
832	The long-term efficacy of <i>Helicobacter pylori</i> eradication therapy in patients with idiopathic thrombocytopenic purpura. 2007 , 22, 2233-7	18
831	Up-regulation of TFF1 (pS2) expression by TNF-alpha in gastric epithelial cells. 2007 , 22, 936-42	15
830	The concerted action of the <i>Helicobacter pylori</i> cytotoxin VacA and of the v-ATPase proton pump induces swelling of isolated endosomes. 2007 , 9, 1481-90	38
829	Immunostaining of antral gastrin cells is quantitatively increased in <i>Helicobacter pylori</i> gastritis. 1990 , 16, 151-5	17
828	Metabolism of glutamine and glutathione via gamma-glutamyltranspeptidase and glutamate transport in <i>Helicobacter pylori</i> : possible significance in the pathophysiology of the organism. 2007 , 64, 396-406	84
827	Inhibitory effect of nordihydroguaiaretic acid, a plant lignan, on <i>Helicobacter pylori</i> -associated gastric carcinogenesis in Mongolian gerbils. 2007 , 98, 1689-95	20
826	Significance of <i>Campylobacter pylori</i> . 1987 , 1 Suppl 1, 527S-539S	3
825	Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate. 1989 , 3, 21-8	52
824	Natural history of <i>Campylobacter pylori</i> in duodenal ulceration treated with an H2-antagonist. 1989 , 3, 315-20	6
823	Review article: metronidazole and the anaerobic gut flora. 1990 , 4, 227-38	7
822	<i>Helicobacter pylori</i> infection treated with a tripotassium dicitrato bismuthate and metronidazole combination. 1990 , 4, 651-7	40

821	Review article: stomach wars--a mucosal defense initiative. 1991 , 5, 105-14	7
820	Eradication of <i>Helicobacter pylori</i> abolishes 24-hour hypergastrinaemia: a prospective study in healthy subjects. 1991 , 5, 283-90	58
819	<i>Helicobacter pylori</i> : review of research findings. 1991 , 5 Suppl 1, 129-43	10
818	Non-ulcer dyspepsia: myths and realities. 1991 , 5 Suppl 1, 145-62	11
817	Review article: the treatment of <i>Helicobacter pylori</i> infection. 1992 , 6, 291-303	28
816	Experience with 'triple' anti- <i>Helicobacter pylori</i> eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. 1992 , 6, 427-35	142
815	A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. 1995 , 9, 521-8	6
814	The effect of indomethacin-induced gastric mucosal injury on 24-h intragastric acidity and plasma gastrin concentration in healthy volunteers. 1995 , 9, 625-31	7
813	<i>Helicobacter pylori</i> infection induces accumulation of V α T cells via CCR2 upregulation. 2007 , 24, 8-15	
812	Correlation of serum pepsinogen with histological atrophy following successful <i>Helicobacter pylori</i> eradication. 2007 , 24, 23-30	4
811	Changes in biochemical parameters related to atherosclerosis after <i>Helicobacter pylori</i> eradication. 2007 , 24, 58-64	9
810	Use of HP selective medium to detect <i>Helicobacter pylori</i> associated with other enteric bacteria in seawater and marine molluscs. 2007 , 45, 213-8	11
809	Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. 2007 , 43, 56-64	56
808	Ten years after the first <i>Helicobacter pylori</i> genome: comparative and functional genomics provide new insights in the variability and adaptability of a persistent pathogen. 2007 , 50, 165-76	22
807	Does <i>Helicobacter pylori</i> infection per se cause gastric cancer or duodenal ulcer? Inadequate evidence in Mongolian gerbils and inbred mice. 2007 , 50, 184-9	12
806	<i>Helicobacter pylori</i> : longer survival in deep ground water and sea water than in a nutrient-rich environment. 2007 , 115, 1285-91	21
805	<i>Helicobacter pylori</i> in bronchiectasis: a polymerase chain reaction assay in bronchoalveolar lavage fluid and bronchiectatic lung tissue. 2007 , 38, 317-21	16
804	Production of mouse monoclonal antibodies against <i>Helicobacter pylori</i> Lpp20 and mapping the antigenic epitope by phage display library. 2007 , 325, 1-8	13

803	Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in <i>H. pylori</i> -infected gastric epithelial cells. 2007 , 1096, 29-36	12
802	Proof of an association between <i>Helicobacter pylori</i> and idiopathic thrombocytopenic purpura in Latin America. 2007 , 12, 265-73	31
801	Efficacy and safety of <i>Saccharomyces boulardii</i> in the 14-day triple anti- <i>Helicobacter pylori</i> therapy: a prospective randomized placebo-controlled double-blind study. 2007 , 12, 309-16	105
800	Systematic review and meta-analysis from Chinese literature: the association between <i>Helicobacter pylori</i> eradication and improvement of functional dyspepsia. 2007 , 12, 541-6	54
799	Eradication of <i>Helicobacter pylori</i> does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. 2007 , 12, 477-85	43
798	Double-dose, new-generation proton pump inhibitors do not improve <i>Helicobacter pylori</i> eradication rate. 2007 , 12, 638-42	29
797	The long-term impact of <i>Helicobacter pylori</i> eradication on gastric histology: a systematic review and meta-analysis. 2007 , 12 Suppl 2, 32-8	153
796	How to influence health providers. 2007 , 12 Suppl 2, 80-4	2
795	Emerging leaders of gastroenterology and hepatology in the Asia-Pacific region. 2007 , 22, 961-2	2
794	Analysis of the survival of <i>H. pylori</i> within a laboratory-based aquatic model system using molecular and classical techniques. 2007 , 54, 771-7	21
793	Impact of preoperative physiological risk profile on postoperative morbidity and mortality after emergency operation of complicated peptic ulcer disease. 2007 , 31, 1449-57	21
792	Experimental infection of pigs with 'Candidatus <i>Helicobacter suis</i> '. 2007 , 31, 385-95	20
791	Biochemical markers of bone metabolism in children with <i>Helicobacter pylori</i> infection. 2007 , 52, 967-72	13
790	Nickel-binding and accessory proteins facilitating Ni-enzyme maturation in <i>Helicobacter pylori</i> . 2007 , 20, 655-64	70
789	Purification of branched-chain amino acid aminotransferase from <i>Helicobacter pylori</i> NCTC 11637. 2007 , 33, 445-9	4
788	<i>Helicobacter pylori</i> : present status and future prospects in Japan. 2007 , 42, 1-15	116
787	Nodular gastritis in Japanese young adults: endoscopic and histological observations. 2007 , 42, 610-5	28
786	Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. 2007 , 3, 30-8	252

785	The risk of gastric cancer in patients with duodenal and gastric ulcer: research progresses and clinical implications. 2007 , 38, 38-45	9
784	Helicobacter pylori and benign upper digestive disease. 2007 , 21, 261-79	14
783	A historical perspective of Helicobacter gastroduodenitis and its complications. 2007 , 21, 335-46	12
782	Screen-printed immunosensor for quantification of human serum IgG antibodies to Helicobacter pylori. 2007 , 128, 23-30	12
781	Specific T cell responses to Helicobacter pylori predict successful eradication therapy. 2007 , 54, 257-61	12
780	Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. 2008 , 53, 1527-31	52
779	Evaluation of gastric cancer risk using topography of histological gastritis: a large-scaled cross-sectional study. 2008 , 53, 1818-23	21
778	The effect of Helicobacter pylori eradication treatment on the MUC 1 and Lewis antigens level in human gastric juice: a preliminary study. 2008 , 53, 2641-5	5
777	Synthesis and in vitro anti-Helicobacter pylori activity of 2-[(chlorobenzyl)thio]-5-(5-nitro-2-furyl)-1,3,4-thiadiazoles. 2008 , 17, 578-586	8
776	Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. 2008 , 30, 315-27	69
775	Helicobacter pylori infection can change the intensity of gastric Lewis antigen expressions differently between adults and children. 2008 , 15, 29-36	9
774	Helicobacter genotyping and detection in peroperative lavage fluid in patients with perforated peptic ulcer. 2008 , 12, 555-60	10
773	The role of Helicobacter pylori in the pathogenesis of gastric malignancies. 2008 , 2, 131-140	4
772	Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. 2008 , 43, 581-8	54
771	Expression, purification, crystallization and preliminary X-ray analysis of an NADP-dependent glyceraldehyde-3-phosphate dehydrogenase from Helicobacter pylori. 2008 , 64, 723-6	1
770	Analysis of growth phase-dependent proteome profiles reveals differential regulation of mRNA and protein in Helicobacter pylori. 2008 , 8, 2665-75	14
769	Antiulcerogenic effects of coconut (Cocos nucifera) extract in rats. 2008 , 22, 970-2	18
768	Annexin A4: A novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. 2008 , 2, 619-34	39

767	Enzymatic characterization and crystal structure analysis of the D-alanine-D-alanine ligase from <i>Helicobacter pylori</i> . 2008 , 72, 1148-60	18
766	Structure of HP0564 from <i>Helicobacter pylori</i> identifies it as a new transcriptional regulator. 2008 , 73, 265-8	4
765	Bacteria and bacterial rRNA genes associated with the development of colitis in IL-10(-/-) mice. 2008 , 14, 1041-1050	38
764	Proteomic analysis of <i>Helicobacter pylori</i> cellular proteins fractionated by ammonium sulfate precipitation. 2008 , 29, 2891-903	12
763	Therapeutic effects of molecularly designed antigen UREB138 for mice infected with <i>Helicobacter pylori</i> . 2008 , 100, 634-43	7
762	Are individuals with lower neutrophil oxidative burst activity more prone to <i>Helicobacter pylori</i> infection?. 2008 , 23, 132-8	7
761	Synthesis and in vitro anti- <i>Helicobacter pylori</i> activity of N-[5-(5-nitro-2-heteroaryl)-1,3,4-thiadiazol-2-yl]thiomorpholines and related compounds. 2008 , 43, 1575-80	40
760	Anti- <i>Helicobacter pylori</i> activity of derivatives of the phthalide-containing antibacterial agents spiroloxine methyl ether, CJ-12,954, CJ-13,013, CJ-13,102, CJ-13,104, CJ-13,108 and CJ-13,015. 2008 , 16, 6179-85	21
759	Prevalence and risk factors for <i>Helicobacter pylori</i> infection in Chinese populations. 2008 , 13, 157-65	89
758	NMR-based metabonomics for detection of <i>Helicobacter pylori</i> infection in gerbils: which is more descriptive. 2008 , 13, 103-11	22
757	A population-based study of <i>Helicobacter pylori</i> infection in Chinese children resident in Hong Kong: prevalence and potential risk factors. 2008 , 13, 219-24	28
756	IL-17 is involved in <i>Helicobacter pylori</i> -induced gastric inflammatory responses in a mouse model. 2008 , 13, 518-24	69
755	<i>Helicobacter</i> and gastric malignancies. 2008 , 13 Suppl 1, 28-34	44
754	Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for <i>Helicobacter pylori</i> eradication: a meta-analysis. 2008 , 13, 532-41	88
753	Immune response to <i>Helicobacter pylori</i> and its association with the dynamics of chronic gastritis in the antrum and corpus. 2008 , 116, 465-76	15
752	<i>Helicobacter pylori</i> colonization in the larynges of patients with hoarseness. 2008 , 118, 389-93	16
751	Convergence of genetic, nutritional and inflammatory factors in gastrointestinal cancers. 2007 , 65, S157-66	18
750	Changing epidemiology of <i>Helicobacter pylori</i> in Asia. 2008 , 9, 186-9	31

749	Isolation of lactobacilli with probiotic properties from the human stomach. 2008 , 47, 269-74	47
748	<i>Helicobacter pylori</i> infection does not accelerate the age-related progression of arteriosclerosis: a 4-year follow-up study. 2008 , 23, e373-8	8
747	Proteomic identification of biomarkers related to <i>Helicobacter pylori</i> -associated gastroduodenal disease: challenges and opportunities. 2008 , 23, 1657-61	23
746	Inverse nickel-responsive regulation of two urease enzymes in the gastric pathogen <i>Helicobacter mustelae</i> . 2008 , 10, 2586-97	31
745	<i>Helicobacter pylori</i> induces lymphocyte activation in peripheral blood cultures. 1990 , 82, 485-8	76
744	Concurrent genotyping of <i>Helicobacter pylori</i> virulence genes and human cytokine SNP sites using whole genome amplified DNA derived from minute amounts of gastric biopsy specimen DNA. 2008 , 8, 175	16
743	Anemia in children with and without <i>Helicobacter pylori</i> infection. 2008 , 39, 536-40	14
742	Knee-jerk dogma. 2008 , 206, 762-3; author reply 763	2
741	Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate <i>H. pylori</i> . 2008 , 125, 33-41	78
740	Peptic ulcers and their complications. 2008 , 26, 452-457	
739	Molten globule and native state ensemble of <i>Helicobacter pylori</i> flavodoxin: can crowding, osmolytes or cofactors stabilize the native conformation relative to the molten globule?. 2008 , 95, 1913-27	17
738	[Management of <i>Helicobacter pylori</i> infection in primary care in Spain]. 2008 , 31, 327-34	5
737	History of Surgery of the Gastrointestinal Tract. 2008 , 743-757	1
736	Control of gastric acid secretion in health and disease. 2008 , 134, 1842-60	305
735	Every gastroenterologist deserves a gastrointestinal pathologist. 2008 , 40, 627-31	3
734	[Gastrointestinal manifestations of <i>Helicobacter pylori</i> infection in adults: from gastritis to gastric cancer]. 2008 , 37, 519-24	0
733	Peptic ulceration may be a hormonal deficiency disease. 2008 , 70, 1103-7	7
732	<i>Helicobacter hepaticus</i> urease is not required for intestinal colonization but promotes hepatic inflammation in male A/JCr mice. 2008 , 45, 18-24	18

731	A vaccine against <i>Helicobacter pylori</i> : towards understanding the mechanism of protection. 2008 , 298, 161-8	12
730	Production of mouse monoclonal antibodies against <i>Helicobacter pylori</i> Catalase and mapping the antigenic epitope by phage display library. 2008 , 26, 1263-9	17
729	<i>Helicobacter pylori</i> : host genetics and disease outcomes. 2008 , 2, 577-85	30
728	The seroepidemiology of <i>Helicobacter pylori</i> infection in Australia. 2008 , 12, 500-4	43
727	Is eradication of <i>Helicobacter pylori</i> the feasible way to prevent gastric cancer? New evidence and progress, but still a long way to go. 2008 , 107, 591-9	7
726	Quantitative analysis of the effect of <i>Helicobacter pylori</i> on the expressions of SOX2, CDX2, MUC2, MUC5AC, MUC6, TFF1, TFF2, and TFF3 mRNAs in human gastric carcinoma cells. 2008 , 43, 25-33	38
725	Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. 2008 , 88, 1547-65	437
724	Eternity and clinical translation of speech-language pathology research (â). 2008 , 10, 118-26	1
723	Floating in situ gelling system of acetohydroxamic acid for clearance of <i>H. pylori</i> . 2008 , 34, 577-87	18
722	Triple therapy-based targeted nanoparticles for the treatment of <i>Helicobacter pylori</i> . 2008 , 16, 694-705	28
721	A History of Drug Discovery. 2008 , 1-62	3
720	Strategies for Strengthening Causal Inferences in Cross Cultural Research: The Consilience Approach. 2008 , 8, 145-169	86
719	Prevalence of <i>Helicobacter pylori</i> infection among Egyptian children: impact of social background and effect on growth. 2008 , 11, 230-6	56
718	Coming of age. 2008 , 9, 111-20	4
717	Emerging therapies for the treatment of <i>Helicobacter pylori</i> infections. 2008 , 42, 1621-39	18
716	Does <i>Helicobacter pylori</i> protect against asthma and allergy?. 2008 , 57, 561-7	171
715	<i>Helicobacter pylori</i> eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. 2008 , 68, 3540-8	95
714	Immunological status of the stomach in inflammatory bowel disease--comparison between ulcerative colitis and Crohn's disease. 2008 , 77, 145-9	2

713	Stomach and Duodenum. 2008 , 841-874	
712	Crystal structure of the cell wall anchor domain of MotB, a stator component of the bacterial flagellar motor: implications for peptidoglycan recognition. 2008 , 105, 10348-53	110
711	Arterial intima and media calcification: distinct entities with different pathogenesis or all the same?. 2008 , 3, 1583-4	38
710	The role of luminal factors in the recovery of gastric function and behavioral changes after chronic <i>Helicobacter pylori</i> infection. 2008 , 295, G664-70	39
709	Recent advances that favor development of a vaccine for <i>Helicobacter pylori</i> infection. 2008 , 2, 539	
708	Infectious Agents and Cancer. 2008 , 67-89	
707	Effects of multispecies probiotic combination on <i>helicobacter pylori</i> infection in vitro. 2008 , 15, 1472-82	52
706	Lurking in the shadows: emerging rodent infectious diseases. 2008 , 49, 277-90	26
705	Extensive atrophic gastritis increases intraduodenal hydrogen gas. 2008 , 2008, 584929	3
704	Parallels between pathogens and gluten peptides in celiac sprue. 2008 , 4, e34	46
703	Alpha1,4GlcNAc-capped mucin-type O-glycan inhibits cholesterol alpha-glucosyltransferase from <i>Helicobacter pylori</i> and suppresses <i>H. pylori</i> growth. 2008 , 18, 549-58	51
702	Differences in virulence markers between <i>Helicobacter pylori</i> strains from Iraq and those from Iran: potential importance of regional differences in <i>H. pylori</i> -associated disease. 2008 , 46, 1774-9	100
701	Gastric cancer and <i>Helicobacter pylori</i> : the bug, the host or the environment?. 2008 , 84, 169-70	5
700	<i>Helicobacter pylori</i> and esophageal cancer risk: a meta-analysis. 2008 , 1, 329-38	246
699	Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express Toll-like receptor 4 in contrast to other lymphomas infiltrating the stomach. 2008 , 19, 566-9	12
698	A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from <i>Helicobacter pylori</i> : implication for nickel homeostasis and bismuth susceptibility. 2008 , 283, 15142-51	87
697	Double-contrast upper gastrointestinal radiography: a pattern approach for diseases of the stomach. 2008 , 246, 33-48	52
696	Back to the future. 2008 , 190, 561-4	2

695	Seroprevalence of <i>Helicobacter pylori</i> infection in patients with chronic nonspecific pharyngitis: preliminary study. 2008 , 122, 61-4	11
694	Vascular depression: myth or reality?. 2008 , 20, 645-52	30
693	Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of <i>Helicobacter pylori</i> . 2008 , 56, 1412-6	2
692	Inhibitory and Killing Activities of Medicinal Plants against Multiple Antibiotic-resistant <i>Helicobacter pylori</i> . 2008 , 54, 81-88	22
691	Homeostatic mass control in gastric non-neoplastic epithelia under infection of <i>Helicobacter pylori</i> : an immunohistochemical analysis of cell growth, stem cells and programmed cell death. 2008 , 41, 23-38	11
690	Reflux esophagitis and <i>Helicobacter pylori</i> infection in patients with scleroderma. 2008 , 47, 1555-9	14
689	Effects of <i>Helicobacter</i> infection on developmental toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Holtzman rats. 2008 , 37, 171-5	4
688	Changes in indications for upper gastrointestinal tract endoscopy and endoscopic findings during the last fifteen years in south-western Greece. 2008 , 336, 21-6	4
687	<i>Helicobacter pylori</i> infection upregulates interleukin-18 production from gastric epithelial cells. 2008 , 20, 1144-50	30
686	<i>Helicobacter pylori</i> IgG antibodies in aqueous humor and serum of subjects with primary open angle and pseudo-exfoliation glaucoma in a South Indian population. 2008 , 17, 605-10	31
685	Expression of CCL18 (Dendritic Cell-Derived Chemokine) mRNA in Gastric Mucosa Infected with <i>Helicobacter pylori</i> . 2008 , 38, 227	
684	Adverse events with bismuth salts for <i>Helicobacter pylori</i> eradication: systematic review and meta-analysis. 2008 , 14, 7361-70	85
683	[Oncogenic mechanism of <i>Helicobacter pylori</i>]. 2008 , 31, 132-40	4
682	[Molecular mechanism of <i>Helicobacter pylori</i> -mediated pathogenesis]. 2008 , 63, 387-90	
681	Identification of Proteins Related to Nickel Homeostasis in <i>Helicobacter pylori</i> by Immobilized Metal Affinity Chromatography and Two-Dimensional Gel Electrophoresis. 2008 , 2008, 289490	18
680	Pathology: The Clinical Description of Human Disease. 2009 , 197-207	2
679	Survey of <i>Helicobacter</i> infection in domestic and feral cats in Korea. 2009 , 10, 67-72	17
678	Validation of POSSUM-physiological Score as Predictors of Post-operative Morbidity and Mortality after Emergency Operation for Peptic Ulcer Complications. 2009 , 77, 391	2

- 677 Altera es histol gicas da pars esophagea de su os e sua rela  com *Helicobacter* spp.. **2009**, 61, 553-560 4
- 676 Ten-years comparative study after surgical treatment of perforated peptic ulcer according to ulcer relapse between *H. Pylori* positive, after eradication, and negative patients. **2009**, 22, 15-18
- 675 Inflammatory Disorders of the Stomach. **2009**, 269-320 6
- 674 *Helicobacter Pylori* associated global gastric cancer burden. **2009**, 14, 1490-504 67
- 673 Bacterial microbiota profiling in gastritis without *Helicobacter pylori* infection or non-steroidal anti-inflammatory drug use. **2009**, 4, e7985 155
- 672 A redox basis for metronidazole resistance in *Helicobacter pylori*. **2009**, 53, 1884-91 33
- 671 *Helicobacter pylori* CagA causes mitotic impairment and induces chromosomal instability. **2009**, 284, 22166-22172 52
- 670 *Helicobacter pylori* moves through mucus by reducing mucin viscoelasticity. **2009**, 106, 14321-6 269
- 669 Vertical *Helicobacter pylori* transmission from Mongolian gerbil mothers to pups. **2009**, 58, 656-662 9
- 668 The CD4+ T cell-mediated IFN-gamma response to *Helicobacter* infection is essential for clearance and determines gastric cancer risk. **2009**, 182, 7085-101 130
- 667 Structural analysis of the DNA-binding domain of the *Helicobacter pylori* response regulator ArsR. **2009**, 284, 6536-45 12
- 666 Cumulative *H. pylori* eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. **2009**, 104, 21-5 110
- 665 Glimpse of the epidemiological research on *Helicobacter pylori* in Saudi Arabia. **2009**, 15, 85 3
- 664 *Helicobacter pylori* infection in children. **2009**, 15, 86-94 30
- 663 The pH-responsive regulon of HP0244 (FlgS), the cytoplasmic histidine kinase of *Helicobacter pylori*. **2009**, 191, 449-60 37
- 662 The role of breast-feeding in the prevention of *Helicobacter pylori* infection: a systematic review. **2009**, 48, 430-7 40
- 661 How Quantification Persuades When It Persuades. **2009**, 4, 132-147 7
- 660 *Helicobacter pylori*-positive versus *Helicobacter pylori*-negative idiopathic peptic ulcers in children with their long-term outcomes. **2009**, 48, 299-305 29

659	Helicobacter pylori's unconventional role in health and disease. 2009 , 5, e1000544	69
658	Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease?. 2009 , 5, e1000234	49
657	A novel system of cytoskeletal elements in the human pathogen Helicobacter pylori. 2009 , 5, e1000669	57
656	Roles of gastric mucin-type O-glycans in the pathogenesis of Helicobacter pylori infection. 2009 , 19, 453-61	42
655	Helicobacter pylori induces gastric mucosal intestinal metaplasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression. 2009 , 297, G312-22	38
654	Loss of the apical V-ATPase α -subunit VHA-6 prevents acidification of the intestinal lumen during a rhythmic behavior in <i>C. elegans</i> . 2009 , 297, C1071-81	45
653	Cancer prevention research: back to the future. 2009 , 2, 503-13	5
652	Differences in genome content among Helicobacter pylori isolates from patients with gastritis, duodenal ulcer, or gastric cancer reveal novel disease-associated genes. 2009 , 77, 2201-11	32
651	Role of ASC in the mouse model of Helicobacter pylori infection. 2009 , 57, 327-38	16
650	Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. 2009 , 18, 1154-68	25
649	In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. 2009 , 53, 4231-9	17
648	Cancer prevention: from 1727 to milestones of the past 100 years. 2009 , 69, 5269-84	94
647	The 3'-to-5' exonuclease (encoded by HP1248) of Helicobacter pylori regulates motility and apoptosis-inducing genes. 2009 , 191, 2691-702	25
646	Laser spectroscopy for atmospheric and environmental sensing. 2009 , 9, 10447-512	77
645	Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. 2009 , 69, 8166-74	50
644	Crystal structure of hypothetical protein HP0062 (O24902_HELPY) from Helicobacter pylori at 1.65 Å resolution. 2009 , 146, 535-40	6
643	Assessing the risks and benefits of treating Helicobacter pylori infection. 2009 , 2, 141-7	16
642	Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers. 2009 , 18, 51-6	21

641	Synergistic effect of imp/ostA and msbA in hydrophobic drug resistance of <i>Helicobacter pylori</i> . 2009 , 9, 136	13
640	Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against <i>Helicobacter pylori</i> in simulated gastric juice. 2009 , 9, 187	37
639	Outer membrane vesicles of <i>Helicobacter pylori</i> TK1402 are involved in biofilm formation. 2009 , 9, 197	171
638	Emodin targets the beta-hydroxyacyl-acyl carrier protein dehydratase from <i>Helicobacter pylori</i> : enzymatic inhibition assay with crystal structural and thermodynamic characterization. 2009 , 9, 91	18
637	In vitro susceptibility of <i>Campylobacter pyloridis</i> to cimetidine, sucralfate, bismuth and sixteen antibiotics. 1987 , 95, 147-9	7
636	Detection of cytotoxin genotypes of <i>Helicobacter pylori</i> in stomach, saliva and dental plaque. 2009 , 54, 684-8	38
635	The secreted <i>Helicobacter</i> cysteine-rich protein A causes adherence of human monocytes and differentiation into a macrophage-like phenotype. 2009 , 583, 1637-43	30
634	Parasitism by the "slow" bacterium <i>Helicobacter pylori</i> leads to altered gastric homeostasis and neoplasia. 1994 , 94, 4-8	283
633	VacA pores as portable portals for urea. 2001 , 108, 803-4	1
632	VacA pores as portable portals for urea. 2001 , 108, 803-804	8
631	Induction of B cell responses in the stomach of <i>Helicobacter pylori</i> -infected subjects after oral cholera vaccination. 1998 , 102, 51-6	68
630	Involvement of the CD95 (APO-1/Fas) receptor and ligand system in <i>Helicobacter pylori</i> -induced gastric epithelial apoptosis. 1998 , 102, 1506-14	191
629	What lurks beneath: IL-11, via Stat3, promotes inflammation-associated gastric tumorigenesis. 2008 , 118, 1628-31	15
628	DC-derived IL-18 drives Treg differentiation, murine <i>Helicobacter pylori</i> -specific immune tolerance, and asthma protection. 2012 , 122, 1082-96	211
627	Unraveling the mystery of the hygiene hypothesis through <i>Helicobacter pylori</i> infection. 2012 , 122, 801-4	9
626	<i>Helicobacter</i> urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. 2015 , 125, 3297-302	92
625	Local pH elevation mediated by the intrabacterial urease of <i>Helicobacter pylori</i> cocultured with gastric cells. 2000 , 106, 339-47	47
624	Influence of pretreatment with H2 receptor antagonists on the cure rates of <i>Helicobacter pylori</i> eradication. 2011 , 17, CR235-40	6

623	Association Between Helicobacter pylori Infection and Risk of Periodontal Diseases in Han Chinese: A Case-Control Study. 2016 , 22, 121-6	13
622	Protective effect of halophyte Salsola komarovi Iljin against gastric ulcer Induced by alcohol treatment in rats. 2014 , 15, 170-175	2
621	Exhaustive exploring using Artificial Neural Network for identification of SNPs combination related to Helicobacter pylori infection susceptibility. 2005 , 5, 15-26	3
620	Phylotyping and functional analysis of two ancient human microbiomes. 2008 , 3, e3703	71
619	One-step chromatographic purification of Helicobacter pylori neutrophil-activating protein expressed in Bacillus subtilis. 2013 , 8, e60786	9
618	Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. 2013 , 8, e62162	63
617	Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance. 2013 , 8, e73867	24
616	Conformational analysis of isolated domains of Helicobacter pylori CagA. 2013 , 8, e79367	13
615	Helicobacter pylori seropositivity's association with markers of iron, 1-carbon metabolism, and antioxidant status among US adults: a structural equations modeling approach. 2015 , 10, e0121390	7
614	Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn's Disease Patients: Results from the CONNECT Study. 2015 , 10, e0144390	26
613	Modeling the Role of Lanthionine Synthetase C-Like 2 (LANCL2) in the Modulation of Immune Responses to Helicobacter pylori Infection. 2016 , 11, e0167440	12
612	Prevalence of Infection in Samples of Gastric Biopsies. 2017 , 10, 33-41	5
611	Prevalence of among children in a training and research hospital clinic in Istanbul and comparison with Updated Sydney Classification Criteria. 2020 , 7, 499-505	0
610	Outcomes after completion total gastrectomy for gastric remnant cancer: experience from a Canadian tertiary centre. 2018 , 61, 270-277	3
609	Recent advances in gastro retentive drug delivery systems and its application on treatment of H. Pylori infections. 2018 , 7,	5
608	Histologic Findings and Inflammatory Reactions After Long-term Colonization of Helicobacter felis in C57BL/6 Mice. 2014 , 19, 224-30	10
607	SHP2-Independent Tyrosine Dephosphorylation of Cortactin and Vinculin during Infection with. 2020 , 10, 20-27	3
606	[The Parkinson puzzle]. 2012 , 153, 2060-9	3

605	PROSPECTIVE STUDY FOR VALIDATION OF A SINGLE PROTOCOL FOR THE 13C-UREA BREATH TEST USING TWO DIFFERENT DEVICES IN THE DIAGNOSIS OF H. PYLORI INFECTION. 2019 , 56, 197-201	4
604	[Expression of ABH and Lewis antigens in chronic gastritis and pre-neoplastic alterations in gastric mucosa]. 2002 , 39, 222-32	10
603	Seroprevalence of Helicobacter pylori in patients with colon adenomas in a Brazilian university hospital. 2009 , 46, 97-101	16
602	Relationship between cagA-positive Helicobacter pylori infection and risk of gastric cancer: a case control study in Porto Alegre, RS, Brazil. 2011 , 48, 41-5	11
601	Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial. 2012 , 49, 56-63	4
600	Determinação histopatológica da presença do helicobacter pylori em câncer gástrico. 2011 , 24, 59-63	3
599	Accuracy of the 14C-urea breath test for the diagnosis of Helicobacter pylori. 2002 , 120, 68-71	7
598	The endoscopically visualized changes in the mucous membrane of the upper gastrointestinal tract of the children depending on Helicobacter pylori and Epstein-Barr. 2018 , 7, 4	4
597	Positive status is associated with better overall survival for gastric cancer patients: evidence from case-cohort studies. 2017 , 8, 79604-79617	4
596	Loss of TFF1 promotes Helicobacter pylori-induced β -catenin activation and gastric tumorigenesis. 2015 , 6, 17911-22	20
595	Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NF κ B pathway in gastric cancer development. 2016 , 7, 9788-800	48
594	Role of Probiotics in Prophylaxis of Helicobacter pylori Infection. 2019 , 20, 137-145	8
593	Achievements in Cancer Research and its Therapeutics in Hundred Years. 2019 , 19, 1545-1562	0
592	Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. 2008 , 3, 190-203	26
591	Role of food in environmental transmission of. 2017 , 8, 146-152	9
590	Comparison of polymerase chain reaction-based genotyping of Helicobacter pylori by direct polymerase chain reaction from biopsies and cultures from patients with dyspepsia in Nigeria. 2019 , 31,	2
589	Pangenomic studies of Helicobacter pylori: a key to understanding pathogenesis and human history. 2019 , 31,	3
588	Helicobacter pylori and hematological disorders. 2019 , 65, 204-213	9

587	From Sidney to OLGA: an overview of atrophic gastritis. 2018 , 89, 93-99	10
586	[European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years]. 2019 , 91, 16-24	10
585	CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection. 2019 , 20, 1243-1247	6
584	Spiral bacteria in the human stomach: the gastric helicobacters. 1995 , 1, 79-85	47
583	Gastritis: update on etiological features and histological practical approach. 2020 , 112, 153-165	4
582	and Gastric Inflammation: Role of MUC1 Mucin. 2012 , 2, 125-132	6
581	Helicobacter pylori and gastroduodenal ulcer disease. 2009 , 106, 801-8	14
580	Use of Fourier-Transform Infrared Spectroscopy (FT-IR) for Monitoring Experimental Infection and Related Inflammatory Response in Guinea Pig Model. 2020 , 22,	4
579	Dysregulated Immune Responses by ASK1 Deficiency Alter Epithelial Progenitor Cell Fate and Accelerate Metaplasia Development during Infection. 2020 , 8,	2
578	Biological characteristics and virulence of Helicobacter pylori. 2018 , 20, 14-23	6
577	Non-invasive diagnosis of H pylori infection: evaluation of serological tests with and without current infection marker CIM. 2008 , 14, 1231-6	21
576	Diversity of Helicobacter pylori isolates in expression of antigens and induction of antibodies. 2008 , 14, 4816-22	26
575	Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. 2008 , 14, 5217-22	56
574	Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. 2008 , 14, 6224-7	16
573	Low grade gastric mucosa associated lymphoid tissue lymphoma: treatment strategies based on 10 year follow-up. 2004 , 10, 223-6	36
572	Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastro-esophageal reflux disease in Chinese. 2004 , 10, 672-5	22
571	One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. 2005 , 11, 1680-4	6
570	Enhanced plasma ghrelin levels in Helicobacter pylori-colonized, interleukin-1-receptor type 1-homozygous knockout (IL-1R1 ^{-/-}) mice. 2005 , 11, 4148-53	15

569	NF-kappaB and ERK-signaling pathways contribute to the gene expression induced by cag PAI-positive-Helicobacter pylori infection. 2005 , 11, 6134-43	21
568	Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization. 2005 , 11, 6305-11	80
567	Helicobacter pylori-infected animal models are extremely suitable for the investigation of gastric carcinogenesis. 2005 , 11, 7063-71	29
566	Helicobacter pylori upregulates prion protein expression in gastric mucosa: a possible link to prion disease. 2005 , 11, 7651-6	21
565	Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. 2005 , 11, 1032-6	21
564	Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients. 2005 , 11, 976-81	40
563	Helicobacter pylori virulence factors in duodenal ulceration: A primary cause or a secondary infection causing chronicity. 2006 , 12, 6-9	11
562	Helicobacter pylori and other Helicobacter species DNA in human bile samples from patients with various hepato-biliary diseases. 2006 , 12, 2181-6	28
561	Third-line rescue therapy for Helicobacter pylori infection. 2006 , 12, 2313-9	34
560	Hydrogen and methane gases are frequently detected in the stomach. 2006 , 12, 3088-91	5
559	Surgical perspectives in peptic ulcer disease and gastritis. 2006 , 12, 3248-52	15
558	Assessing risks for gastric cancer: new tools for pathologists. 2006 , 12, 5622-7	13
557	Distinct patterns of mucosal apoptosis in H pylori-associated gastric ulcer are associated with altered FasL and perforin cytotoxic pathways. 2006 , 12, 6133-41	6
556	Does gastric atrophy exist in children?. 2006 , 12, 6274-9	29
555	Precise role of H pylori in duodenal ulceration. 2006 , 12, 6413-9	47
554	Influence of H pylori on plasma ghrelin in patients without atrophic gastritis. 2007 , 13, 1595-8	16
553	Cross-reactivity of anti-H pylori antibodies with membrane antigens of human erythrocytes. 2007 , 13, 3742-6	4
552	Adherence and invasion of mouse-adapted H pylori in different epithelial cell lines. 2007 , 13, 845-50	6

551	Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates. 2010 , 16, 320-9	3
550	Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. 2010 , 16, 5118-21	59
549	Five methods for detection of Helicobacter pylori in the Turkish population. 2011 , 17, 5172-6	16
548	Gastroenterostoma after Billroth antrectomy as a premalignant condition. 2012 , 18, 3201-6	17
547	Gastric carcinogenesis. 2012 , 18, 5164-70	37
546	Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. 2012 , 18, 5669-78	39
545	Helicobacter pylori and interleukin-8 in gastric cancer. 2013 , 19, 8192-202	71
544	Pseudomonas fluorescens-like bacteria from the stomach: a microbiological and molecular study. 2013 , 19, 1056-67	18
543	Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications. 2014 , 20, 5294-301	37
542	Biofilm and Helicobacter pylori: from environment to human host. 2014 , 20, 5632-8	37
541	Helicobacter pylori infection in older people. 2014 , 20, 6364-73	33
540	Critical pathogenic steps to high risk Helicobacter pylori gastritis and gastric carcinogenesis. 2014 , 20, 6412-9	14
539	Carcinogenic Helicobacter pylori in gastric pre-cancer and cancer lesions: association with tobacco-chewing. 2014 , 20, 6860-8	7
538	Helicobacter pylori eradication in patients with chronic immune thrombocytopenic purpura. 2014 , 20, 6918-23	9
537	Helicobacter pylori: friend or foe?. 2014 , 20, 8979-85	25
536	Structural modifications of Helicobacter pylori lipopolysaccharide: an idea for how to live in peace. 2014 , 20, 9882-97	37
535	Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique?. 2014 , 20, 11546-51	24
534	Clinical proteomics identifies potential biomarkers in Helicobacter pylori for gastrointestinal diseases. 2014 , 20, 1529-36	12

533	Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line <i>Helicobacter pylori</i> eradication. 2015 , 21, 10234-41	9
532	Seven-day triple therapy is a better choice for <i>Helicobacter pylori</i> eradication in regions with low antibiotic resistance. 2015 , 21, 13073-9	13
531	Impact of <i>Helicobacter pylori</i> on the healing process of the gastric barrier. 2016 , 22, 7536-58	25
530	inhibits the cleavage of TRAF1 a CagA-dependent mechanism. 2016 , 22, 10566-10574	2
529	Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 , 23, 668-675	28
528	Nutrition status and infection in patients receiving hemodialysis. 2018 , 24, 1591-1600	5
527	Clinicopathological features of early gastric cancers arising in uninfected patients. 2020 , 26, 2618-2631	6
526	Deletion of <i>Helicobacter pylori</i> vacuolating cytotoxin gene by introduction of directed mutagenesis. 2003 , 9, 2251-7	10
525	MicroRNA-146a inhibits the inflammatory responses induced by interleukin-17A during the infection of <i>Helicobacter pylori</i> . 2019 , 19, 1388-1395	5
524	The effect of eradication of <i>Helicobacter pylori</i> upon the duodenal ulcer recurrence--a 24 month follow-up study. 1994 , 9, 72-9	8
523	Electron microscopic evaluation of adhesion of <i>Helicobacter pylori</i> to the gastric epithelial cells in chronic gastritis. 2002 , 17, 45-50	10
522	Antimicrobial and Antiulcer Activities of Methanol Extract of <i>Allium sativum</i> on <i>Helicobacter pylori</i> . 2006 , 6, 521-526	8
521	Peptic Ulcer Disease: Clinically Relevant Causes and Treatments. 2009 , 32,	5
520	Evaluation of methods for <i>H. pylori</i> detection in PPI consumption using culture, rapid urease test and smear examination. 2015 , 3, 11	8
519	Dietary, non-microbial intervention to prevent <i>Helicobacter pylori</i> -associated gastric diseases. 2015 , 3, 122	11
518	Alopecia areata is not associated with <i>Helicobacter pylori</i> . 2009 , 54, 17-9	11
517	The Interaction of Infection and Type 2 Diabetes Mellitus. 2019 , 8, 15	22
516	in Dyspepsia: Phenotypic and Genotypic Methods of Diagnosis. 2017 , 9, 131-134	6

515	Infection in Malnourished Children in Lagos. 2019 , 60, 205-210	3
514	Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. 2017 , 23, 275-280	18
513	[Guidelines of treatment for non-bleeding peptic ulcer disease]. 2009 , 54, 285-97	13
512	Prevalence of <i>Helicobacter pylori</i> vacA, cagA, dupA and oipA Genotypes in Patients with Gastric Disease. 2017 , 07, 1-9	7
511	Study on Tongue Coating Microbiota in Patients with Atrophic Gastritis. 2020 , 10, 681-690	1
510	Detection of <i>Helicobacter pylori</i> in dental plaque of mexican children by real-time PCR. 2014 , 06, 231-235	5
509	<i>Helicobacter pylori</i> and upper gastrointestinal diseases: A review. 2014 , 06, 263-273	2
508	Helicobacter Pylori Infection Is Associated with Dyslipidemia and Increased Levels of Oxidized LDL in Type-2 Diabetes Mellitus. 2016 , 06, 185-190	2
507	Role of interleukin polymorphisms in gastric cancer: "Pros and cons". 2010 , 2, 265-71	5
506	Role of Helicobacter pylori in gastric cancer: Updates. 2016 , 8, 147-58	44
505	Management of Antibiotic-Resistant Infection: Perspectives from Vietnam. 2019 , 13, 483-497	17
504	Anti-Helicobacter pylori Activity and Structure-Activity Relationships of Berberine Derivatives. 2009 , 30, 3147-3149	25
503	Helicobacter pylori: Prevalence in 352 consecutive patients with dyspepsia. 1994 , 14, 134-5	6
502	Helicobacter pylori-associated chronic antral gastritis in Kuwait - A histopathological study. 1995 , 15, 570-4	4
501	Does Helicobacter pylori infection influence the major postoperative complication rate after sleeve gastrectomy? A retrospective cohort study in an endemic region. 2018 , 29, 379-383	3
500	13C-Urea Breath Test Accuracy for Helicobacter pylori Infection in the Asian Population: A Meta-Analysis. 2019 , 85,	10
499	Irregular Meal Timing Is Associated with Helicobacter pylori Infection and Gastritis. 2013 , 2013, 714970	6
498	Detection of Helicobacter pylori in Oral Lesions. 2013 , 7, 230-7	16

497	Bacteria, gastritis, acid hyosecretion and peptic ulcer. 1985 , 142, 431	10
496	Pyloric CLO in the human stomach. 1985 , 143, 174	18
495	The state of medical research in Australia. 1994 , 161, 649-649	2
494	Helicobacter pylori: what does it taste like?. 2014 , 201, 22	3
493	Relevance Epistasis Network of Gastritis for Intra-chromosomes in the Korea Associated Resource (KARE) Cohort Study. 2014 , 12, 216-24	3
492	Sequence Analysis of Hypothetical Proteins from 26695 to Identify Potential Virulence Factors. 2016 , 14, 125-135	12
491	Prevalence of Helicobacter pylori and Determination of Antibiotic Resistance in Patients with Gastritis Referred to Shahid Beheshti University of Medical Sciences Hospitals in Tehran Between 2010 and 2011. 2012 , 8, 18-22	5
490	Frequency of sabA Gene in Helicobacter pylori Strains Isolated From Patients in Tehran, Iran. 2013 , 15, 767-70	11
489	Association Between IL-17, IL-8 and IL-18 Expression in Peripheral Blood and Helicobacter Pylori Infection in Mongolian Gerbils. 2015 , 8, e21503	1
488	Development and Diagnostic Evaluation of Loop-Mediated Isothermal Amplification Using a New Gene Target for Rapid Detection of Helicobacter pylori. 2016 , 9, e28831	12
487	Evaluation of Gastric Lesions Based on Helicobacter pylori and Helicobacter-Like Organisms (HLOs) in Cats; A Histopathological and Bacteriological Study. 2014 , 7, e9129	3
486	[Relationship between oral and gut microbes]. 2017 , 35, 322-327	1
485	Are theoretical results 'Results'?. 2018 , 7,	15
484	The Effect of Probiotics for Helicobacter pylori. 2011 , 11, 26	1
483	Annual Eradication Rates of Helicobacter pylori Infection over 9 Years in Incheon. 2015 , 15, 103	2
482	Eradication Rates of First-line and Second-line Therapy for Helicobacter pylori Infection in Gyeongnam Province. 2015 , 15, 160	0
481	Application of 16S rRNA gene sequencing in detection. 2020 , 8, e9099	6
480	Seasonal Variations and Trends in Hospitalization for Peptic Ulcer Disease in the United States: A 12-Year Analysis of the Nationwide Inpatient Sample. 2016 , 8, e854	12

- 479 Concerning Pharmacogenetics, Pharmacogenomics and Personalized Medicine. **2021**, 541-569
- 478 Human gastric cancer risk screening: From rat pepsinogen studies to the ABC method. **2021**, 97, 462-478 1
- 477 Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and β -Lactams. **2021**, 26, 5
- 476 A colon cancer "prequel". **2021**, 29, 1480-1481
- 475 Pattern recognition receptors and their roles in the host response to infection. **2021**, 16, 1229-1238 0
- 474 Time trends in the prevalence of infection in patients with peptic ulcer disease: a single-center retrospective study in Shanghai. **2021**, 49, 3000605211051167 0
- 473 The Helicobacter pylori detection rate by using combination of rapid urease test at antrum and body vs histopathology in population who stop proton pump inhibitor less than 2 weeks. **2021**, 3, 339
- 472 Bismuth triple and quadruple studies for Helicobacter pylori eradication in Canada. **2000**, 567-573
- 471 The agenda for the immunologist. **2000**, 663-668
- 470 Autoimmune gastritis and antigenic mimicking. **2000**, 289-293
- 469 Less Conventional Inflammatory Diseases. **2000**, 217-229
- 468 Die Renaissance des morphologischen Bedürfnisses im 20. Jahrhundert: Endoskopische Biopsie und Punktionshistologie. **2001**, 583-605
- 467 [Changes in ultra rapid urease test and histopathological examination for Helicobacter pylori by antisecretory drugs]. **2001**, 38, 3-8 2
- 466 Microvascular Leukocyte Activation and Apoptosis in Helicobacter pylori-Colonized Gastric Mucosa. **2001**, 249-256
- 465 The role of vaccines in cancer prevention. **2001**, 106, 283-306 2
- 464 Immunological aspects of Helicobacter pylori infection. **2001**, 153-175
- 463 Modeling Cancer as an Infectious Disease: The Epidemiology of Helicobacter Pylori. **2002**, 325-339
- 462 Vaccine Development. **2002**, 263-279

- 461 Toxins, Travels and Tropisms: H. pylori and Host Cells. **2002**, 173-201 1
- 460 Measurement of $^{13}\text{CO}_2/^{12}\text{CO}_2$ ratio using tunable diode laser based Raman spectroscopy and an atomic vapor filter. **2002**,
- 459 Gutartige Erkrankungen von Magen und Duodenum. **2002**, 337-438 1
- 458 Helicobacter pylori: the unique organism. **2002**, 22, 192-201
- 457 Helicobacter pylori and gastric cancer. **2003**, 11, 233-237 0
- 456 Novel targets for Helicobacter pylori eradication. **2003**, 413-422
- 455 Ethical issues in the management of Helicobacter pylori infection. **2003**, 433-437
- 454 Priorities for future research: microbiology. **2003**, 515-522
- 453 Helicobacter pylori. **2003**,
- 452 Actualit'dâHelicobacter pylori. **2003**, 187, 1095-1105
- 451 Gastrin. **2004**, 165-171
- 450 Fetal and Maternal Responses to Intrauterine Infection. **2004**, 131-142
- 449 Helicobacter pylori and Gastric Cancer. **2004**,
- 448 Chapter 8. **2004**, 163-180
- 447 Prevention of Cancers of the Esophagus and Stomach. **2005**, 25-54 1
- 446 Study on Production of Antibody in Milk Immunized Cows with Some Helicobacter pylori Antigen. **2005**, 34, 484-488
- 445 Study on Characteristics of Antibody from Milk Immunized with Some Helicobacter pylori Antigen. **2005**, 34, 619-625
- 444 [Helicobacter pylori identification by brush gastric cytology: a comparison with histologic method]. **2005**, 38, 322-5 2

- 443 Treatment of chronic inflammatory diseases among children â€” DRAMa helicobacteriosis. 4, 10-13
- 442 Moet een kind met een positieve Helicobacter Pylori-bloedtest worden behandeld?. **2006**, 1866-1867
- 441 A Case of Helicobacter pylori Infection and Rectal MALT Lymphoma Following Erythema Nodosum. **2007**, 69, 126-130
- 440 Treatment of duodenal ulceration with Furazolidine in China preceded the discovery of its association with H pylori. **2007**, 13, 3147 1
- 439 Pathways to innovation in addiction practice. **2007**, 461-472
- 438 Gastric and Gastroesophageal Adenocarcinoma. **2008**, 511-517
- 437 The Stomach. **2008**, 627-652
- 436 Peptic Ulcer Disease. **2008**, 279-287
- 435 Apoe+/- ldlr+/- mice as a useful model to evaluate accelerated atherogenesis by Helicobacter pylori infection. **2008**, 119, 253-260
- 434 Gastritis, Gastropathy, and Ulcer Disease. **2008**, 2082-2091
- 433 Eradication of Helicobacter pylori Infection in Outpatient Care. **2008**, 2, 161-172
- 432 Immunotoxicity Study of Separated Antigen from Helicobacter pylori.. **2008**, 18, 494-502
- 431 Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First- and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen. **2008**,
- 430 Peripheral Actions and Therapeutic Potential in Periphery. **2008**, 167-209
- 429 Persistent H. pylori colonization in early acquisition age of mice related with higher gastric sialylated Lewis x, IL-10, but lower interferon- γ expressions.
- 428 Future Prospects for Helicobacter pylori Vaccination. **2009**, 601-620
- 427 Epidemiology of Gastric Cancer and Helicobacter pylori. **2009**, 25-57
- 426 Antibiotic treatment in patients with low-back pain associated with Modic changes Type 1 (bone oedema): a pilot study. **2009**, 2009, 281-282

- 425 Prevention of Upper Gastrointestinal Tract Cancers. **2010**, 145-174
- 424 Therapies for the eradication of *Helicobacter pylori*.
- 423 *Helicobacter pylori* and gastric cancer: a marital risk?. **2009**, 102, 1104-5
- 422 Innovation in scientific researches. **2009**, 29, 1101-1105
- 421 *Helicobacter pylori* and Other Gastric *Helicobacter* Species. **2010**, 2803-2813 1
- 420 *Helicobacter Pylori* and Peptic Ulcer Disease. **2010**, 73-78
- 419 Treatment of Peptic Ulcer Disease. **2010**, 869-886.e4
- 418 Case 81. **2010**, 180-181
- 417 The potential role of infectious agents in diseases of unknown etiology. **2010**, 696-701 1
- 416 Clinicians as Effective Researchers. **2010**, 42, 1
- 415 Foraging. **2011**, 87-137
- 414 Gutartige Erkrankungen von Magen und Duodenum. **2011**, 381-449
- 413 Fetal and Maternal Responses to Intrauterine Infection. **2011**, 155-172
- 412 Adherent properties of *Helicobacter pylori* to human epithelial cells. **1997**, 3, 35-7 3
- 411 Drug Development for Eradication with InclusionComplex of Multifunctional-modified CD. **2011**, 10, 88-97
- 410 Erkrankungen von Mund, Speiseröhre und Magen. **2011**, 273-357
- 409 Management of Peptic Ulcer Disease. **2011**, 125-142
- 408 CagA *Helicobacter pylori* Seropositivity in Asymptomatic, Apparently Healthy, Young Adult Egyptian Food Handlers. **2012**, 2, 20-23 0

- 407 Pathophysiology of Gastric MALT Lymphoma. **2012**, 83, 689 2
- 406 Helicobacter Pylori Infection and Upper Gastrointestinal Disease. **2012**, 29,
- 405 What Do We Know About Blastocystis Analyzing Research Studies with Statistical Methods. **2012**, 95-131
- 404 Clinical and Endoscopic Findings in Children with Peptic Ulcer in Terms of Helicobacter pylori in Incheon. **2012**, 15, 23
- 403 Intestinal Dysfunction in Parkinson's Disease. **2013**, 155-171 0
- 402 Helicobacter pylori; microbe and detecting with data mining algorithms. **2013**, 03, 93-98 0
- 401 Gastrointestinal Disease. **2013**, 169-184
- 400 Histological Changes of Gastric Mucosa after Helicobacter pylori Eradication. **2013**, 13, 229
- 399 Pathogens as Symbionts. **2013**, 129-149
- 398 Hydroxamic Acids as Inhibitors of Urease in the Treatment of Helicobacter pylori Infections. **2013**, 241-253
- 397 Forschungsstand beim peptischen Ulkus. **1986**, 280-293
- 396 Gastrointestinal Campylobacter-Like Organisms. **1987**, 43-55
- 395 Ulcus ventriculi und Ulcus duodeni. **1987**, 224-237
- 394 Therapy. **1987**, 177-182
- 393 Ulcera peptica: Assoziation mit der Campylobacter pylori-Besiedlung der Antrum- und Bulbusmukosa. **1988**, 101-118 0
- 392 Die Campylobacter pylori -assoziierte Gastritis: Auf der Suche nach einem Tiermodell - Darstellung bisheriger eigener und Versuche anderer - **1988**, 41-46
- 391 Local Immune Responses to Campylobacter pylori Colonisation. **1988**, 164-167
- 390 Attempts to Eradicate Campylobacter pylori - Irish Experiences. **1988**, 220-224

- 389 Attempts to Eradicate *Campylobacter pylori* –Dutch Experiences. **1988**, 215-218
- 388 Semiquantitative Histopathology of Active Chronic Gastritis in *Campylobacter pylori* Infection and Its Relationship to Peptic Ulcer Disease and Gastric Carcinoma. **1988**, 78-87
- 387 Systemic Immune Responses to *Campylobacter pylori* Colonization. **1988**, 157-163 2
- 386 Bacteria and gastroduodenal inflammation. **1988**, 101-119
- 385 Incidence of *Campylobacter pylori* in Patients with Gastritis and Peptic Ulcer Disease in Various Countries. **1988**, 95-102 1
- 384 Why Should We Treat *Helicobacter pylori* Infection?. **1990**, 381-387
- 383 *Helicobacter pylori* in the Pathogenesis of Peptic Ulcer –Evidence in Favour. **1990**, 345-349
- 382 Comparison of Several Methods of Detecting *Helicobacter (Campylobacter) pylori*. **1990**, 188-194
- 381 The rod-to-coccoid body transformation in cultures of *Helicobacter pylori*. **1990**, 48, 626-627
- 380 Clinical Pharmacology of Bismuth –Studies from the Royal Free Hospital. **1991**, 175-182
- 379 Hauptthema: Neue Infektionskrankheiten. **1991**, 195-221
- 378 Optimal Study Design for Therapeutic Trials in *Helicobacter pylori*- Associated Nonulcer Dyspepsia. **1991**, 252-259 1
- 377 Gastritis Epidemiology and Natural History. **1991**, 120-128
- 376 *Helicobacter pylori* and chronic gastritis. **1991**, 11, 435-8 6
- 375 Non-Ulcer Dyspepsia. **1992**, 1-22
- 374 What role does *Helicobacter pylori* infection play in NSAID-associated gastric inflammation?. **1992**, 59-63
- 373 Colloidal Bismuth Subcitrate Plus Amoxicillin Versus Colloidal Bismuth Subcitrate Plus Ofloxacin in the Treatment of Chronic Antral Gastritis Positive for *Helicobacter pylori*. **1993**, 324-326
- 372 Prevalence of *Helicobacter pylori* in Patients with Malignant Growth of Gastric Mucosa. **1993**, 219-223

- 371 Computerised History Taking for the Assessment of Helicobacter pylori in Non-ulcer Dyspepsia: The Quest for the Clinical Syndrome. **1993**, 211-215
- 370 Gastritis: A Short Appraisal of Classification and the Sydney System. **1993**, 151-155
- 369 Helicobacter pylori and the Oesophagus. **1993**, 142-150 1
- 368 Reinfection with Helicobacter pylori Due to Intrafamilial Clustering of the Organism. **1993**, 53-56
- 367 Historical and microbiological perspectives. **1993**, 1-10 1
- 366 A current view of gastric cancer in the US. **1993**, 218, 579-82
- 365 Determinants of gastritis phenotype in H. pylori infection. **1994**, 381-389
- 364 Explaining Scientific Change: Integrating the Cognitive and the Social. **1994**, 1994, 298-303
- 363 The clinical value of a saliva diagnostic assay for antibody to H. pylori. **1994**, 342-350 1
- 362 Prospects for vaccination against H. pylori infection. **1994**, 593-599
- 361 Mucosal Immunity to H. pylori: Implications for Vaccine Development. **1996**, 255-267
- 360 Indigenous Microorganisms as a Host Defense. **1996**, 1-14
- 359 Disease associations. **1996**, 39-92
- 358 Helicobacter pylori infection. **1996**, 25, 491-3
- 357 Diagnostic esophago-gastroduodenoscopy. **1997**, 1-29
- 356 Ulcusforschung: Bestandsaufnahme, Perspektiven. **1997**, 271-281
- 355 Ruolo di Helicobacter Pylori Nella Patologia Gastroenterica Dei Pazienti Emodializzati. **1998**, 10, 5-10
- 354 Effect of Helicobacter pylori Lipopolysaccharides on Human Polymorphonuclear Neutrophils and Endothelial Cells. **1999**, 18, 119-124

353 Mycobacteria: Leprosy, a Battle Turned; Tuberculosis, a Battle Raging; Paratuberculosis, a Battle Ignored. 135-167

352 Overview of Bacterial Pathogens. 155-164

351 Application of Microarray Analysis to the Investigation of Host-Pathogen Interactions. 121-140

350 The Genome. 293-311

349 ROLE OF HELICOBACTER PYLORI IN DIABETES MELLITUS & ITS COMPLICATIONS. **2014**, 3, 8870-8876

348 Gastric Cancer: Molecular Mechanisms, Diagnosis, and Treatment. **2015**, 229-261

347 Climate, Science and Truth. **2015**, 15-34

346 Magen & Duodenum. **2015**, 187-228

345 Ulcus-ventriculi- und Uicus-duodeni-Krankheit. **2015**, 1-10

344 Oral Intake of N-acetyl-D-glucosamine Suppresses the Growth of Helicobacter Pylori in Gastric Mucosa of Mongolian Gerbils by Increasing Gland Mucus. **2015**, 2,

343 Helicobacter pylori Associated Gastritis in Northern Maharashtra, India: A Histopathological Study of Gastric Mucosal Biopsies. **2015**, 9, EC04-6 2

342 TO COMPARE THE SAFETY AND EFFICACY OF THREE DIFFERENT, PROTON PUMP INHIBITORS OMEPRAZOLE, ESO M EPRAZOLE AND RABEPRAZOLE IN A TRIPLE DRUG REGIMEN IN PATIENTS WITH PEPTIC ULCER DISEASE IN THE ERADICATION OF H. PYLORI INFECTION. **2015**, 2, 2007-2026

341 Epidemiology and Pathophysiology of <i>Helicobacter Pylori</i> Infections in Korea. **2015**, 89, 133-141 3

340 How to design a study that everyone will believe. 115-120

339 Gastritis and Gastropathy. 1103-1120

338 Self-Experimenting Physicians: Mavericks or martyrs?. **2015**, 15, e452-5

337 Endoscopic mucosal biopsy & histopathological interpretation. 2980-3057

336 Gastric Cancer Among Asian Americans. **2016**, 249-269 1

- 335 Helicobacter pylori CagA: The Bacterial Oncoprotein. **2016**, 1-19
- 334 The Disrupted Steady-State: Tipping the Balance in Favour of Cancer. **2016**, 1-37
- 333 Gastric cancer development after the successful eradication of Helicobacter pylori. **2016**, 8, 271-81 2
- 332 Quadruple Regimens for Helicobacter pylori Infection. **2016**, 237-252
- 331 INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY. **2016**, 5, 1998-2004
- 330 The microbiota of upper parts of gastrointestinal tract and its role in the development of obesity in children. **2016**, 44, 770-774
- 329 Small Bowel: The Problematic Duodenal Perforation. **2017**, 145-151
- 328 STUDY OF INCIDENCE OF HELICOBACTER PYLORI IN CASES OF DUODENAL ULCER PERFORATION IN GOVERNMENT VELLORE MEDICAL COLLEGE. **2016**, 5, 7599-7604
- 327 Overview of Infectious Causes of Human Cancers. **2017**, 1018, 1-9 1
- 326 <i>Helicobacter pylori</i>âThe Cause of Human Gastric Cancer. **2017**, 05, 1-9 4
- 325 Association between <i>Helicobacter pylori</i> Infection and Iron Deficiency Anemia among School-Age Children in Sohag University Hospital, Upper Egypt. **2017**, 07, 36-46 1
- 324 Clinical research: A personal perspective. **2017**, 8, 37-40 1
- 323 Antimicrobial Resistance in Helicobacter and Campylobacter. **2017**, 991-1006
- 322 Patientâ Guide: Helicobacter pylori in Peptic Ulcer Disease. **2017**, 83-92
- 321 HELICOBACTER PYLORI INFECTION IN DYSPEPTIC PATIENTS IN INDUSTRIAL BELT IN JHARKHAND. **2017**, 4, 445-448
- 320 Relevance between Helicobacter pylori Infection and Immune Thrombocytopenia. **2017**, 3, 1-6
- 319 Molecular Epidemiology of Helicobacter pylori in Dental Plaque among Jordanians; A Probable Source for Infection and Treatment Failure. **2017**, 11, 09-14
- 318 Rate of Isolation of Helicobacter pylori from Different Clinical Samples In Patients Suffering from Gastritis Attending Tertiary Care Hospital. **2017**, 11, 903-906

317 PREVALENCE OF HELICOBACTER PYLORI DISEASE IN PATIENTS WITH DYSPEPSIA ON UPPER GI ENDOSCOPY. **2017**, 6, 5132-5136

316 Encyclopedia of Animal Cognition and Behavior. **2018**, 1-13

315 PREVALENCE OF HELICOBACTER PYLORI IN PATIENTS WITH DYSPEPSIA UNDERGOING UPPER GASTRO INTESTINAL ENDOSCOPY IN TERTIARY CARE HOSPITAL. **2017**, 4, 5833-5840

314 Witnessing history: a personal view of half a century in public health. **2018**, 48, 181-191

313 Helicobacter pylori CagA: The Bacterial Oncoprotein. **2018**, 247-265

312 ERCP in Surgically Altered Anatomy Patients. **2018**, 387-397

311 Gastro Oesophageal Reflux and Bronchiectasis. **2018**, 175-186

310 Effect of Helicobacter pylori Infection on Haematological Parameters in Kosti Teaching Hospital, Sudan. **2018**, 20,

309 STUDY ON PREVALENCE OF H. PYLORI INFECTION DETECTED BY RAPID UREASE TEST IN PATIENTS WITH DYSPEPSIA. **2018**, 5, 2240-2244

308 Pathogenetic Treatment of Gastritis as a Basis for the Prevention of Gastric Cancer in the Countries of the Commonwealth of Independent States: Literature Review and the Resolution of a Scientific Symposium Held in Minsk, Republic of Belarus, January, 27, 2018. **2018**, 28, 7-14 3

307 Implications of Lateral or Horizontal Gene Transfer from Bacteria to the Human Gastrointestinal System for Cancer Development and Treatment. **2019**, 377-397 0

306 Diagnostic and Therapeutic Endoscopy of the Stomach and Small Bowel. **2019**, 647-662

305 Human Microbiome and Malignancy: Principles, Mechanisms, and Challenges. **2019**, 317-335

304 Helicobacter pylori gastriti iñ tanñlanan etat mamillone gññññññ histopatolojik bulgular ile korelasyonu. 1-4

303 Helicobacter pylori Infection: Challenges in India. **2019**, 13, 715-723

302 Phylogenetic analysis of clinical strains of isolated from patients with gastric diseases in Tibet. **2019**, 7, 320 1

301 A PROSPECTIVE STUDY ON PREVALENCE OF HELICOBACTER PYLORI IN GASTRODUODENAL PERFORATION. **2019**, 6, 2509-2512

300 Overview of the Immune System and Its Pharmacological Targets. **2020**, 1-42 1

- 299 The Psychotic Impact of *Helicobacter pylori* Gastritis and Functional Dyspepsia on Depression: A Systematic Review. **2019**, 11, e5956 1
- 298 Inhibitory effects of Caryophyllene on *Helicobacter pylori* infection in vitro and in vivo.
- 297 Investigation of Hemogram, Endoscopy, Demographic Properties of Patients Applied by Fecal Occult Blood Test Screening. 180-185
- 296 Prevalence and Risk Factors of *H. pylori* Induced Gastritis among Selangor Urban Population. **2019**, 13, 79-85 0
- 295 Wissenschaftliche Grundlagen der herzchirurgischen Fachliteratur. **2020**, 327-345
- 294 Deep learning-based *Helicobacter pylori* detection for histopathology: A diagnostic study.
- 293 Geographic diversity in *Helicobacter pylori* oipA genotype between Korean and United States isolates. **2021**, 59, 1125-1132 1
- 292 Histopathological Changes in *Helicobacter pylori* Associated Gastritis and Scope of Special Stain and Immunohistochemistry as Diagnostic Aids. **2020**, 7, 3027-3032
- 291 Evaluation of long-term adherence to oesophagogastroduodenoscopy quality indicators. **2020**, 43, 589-597 1
- 290 Current Prevalence of Oral among Japanese Adults Determined Using a Nested Polymerase Chain Reaction Assay. **2020**, 10, 2 2
- 289 Synthesis and *In Vitro* Anti-*Helicobacter* and Anti-Staphylococcal Activities of Novel Diaryldisulfides and Diarylthiosulfonates. **2021**, 11, 251-265
- 288 ERKRANKUNGEN DER VERDAUUNGSORGANE. **2020**, pA-1-pA7.8-14
- 287 Subgingival Microbes. **2020**, 145-210
- 286 Peptic ulcer disease. **2020**, 2849-2861
- 285 [Two unusual causes of peptic anastomotic ulcer]. **2020**, 100-101
- 284 *H. pylori* infection and antral nodular gastritis in children. **2020**, 10, 31-34
- 283 *Helicobacter pylori* and gastric cardia cancer: What do we know about their relationship?. **2020**, 8, 89-97
- 282 Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in *Helicobacter pylori* infected patients in Shahrekord, Southwest Iran. **2021**, 11, 147 1

- 281 Higher Risk of Gastric Infection in Patients with Periodontitis: A Nationwide Population-Based Retrospective Cohort Study in Taiwan. **2021**, 18, 1
- 280 Prevalence of among Patients with Gastrointestinal Tract (GIT) Symptoms: A Retrospective Study at Selected Africa Air Rescue (AAR) Clinics in Kampala, Uganda, from 2015 to 2019. **2021**, 2021, 9935142 1
- 279 In the search of a cause of Crohn's disease.
- 278 The Immunoproteome of *H. pylori*. **2004**, 317-338
- 277 Pathogenesis of peptic ulcer and distal gastric cancer. 57-66
- 276 *Helicobacter pylori* and Gastric Carcinoma. **2005**, 75-86 1
- 275 Probiotics and inflammatory bowel disease. 281-295
- 274 *Helicobacter pylori* Pathogenesis and Vaccines. **2008**, 195-218
- 273 The Molecular Mechanisms of *Helicobacter pylori*-Associated Gastroduodenal Disease. **2006**, 590-602
- 272 Magen- Und Darmkanal. 79-102
- 271 Pathogens as Symbionts. **2013**, 129-149 1
- 270 Unkompliziertes Ulcus duodeni: Pathogenese und konservative Therapie. **2006**, 348-353
- 269 A TEM and SEM Study of *Campylobacter pylori*-like organisms in the human stomach. **1989**, 47, 1060-1061
- 268 History of *Helicobacter pylori* and Human: An Intimate Story of Pathogen-Host Relationship. 516-525
- 267 Changes in Gastric Microbial Composition before and after *Helicobacter pylori* Eradication Therapy. **2020**, 20, 177-186
- 266 Alternations of Gastric Microbiota with Mucosal Atrophy and Intestinal Metaplasia. **2020**, 20, 187-195
- 265 Gut Microbiome: The Third Musketeer in the Cancer-Immune System Cross-Talk. **2020**, 3, 181-187 1
- 264 Clinical haematology. **1986**, 144, 387-387 1

- 263 Is peptic ulcer disease an infectious disease?. **1993**, 159, 616-8 1
- 262 Trends in *Campylobacter pylori* in pediatric and adult antral biopsies. A 5-year retrospective analysis. **1989**, 151, 406-9 1
- 261 Observation of *Helicobacter*-like organisms in gastric mucosa of grey foxes (*Urocyon cinereoargenteus*) and bobcats (*Lynx rufus*). **2004**, 68, 154-6 4
- 260 The prevalence of *Campylobacter pylori* gastritis among asymptomatic adults. **1989**, 140, 1449-53 8
- 259 In-practice evaluation of whole-blood *Helicobacter pylori* test: its usefulness in detecting peptic ulcer disease. **2000**, 50, 13-6 6
- 258 *Helicobacter pylori* culture supernatant interferes with epidermal growth factor-activated signal transduction in human gastric KATO III cells. **1998**, 152, 1617-24 26
- 257 *Helicobacter pylori*--our knowledge is growing. **1991**, 67, 487
- 256 A comparison of symptoms between non-ulcer dyspepsia patients positive and negative for *Helicobacter pylori*. **1991**, 60, 21-7 3
- 255 Changing times. Annual oration: Royal Victoria Hospital, Belfast, October 2001. **2002**, 71, 47-54
- 254 Hunterian peptic ulcers and *Helicobacter pylori*. **1997**, 79, 368-71 1
- 253 Pathobiology of *Helicobacter pylori* infection. **1998**, 71, 43-51 1
- 252 Placebo: feeling better, getting better, and the problems of mind and body. **2008**, 11, 212-4 1
- 251 *Helicobacter pylori* and its interaction with chief and parietal cells. **1996**, 69, 91-8 5
- 250 Pathophysiology and clinical relevance of *Helicobacter pylori*. **1992**, 65, 625-38 6
- 249 A morphometric study of antral G-cell density in a sample of adult general population: comparison of three different methods and correlation with patient demography, *helicobacter pylori* infection, histomorphology and circulating gastrin levels. **2009**, 2, 239-48
- 248 Contribution of intestinal flora to surgical infections. **1988**, 80, 765-8 1
- 247 Effects of *Helicobacter* infection on research: the case for eradication of *Helicobacter* from rodent research colonies. **2009**, 59, 10-7 26
- 246 In situ detection of urease-positive *Helicobacter pylori*-like organisms on swine gastric mucosa. **2010**, 74, 237-40

245	The antibacterial activity of honey on helicobacter pylori. 2006 , 6, 71-6	10
244	Analysis of Helicobacter pylori genotypes in Afghani and Iranian isolates. 2010 , 59, 61-6	11
243	Formulation and In Vitro evaluation of pH sensitive oil entrapped polymeric blended gellan gum buoyant beads of clarithromycin. 2010 , 18, 247-53	12
242	The care and feeding of evidence based medicine. 2012 , 71, 97-102	
241	Diagnostic values of Helicobacter pylori diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology. 2011 , 16, 1097-104	26
240	IL-1B-511 Allele T and IL-1RN-L/L Play a Pathological Role in Helicobacter Pylori (H. Pylori) Disease Outcome in the African Population. 2012 , 22, 163-9	8
239	Imprint cytology: a simple, cost effectiveness analysis for diagnosing Helicobacter pylori, in west of Iran. 2012 , 26, 12-6	3
238	Prevalence of Helicobacter pylori in a First Nations population in northwestern Ontario. 2013 , 59, e182-7	20
237	Helicobacter pylori infection and pediatric asthma. 2013 , 5, 132-5	13
236	Developing physician-scientists: a perspective. 2013 , 124, 218-29	3
235	Formulation and In-vitro Evaluation of pH-Sensitive Oil Entrapped Polymeric Blend Amoxicillin Beads for the Eradication of Helicobacter pylori. 2012 , 11, 447-55	7
234	Eradication Rate of Helicobacter pylori using a Two-week Quadruple Therapy: A Report from Southern Iran. 2013 , 5, 81-5	5
233	The role of adenotonsillar tissues as a reservoir for Helicobacter pylori and Helicobacter hepaticus. 2011 , 4, 153-8	1
232	Epidemiology of peptic ulcer disease: endoscopic results of a systematic investigation in iran. 2012 , 4, 90-6	14
231	Laryngopharyngeal reflux and Helicobacter pylori. 2014 , 20, 8964-70	5
230	Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance. 2014 , 10, 1-19	1
229	Pathogenicity of Helicobacter ganmani in mice susceptible and resistant to infection with H. hepaticus. 2015 , 65, 15-22	10
228	Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. 2015 , 8, 6530-43	13

227	The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study. 2015 , 8, S54-9	3
226	Gordon Wilson Lecture: Infectious Disease Causes of Cancer: Opportunities for Prevention and Treatment. 2015 , 126, 117-32	8
225	State of the art management of metastatic gastroesophageal cancer. 2015 , 3, 236	4
224	New Diagnostic Strategies for Detection of Helicobacter pylori Infection in Pediatric Patients. 2014 , 10, 1-19	5
223	Prevalence of Helicobacter Pylori-Negative, Non-Steroidal Anti-Inflammatory Drug Related Peptic Ulcer Disease in Patients Referred to Afzalipour Hospital. 2015 , 7, 241-4	1
222	Antral gastritis caused by Helicobacter pylori infection in the pediatric age group is associated with increased mesenteric lymph node dimension observed by ultrasonography. 2015 , 5, 829-34	2
221	Agglutination of Helicobacter pylori coccoids by lectins. 2000 , 6, 202-209	14
220	Prevalence of Helicobacter pylori infection measured with urinary antibody in an urban area of Japan, 2008-2010. 2012 , 74, 63-70	12
219	Piperine treatment suppresses Helicobacter pylori toxin entry in to gastric epithelium and minimizes Hcatenin mediated oncogenesis and IL-8 secretion in vitro. 2016 , 8, 885-98	8
218	Rallying Community Health Care Providers to Close the Gap Between H pylori Guidelines and the Challenges of Eradication. 2014 , 10, 811-4	1
217	Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection. 2016 , 7, 267-271	5
216	Infection with Campylobacter pylori. 1988 , 22, 97-100	6
215	Evaluation of Invasive and Noninvasive Methods for the Diagnosis of Helicobacter Pylori Infection. 2016 , 17, 5265-5272	3
214	Adding ofloxacin to standard triple-drug regimens increased the Helicobacter pylori eradication rate: Data from randomized clinical trial. 2017 , 8, 108-111	
213	Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. 2017 , 18, 2839-2843	2
212	The Mechanisms Underlying -Mediated Protection against Allergic Asthma. 2017 , 16, 251-259	8
211	Prevalence of infection in Sari Northern Iran; a population based study. 2019 , 12, 31-37	3
210	Relationship between Helicobacter pylori infection and GERD. 2018 , 89, 40-43	7

- 209 Preventing Gastric Cancer Development by Inhibiting the Virulence of H. pylori Infection. **2019**, 33, 227-31
- 208 Helicobacter pylori Infection in Children: a Comprehensive Review. **2019**, 14, 292-297 1
- 207 Detection of gastritis-associated pathogens by culturing of gastric juice and mucosa. **2018**, 11, 2214-2220 11
- 206 [Research progress on the relationship between oral microbial community and tumor]. **2014**, 32, 527-31 0
- 205 [Overview of researches for Helicobacter pylori in oral cavity and stomach]. **2014**, 32, 314-8 4
- 204 Probiotics in the prevention and treatment of infections with Helicobacter pylori, Enterohemorrhagic Escherichia coli, and Rotavirus. **2022**, 281-304 0
- 203 Mucosal microbiome associates with progression to gastric cancer.. **2022**, 12, 48-58 0
- 202 Histologic detection of Helicobacter pylori by the immunohistochemical method using anti-Helicobacter pylori polyclonal antibody: A cross-sectional study of patients with gastric pathologies at the Muhimbili National Hospital in Dar-es-salaam, Tanzania. **2021**, 23, 7-7 1
- 201 Pulcer disease in women. **2021**, 160-166 1
- 200 When will gastritis disappear in history in Finland?. **2021**, 1-4
- 199 Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity.. **2021**, 9, 752346 2
- 198 Characterization of East-Asian Helicobacter pylori encoding Western EPIYA-ABC CagA. **2021**, 60, 207 0
- 197 Potential Therapeutic Effects of Egg Yolk Antibody (IgY) in Infections-A Review. **2021**, 69, 13691-13699 1
- 196 Demonstration of Helicobacter pylori (HP) and Other Related Organisms. **2022**, 47-57
- 195 Chronic Gastritis: Infectious, Non-infectious (Autoimmune, Chemical, Granulomatous), Chronic Superficial and Diffuse Antral Gastritis. **2022**, 77-90
- 194 Epidemiology of Helicobacter pylori.. **2022**, 55 Suppl 1, S1-S13 1
- 193 The Effects of and Knockout Mutations on the Structure and Function of Lipopolysaccharide in Strain 26695.. **2022**, 10, 0
- 192 Prevalence of Helicobacter Pylori Infection in Patients with Dyspepsia in North of Iran. **2021**, 13, 230-236

191	Modern knowledge on pathogenesis, diagnosis and treatment of helicobacter infection. 2021 , 15-26	
190	Association Between Helicobacter pylori Eradication and Kidney Function in Patients With Chronic Gastritis: A Retrospective Single-Center Study.. 2022 , 14, e21621	0
189	Predictive value of nomogram based on Kyoto classification of gastritis to diagnosis of gastric cancer.. 2022 , 1-7	0
188	Zinc carnosine-based modified bismuth quadruple therapy standard triple therapy for eradication: A randomized controlled study.. 2022 , 10, 227-235	1
187	Host miRNAs-microbiota interactions in gastric cancer.. 2022 , 20, 52	0
186	Next-Generation Sequencing-Based Study of Isolates from Myanmar and Their Susceptibility to Antibiotics.. 2022 , 10,	4
185	Extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis.. 2022 , e12877	1
184	A unique aromatic cluster near the active site of H. pylori CPA is essential for catalytic function.. 2021 ,	0
183	Toll-like receptor 1 locus re-examined in a genome-wide association study update on anti-Helicobacter pylori IgG titers.. 2022 ,	2
182	Study on the value of antibiotic-resistant gene detection in in China.. 2022 , 23, 228	1
181	An exploratory study on the presence of Helicobacter heilmannii and Helicobacter billis in the faces of companion dogs.. 2022 ,	1
180	Time to Classify Tumours of the Stomach and the Kidneys According to Cell of Origin.. 2021 , 22,	2
179	Helicobacter pylori and gastric cancer: a lysosomal protease perspective.. 2021 , 25, 306	3
178	Rapid identification of pyloric Campylobacter in Peruvians with gastritis. The Gastrointestinal Physiology Working Group. 1986 , 31, 1089-94	14
177	Defining core patient descriptors for perforated peptic ulcer research: international Delphi.. 2022 ,	
176	Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.. 2022 , 9, 814269	2
175	Helicobacter pylori may participate in the development of inflammatory bowel disease by modulating the intestinal microbiota.. 2022 ,	1
174	The history of the discovery of the Helicobacter pylori. 2022 , 94, 283-288	

173	The TNF-Alpha Inducing Protein is Associated With Gastric Inflammation and Hyperplasia in a Murine Model of Infection.. 2022 , 13, 817237	0
172	Evolution of Diagnostic Methods for Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools.. 2022 , 12,	5
171	Changes in Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications.. 2022 , 15, 51-58	
170	Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.. 2022 , 14,	0
169	Evaluation of the diagnostic value of FliD, a Helicobacter pylori flagellar protein.. 2022 ,	0
168	Role of Porphyromonas gingivalis in oral and orodigestive squamous cell carcinoma.. 2022 ,	4
167	Roles of Plasmacytoid Dendritic Cells in Gastric Cancer.. 2022 , 12, 818314	0
166	The immune microenvironment in gastric adenocarcinoma.. 2022 ,	5
165	Role of New Anatomy, Biliopancreatic Reflux, and Helicobacter Pylori Status in Postgastrectomy Stump Cancer.. 2022 , 11,	0
164	Helicobacter pylori infection affects the human gastric microbiome, as revealed by metagenomic sequencing.. 2022 ,	0
163	Helicobacter pylori-induced DNA double-strand break in the development of gastric cancer.. 2022 ,	1
162	Differential -Induced MAPK Responses Regulate Lewis Antigen Expression and Colonization Density on Gastric Epithelial Cells Between Children and Adults.. 2022 , 13, 849512	0
161	Validation and improvement of a multiplex PCR method to detect murine Helicobacter species in feces samples of mice.. 2022 , e12888	
160	Characterization of the cagA-gene in Helicobacter pylori in Mongolia and detection of two EPIYA-A enriched CagA types.. 2022 , 312, 151552	
159	Eradication of Helicobacter pylori alleviates lipid metabolism deterioration: a large-cohort propensity score-matched analysis.. 2022 , 21, 34	0
158	infection treatment in the United States: clinical consequences and costs of eradication treatment failure.. 2022 ,	0
157	The role of <i>Helicobacter pylori</i> in complex human comorbidity. 2022 , 12, 21-32	
156	Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. 2021 , 31, 70-99	3

- 155 Regulation of β -integrin in autophagy and apoptosis of gastric epithelial cells infected with *Helicobacter pylori*. **2021**, 38, 12 0
- 154 Outer Membrane Vesicles Secreted by Transmitting Gastric Pathogenic Virulence Factors.. **2022**, 7, 240-258 1
- 153 Biophysical characterization of the homodimers of HomA and HomB, outer membrane proteins of *Helicobacter pylori*.. **2021**, 11, 24471 1
- 152 *Helicobacter pylori* infection and increased diabetes prevalence were the risks of colorectal adenoma for adults: A systematic review and meta-analysis (PRISMA-compliant article).. **2021**, 100, e28156 0
- 151 Coinfection of and Hepatitis C Virus in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.. **2021**, 13, 530-540 0
- 150 Follow-up analysis and histopathological study of gastric mucosa in patients with infection.. **2021**, 49, 3000605211055397 1
- 149 Dramatic shift in the epidemiology of peptic ulcer in Japan: the impact of *Helicobacter pylori* eradication therapy. **2022**, 150, 0
- 148 Association of Alcohol Drinking and *Helicobacter pylori* Infection: A Meta-analysis.. **2021**, 0
- 147 *Helicobacter pylori* Eradication and Gastric Cancer Prevention. **2021**, 21, 267-274 0
- 146 Interactions of 2,6-substituted purines with purine nucleoside phosphorylase from in solution and in the crystal, and the effects of these compounds on cell cultures of this bacterium.. **2022**, 37, 1083-1097 1
- 145 The stomach. 1853-1924 0
- 144 Image_1.TIF. **2018**, 0
- 143 Image_2.TIF. **2018**, 0
- 142 Image_3.TIF. **2018**, 0
- 141 Table_1.docx. **2020**, 0
- 140 Table_2.docx. **2020**, 0
- 139 Table_3.docx. **2020**, 0
- 138 Table_4.xlsx. **2020**, 0

137 Presentation_1.PDF. **2018**,

136 Image_1.JPEG. **2019**,

135 Table_1.XLSX. **2019**,

134 Table_2.XLSX. **2019**,

133 Curcumin: A therapeutic strategy for targeting the Helicobacter pylori-related diseases.. **2022**, 105552 ○

132 Clinical Evaluation of a Novel Stool Antigen Test Using Bioluminescent Enzyme Immunoassay for Detecting .. **2022**, 2022, 5571542 ○

131 The Effects of Infection on Gastric Microbiota in Children With Duodenal Ulcer.. **2022**, 13, 853184 ○

130 Systematic Retesting for : The Potential Overestimation of Suppressive Conditions.. **2022**, 2022, 5380001

129 Seroprevalence of Helicobacter pylori among dyspeptic patients in northern Lebanon: a 6-year retrospective study in two tertiary hospitals. **2022**, 4,

128 Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance from Helicobacter pylori Next Generation Sequencing Data. **2022**, 12, 691 2

127 Helicobacter Species and Their Association with Gastric Pathology in a Cohort of Dogs with Chronic Gastrointestinal Signs. **2022**, 12, 1254 ○

126 Everolimus ameliorates Helicobacter pylori infection-induced inflammation in gastric epithelial cells.. **2022**, 13, 11361-11372 1

125 A Multi-Omics Study on the Effect of Helicobacter Pylori-Related Genes in the Tumor Immunity on Stomach Adenocarcinoma. **2022**, 12, ○

124 Caracterizaci3n del c3ncer g3strico en Guatemala. **2015**, 25, 9-20

123 The role of non-Helicobacter pylori bacteria in the pathogenesis of gastroduodenal diseases. **2022**, 14, ○

122 The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics. **2022**, 9, 795 3

121 Radioactive Iodine Treatment for Thyroid Cancer Patients Increases the Risk of Long-Term Gastrointestinal Disorders: A Nationwide Population-Based Cohort Analysis. **2022**, 14, 2505 ○

120 The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease. **2022**, 12,

119	Sex Differences in the Prevalence of Head and Neck Cancers: A 10-Year Follow-Up Study of 10 Million Healthy People. 2022 , 14, 2521	3
118	Editorial Spotlight/Take 5: Discussing Two Systematic Reviews With Opposing Conclusions on Shoulder Pain After Vaccine Administration. 2022 , Publish Ahead of Print,	0
117	Is Helicobacter pylori colonization associated with chronic tonsillitis? A meta-analysis and systematic review. 2022 , 103515	0
116	Wrapped Up: The Motility of Polarly Flagellated Bacteria. 2022 , 76,	2
115	Differences in Helicobacter pylori Prevalence by Race. 2022 ,	1
114	Medical Reasoning and the GW Model of Abduction. 2022 , 1-26	
113	Comparison of the gastric microbiome in Billroth I and Roux-en-Y reconstructions after distal gastrectomy. 2022 , 12,	
112	Gastric Helicobacter species associated with dogs, cats and pigs: significance for public and animal health. 2022 , 53,	0
111	Helicobacter pylori-mediated gastric pathogenesis is attenuated by treatment of 2-deoxyglucose and metformin.	1
110	Inflammation and Gastric Cancer. 2022 , 10, 35	1
109	Evaluation of Antimicrobial Activities of Various Herbal Oils Against Helicobacter pylori And Their Cytotoxic Effects On HUVEC Cell Line.	
108	Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study.	1
107	Potassium-competitive acid blocker and proton pump inhibitor-based regimens for first-line Helicobacter pylori eradication: a network meta-analysis. 2022 ,	0
106	Exploring biocultural determinants of intestinal health: Do resource access and parasite exposure contribute to intestinal inflammation among a preliminary sample of children in rural Mississippi?.	1
105	CHAPTER 5. Probiotics, Prebiotics, and Synbiotics in Human Health. 2022 , 86-119	
104	Inflammatory Biomarkers for Cancer. 2022 , 195-205	
103	Helikobakter pylori enfeksiyonunun Endoskopik, Patolojik ve Laboratuvar Bulgular ile Değerlendirilmesi.	
102	A phase 1b study of andecaximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. 2022 , 12,	1

- 101 Comparative Transcriptome Analysis of Zerumbone-Treated *Helicobacter pylori*. **2022**, 50, 301-309
- 100 Negative correlations between bile reflux gastritis and *Helicobacter pylori* infection. 1-5
- 99 Draft Genome Sequence of *Helicobacter* sp. Strain CaF467b, Isolated from a Pig Manure Storage Tank.
- 98 Traditional and Modern Diagnostic Approaches in Diagnosing Pediatric *Helicobacter pylori* Infection. **2022**, 9, 994 3
- 97 Vacuolating Cytotoxin A Triggers Mitophagy in *Helicobacter pylori*-Infected Human Gastric Epithelium Cells. 12,
- 96 Evidence Construction of Chinese Herbal Formulae for the Treatment of *H. pylori* Positive Peptic Ulcer: A Bayesian Network Meta-analysis. **2022**, 154327
- 95 *Helicobacter pylori* Chronic Gastritis in Children and Adolescents was not Associated with Anaemia. **2022**, 4, 6-11
- 94 Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. *gutjnl-2022-327209* 4
- 93 Whole-genome sequencing and comparative analysis of *Helicobacter pylori* GZ7 strain isolated from China. 0
- 92 Association between dental caries and *Helicobacter pylori* infection in Japanese adults: A cross-sectional study. **2022**, 17, e0271459 0
- 91 How We Manage the Dyspeptic Patient with *Helicobacter Pylori* 'Infection'. **1999**, 29, 51-53
- 90 Immunology. **2010**,
- 89 Aerobic Bacteriology. **2010**, 0
- 88 The Role of the Microbiome in Pancreatic Oncogenesis. 0
- 87 Chemical Composition and In Vitro Anti-*Helicobacter pylori* Activity of *Campomanesia lineatifolia* Ruiz & Pav. (Myrtaceae) Essential Oil. **2022**, 11, 1945 1
- 86 Gastrointestinal microbiome in the context of *Helicobacter pylori* infection in stomach and gastroduodenal diseases. **2022**,
- 85 Gastric Cancer Due to Chronic *H. pylori* Infection: What We Know and Where We Are Going. **2022**, 10, 57 0
- 84 Analysis of genetic relatedness between gastric and oral *H. pylori* in patients with early gastric cancer using multilocus sequence typing.

- 83 Prevalence of *Helicobacter pylori* resistance to clarithromycin in Tunisia. **2022**, 71,
- 82 Salivary *Fusobacterium nucleatum* serves as a potential diagnostic biomarker for gastric cancer. **2022**, 28, 4120-4132 ○
- 81 Insights Into the Helical Shape Complex of *Helicobacter pylori*. 13,
- 80 Efficacy and safety of vonoprazan-based quadruple therapy for the eradication of *Helicobacter pylori* in patients with peptic ulcers: a pooled analysis of two randomized, double-blind, double-dummy, phase 3 trials. ○
- 79 Inhibition of urease by hydroquinones: a structural and kinetic study. ○
- 78 Targeted delivery of hydrogels in human gastrointestinal tract: A review. **2023**, 134, 108013 1
- 77 Prevalence, diversity and public health implications of *Helicobacter* species in pet and stray dogs. **2022**, 15, 100430 ○
- 76 *Helicobacter pylori* har sin nisje i magesekken, men den kan også finnes i munnhulen. **2002**, 112, ○
- 75 Microorganisms in Pathogenesis and Management of Hashimoto Thyroiditis. **2022**, 365-383 ○
- 74 Development of Probiotics for *Helicobacter pylori* Infection Management. **2022**, 499-523 ○
- 73 Das Wort „psychosomatisch“ als Sprechhandlung. **2022**, 89-109 ○
- 72 Perforated Peptic Ulcer. **2022**, 253-261 ○
- 71 The Relationship between Anemia and *Helicobacter Pylori* Infection in Children. **2022**, 9, 1324 2
- 70 Mass screening and eradication of *Helicobacter pylori* as the policy recommendations for gastric cancer prevention. **2022**, 1 ○
- 69 Modelling adult stem cells and their niche in health and disease with epithelial organoids. **2022**, ○
- 68 Is Stomach a Sterile Environment. 81-89 ○
- 67 Use of digital pathology and artificial intelligence for the diagnosis of *Helicobacter pylori* in gastric biopsies. **2022**, 114, 295-303 ○
- 66 Refractory *Helicobacter pylori* infection and the gastric microbiota. 12, ○

- 65 Clinical implications of interleukins-31, 32, and 33 in gastric cancer. **2022**, 14, 1808-1822 ○
- 64 A look at the face of the molten globule: structural model of the Helicobacter pylori apoflavodoxin ensemble at acidic pH. ○
- 63 A Review on Traditional Anti-Ulcer Medicinal Plants. **2022**, 19, ○
- 62 Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. **2022**, 14, ○
- 61 Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. 13, ○
- 60 Retention Time Extended by Nanoparticles Improves the Eradication of Highly Antibiotic-Resistant Helicobacter pylori. **2022**, 14, 2117 ○
- 59 Helicobacter pylori. **2023**, ○
- 58 Current developments in gastric cancer: from molecular profiling to treatment strategy. 2
- 57 The pursuit of new alternative ways to eradicate Helicobacter pylori continues: Detailed characterization of interactions in the adenylosuccinate synthetase active site. **2023**, 226, 37-50 ○
- 56 PHYLOGENETIC STRUCTURE OF THE GLOBAL POPULATION OF HELICOBACTER PYLORI. ○
- 55 Global trends of Helicobacter pylori biofilm research in the past two decades: A bibliometric study (Preprint). ○
- 54 Management of Helicobacter pylori infection. ○
- 53 About the constitutional features of gastric and duodenal ulcer in children. **2022**, 36-40 ○
- 52 The History of the Intestinal Microbiota and the Gut-Brain Axis. **2022**, 11, 1540 ○
- 51 Mechanistic insights into the nickel-dependent allosteric response of the Helicobacter pylori NikR transcription factor. **2022**, 102785 ○
- 50 Reassessment of the Broth Microdilution Method for Susceptibility Testing of Helicobacter pylori. **2022**, 226, S486-S492 ○
- 49 An Ultrasensitive PCR-Based CRISPR-Cas13a Method for the Detection of Helicobacter pylori. **2022**, 12, 2082 ○
- 48 The Role of Helicobacter pylori Neutrophil-Activating Protein in the Pathogenesis of H. pylori and Beyond: From a Virulence Factor to Therapeutic Targets and Therapeutic Agents. **2023**, 24, 91 ○

- 47 *Helicobacter pylori*: A Bacterium Influencing and Causing Most of the Diseases in the Upper Gastrointestinal Tract. An Overview with Respect to Pathogenesis and Treatment Based on Basic Physiology. ○
- 46 Comparisons of pathologic findings and outcomes of gastric cancer patients younger and older than 40: a propensity score matching study in a single center of Korea. ○
- 45 <i>Helicobacter Pylori</i> Infection and Gastroduodenal Lesions in Patients with Chronic Kidney Disease: A Comparative Study. **2023**, 13, 49-60 ○
- 44 Clarithromycin-based *Helicobacter pylori* eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland. **2023**, 153, 40024 ○
- 43 Characteristics of digestive system lesions in patients with diabetes mellitus. **2023**, 29-36 ○
- 42 Gut Microbiome and Immune Responses in Gastrointestinal Cancer. **2023**, 163-179 ○
- 41 Effect of polyphenol compounds on *Helicobacter pylori* eradication: a systematic review with meta-analysis. **2023**, 13, e062932 ○
- 40 Highly sensitive surface plasmon resonance sensor for refractive index detection of *Helicobacter Pylori*. **2023**, 274, 170516 ○
- 39 The Importance of Accurate Early Diagnosis and Eradication in *Helicobacter pylori* Infection: Pictorial Summary Review in Children and Adults. **2023**, 12, 60 1
- 38 *Helicobacter pylori* Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. **2023**, 12, 191 ○
- 37 About the constitutional features of gastric and duodenal ulcer in children. **2023**, 67, 63-67 ○
- 36 Gastroesophageal reflux disease and the role of *Helicobacter pylori*. **2023**, 61-76 ○
- 35 *Helicobacter pylori* and gastric microbiota homeostasis: progress and prospects. ○
- 34 Analysis of Genetic Relatedness between Gastric and Oral *Helicobacter pylori* in Patients with Early Gastric Cancer Using Multilocus Sequence Typing. **2023**, 24, 2211 ○
- 33 Regulatory B cells (Bregs) in *Helicobacter pylori* chronic infection. ○
- 32 Causes of Cancer and Mechanisms of Carcinogenesis. **2023**, 229-279 ○
- 31 Gastrointestinal microbiome: Evaluation of testing technologies. **2023**, 147-161 ○
- 30 Epidemiological and Histopathological Aspects of Chronic Gastritis at the Departmental University Teaching Hospital of Borgou Alibori (CHUD-BA) from 2011 to 2021. **2023**, 13, 54-71 ○

- 29 Gastroprotective action of the extract of *Corydalis yanhusuo* in *Helicobacter pylori* infection and its bioactive component, dehydrocorydaline. **2023**, 307, 116173 ○
- 28 Medical Reasoning and the GW Model of Abduction. **2023**, 481-506 ○
- 27 A Quandary in Creativity Studies: Conflicting Theoretical Views from In Vivo versus In Vitro Research. 1-30 ○
- 26 Characteristics of digestive system lesions in patients with diabetes mellitus. **2023**, 216-226 ○
- 25 DNA Damage and the Gut Microbiome: From Mechanisms to Disease Outcomes. **2023**, 3, 13-32 ○
- 24 Biological Characteristics of Polyurethane-Based Bone-Replacement Materials. **2023**, 15, 831 ○
- 23 Homoeopathy in Treatment of Gastro Intestinal Disorders - A Retrospective Study. **2023**, 8, 41-46 ○
- 22 IL-8 Secreted by Gastric Epithelial Cells Infected with *Helicobacter pylori* CagA Positive Strains Is a Chemoattractant for Epstein-Barr Virus Infected B Lymphocytes. **2023**, 15, 651 ○
- 21 In Search for Reasons behind *Helicobacter pylori* Eradication Failure—Assessment of the Antibiotics Resistance Rate and Co-Existence of *Helicobacter pylori* with *Candida* Species. **2023**, 9, 328 ○
- 20 Increased IL-17A Serum Levels and Gastric Th17 Cells in *Helicobacter pylori*-Infected Patients with Gastric Premalignant Lesions. **2023**, 15, 1662 ○
- 19 Critical appraisal of international guidelines for the management of *Helicobacter pylori* infection in case of dyspepsia. **2023**, 28, ○
- 18 Prevention of malignant digestive system tumors should focus on the control of chronic inflammation. 15, 389-404 ○
- 17 Modern aspects of *Helicobacter pylori* infection. **2023**, 26, 67-74 ○
- 16 A review on the research progress on non-pharmacological therapy of *Helicobacter pylori*. 14, ○
- 15 A Study of Various Medicinal Plants used in Ulcer Treatment: A Review. **2023**, 2, 234-246 ○
- 14 Synbiotics in Gastric Cancer. **2023**, 157-173 ○
- 13 **İNİC BASAMAK DEVLET HASTANESİNDE KİFARKLI HELICOBACTER PYLORI TEDAVİ REJİMİNİN ETKİNLİĞİNİN DEĞERLENDİRİLMESİ** ○
- 12 *Helicobacter pylori* and Human Immunodeficiency Virus Co-Infection: Potential Implications for Future Gastric Cancer Risk. **2023**, 11, 887 ○

- 11 Clinical and Forensic Signs Resulting from Exposure to Heavy Metals and Other Chemical Elements of the Periodic Table. **2023**, 12, 2591 ○
- 10 Gastric microbiota dysbiosis and Helicobacter pylori infection. 14, ○
- 9 Intratumoral microbiota is associated with prognosis in patients with adrenocortical carcinoma. ○
- 8 Phospholipase C: underrated players in microbial infections. 13, ○
- 7 Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy. ○
- 6 Programmed ageing: decline of stem cell renewal, immunosenescence, and Alzheimer's disease. ○
- 5 Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. **2023**, ○
- 4 Unwelcome guests – The role of gland-associated Helicobacter pylori infection in gastric carcinogenesis. 13, ○
- 3 Illuminating the structure–function landscape of an evolutionary nonconserved motif in the arginases of Helicobacter gastric pathogens. ○
- 2 Cornu aspersum mucin attenuates indomethacins-induced gastric ulcers in mice via alleviating oxidative stress and inflammation. **2023**, e15677 ○
- 1 A Reappraisal of the Pathophysiology of Cushing Ulcer: A Narrative Review. Publish Ahead of Print, ○